ASX Code,Company Name,Item,1990,1991,1992,1993,1994,1995,1996,1997,1998,1999,2000,2001,2002,2003,2004,2005,2006,2007,2008,2009,2010,2011,2012,2013,2014,2015,2016
1ST,1st Available Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , , , , , ,0.00%,-34.50%, 
1ST,1st Available Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , , , , , ,--,"288,046.00", 
1ST,1st Available Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , , , , , ,0.00,"-3,309,803.00", 
1ST,1st Available Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , , , , , ,"1,445,449.00","9,593,068.00", 
1ST,1st Available Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , , , , , ,"2,438,317.00","10,822,246.00", 
AAH,Arana Therapeutics Limited,Annual Ratio Analysis - ROE,-16.88%,-11.04%,2.80%,0.81%,0.82%,-99.27%,-29.07%,-14.20%,-17.06%,-8.54%,3.74%,56.23%,-17.33%,-46.24%,49.80%,33.68%,5.93%,1.07%,-1.51%, , , , , , , , 
AAH,Arana Therapeutics Limited,Annual Profit and Loss - Operating Revenue,"514,000.00","912,000.00","2,242,000.00","3,061,000.00","3,045,000.00","4,118,000.00","3,684,000.00","889,000.00","1,982,000.00","2,285,000.00","3,219,000.00","28,190,000.00","3,702,000.00","2,094,000.00","44,373,000.00","5,882,000.00","5,817,000.00","8,126,000.00","7,519,000.00", , , , , , , , 
AAH,Arana Therapeutics Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-3,211,000.00","-1,846,000.00","1,066,000.00","2,045,000.00","1,613,000.00","-50,443,000.00","-5,307,000.00","-11,028,000.00","-25,077,000.00","-874,000.00","-314,000.00","30,667,000.00","-8,925,000.00","-15,771,000.00","28,341,000.00","25,711,000.00","5,093,000.00","133,414,000.00","-4,092,000.00", , , , , , , , 
AAH,Arana Therapeutics Limited,Annual Balance Sheet - Total Equity,"26,278,000.00","27,942,000.00","45,697,000.00","79,077,000.00","90,167,000.00","74,199,000.00","55,630,000.00","45,680,000.00","11,337,000.00","10,232,000.00","9,898,000.00","46,226,000.00","39,962,000.00","34,107,000.00","66,023,000.00","76,332,000.00","85,945,000.00","309,246,000.00","304,073,000.00", , , , , , , , 
AAH,Arana Therapeutics Limited,Annual Balance Sheet - Total Assets,"48,586,000.00","49,323,000.00","69,011,000.00","113,570,000.00","128,904,000.00","136,542,000.00","103,676,000.00","80,312,000.00","48,755,000.00","45,943,000.00","21,835,000.00","50,126,000.00","41,763,000.00","36,581,000.00","69,390,000.00","84,441,000.00","100,186,000.00","329,484,000.00","329,513,000.00", , , , , , , , 
ACG,AtCor Medical Holdings Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , ,-14.34%,-27.80%,-55.24%,-63.62%,-36.41%,-32.65%,-101.61%,-105.36%,56.04%,-81.11%,-33.23%, 
ACG,AtCor Medical Holdings Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , ,"3,106,000.00","3,334,000.00","4,874,000.00","6,450,599.00","11,209,113.00","9,198,496.00","7,458,450.00","6,441,493.00","9,055,721.00","5,053,284.00","5,467,457.00", 
ACG,AtCor Medical Holdings Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , ,"-2,696,000.00","-4,005,000.00","-5,183,000.00","-3,792,731.00","-1,691,433.00","-1,220,057.00","-3,081,084.00","-1,985,519.00","2,734,023.00","-2,663,508.00","-1,440,177.00", 
ACG,AtCor Medical Holdings Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , ,"18,795,000.00","14,406,000.00","9,382,000.00","5,961,497.00","4,645,022.00","3,736,765.00","3,032,122.00","1,884,420.00","4,878,933.00","3,283,947.00","4,333,993.00", 
ACG,AtCor Medical Holdings Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , ,"20,336,000.00","15,845,000.00","11,404,000.00","7,950,918.00","7,900,161.00","5,901,303.00","5,251,336.00","4,181,758.00","6,375,007.00","4,631,270.00","5,953,596.00", 
ACL,Alchemia Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , ,-24.87%,-29.43%,-63.17%,-33.35%,-45.97%,-33.65%,-34.05%,-27.91%,-71.38%,-62.16%,-14.73%,-25.60%,-13.70%, 
ACL,Alchemia Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , ,0.00,0.00,0.00,"26,000.00","768,000.00","9,000.00",0.00,0.00,0.00,"6,000.00","10,165,000.00","8,135,000.00","5,583,000.00", 
ACL,Alchemia Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , ,"-6,863,596.00","-6,522,000.00","-8,853,000.00","-12,732,000.00","-12,929,000.00","-10,943,000.00","-8,367,000.00","-8,801,000.00","-13,430,000.00","-15,083,000.00","-4,770,000.00","-6,924,000.00","-15,816,000.00", 
ACL,Alchemia Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , ,"27,592,826.00","22,159,000.00","14,014,000.00","40,426,000.00","28,127,000.00","32,520,000.00","24,571,000.00","31,531,000.00","18,814,000.00","24,265,000.00","32,379,000.00","27,050,000.00","11,509,000.00", 
ACL,Alchemia Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , ,"29,746,582.00","25,575,000.00","17,778,000.00","52,299,000.00","35,067,000.00","39,680,000.00","30,606,000.00","37,230,000.00","24,325,000.00","32,371,000.00","41,486,000.00","33,996,000.00","14,632,000.00", 
ACR,Acrux Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , ,-17.99%,-51.27%,-50.44%,-20.42%,-48.29%,-43.08%,-13.19%,-24.71%,57.85%,125.02%,13.92%,14.81%,66.50%,27.40%, 
ACR,Acrux Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , ,--,"746,307.00","3,264,806.00","3,471,736.00","1,481,000.00","4,044,000.00","4,496,000.00","1,323,000.00","55,069,000.00","89,603,000.00","8,797,000.00","15,585,000.00","53,368,000.00","24,616,000.00", 
ACR,Acrux Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , ,"-3,144,783.00","-5,956,800.00","-4,232,632.00","-6,044,034.00","-9,939,000.00","-7,861,000.00","-5,026,000.00","-7,716,000.00","46,554,000.00","57,148,000.00","7,391,000.00","6,926,000.00","27,970,000.00","11,130,000.00", 
ACR,Acrux Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , ,"17,485,116.00","11,664,921.00","8,408,905.00","29,481,791.00","20,583,000.00","18,246,000.00","38,109,000.00","31,223,000.00","80,469,000.00","45,712,000.00","53,103,000.00","46,753,000.00","42,057,000.00","40,625,000.00", 
ACR,Acrux Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , ,"18,355,576.00","12,846,083.00","9,757,512.00","31,093,624.00","23,234,000.00","20,369,000.00","41,267,000.00","34,950,000.00","83,605,000.00","58,995,000.00","58,499,000.00","52,895,000.00","53,221,000.00","48,495,000.00", 
ACW,Actinogen Medical Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , ,-15.24%,-48.73%,-63.13%,-70.96%,-248.33%,-84.72%,-34.47%,-35.36%, 
ACW,Actinogen Medical Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , ,"13,639.00","25,589.00","48,411.00","58,820.00","51,562.00",0.00,"20,000.00",0.00, 
ACW,Actinogen Medical Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , ,"-435,658.00","-926,942.00","-737,471.00","-742,380.00","-1,529,156.00","-164,663.00","-440,222.00","-5,431,009.00", 
ACW,Actinogen Medical Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , ,"2,859,172.00","1,902,230.00","1,168,259.00","1,046,127.00","346,990.00","194,353.00","1,211,812.00","15,356,608.00", 
ACW,Actinogen Medical Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , ,"2,941,506.00","2,007,649.00","1,341,837.00","1,140,807.00","465,799.00","275,672.00","1,261,739.00","15,579,248.00", 
ADO,Anteo Diagnostics Limited,Annual Ratio Analysis - ROE, , , , , , , , , ,0.03%,-7.47%,-13.74%,-54.97%,-62.88%,-116.88%,-255.93%,-392.34%,-100.88%,-58.54%,-188.77%,-161.75%,-32.25%,-49.87%,-78.51%,-35.09%,-78.93%, 
ADO,Anteo Diagnostics Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , ,--,0.00,"55,640.00","1,291,151.00","3,989,863.00","4,280,284.00","1,991,478.00","809,604.00","91,141.00","81,114.00","226,312.00","265,752.00","210,063.00","405,175.00","510,294.00","309,759.00","465,131.00", 
ADO,Anteo Diagnostics Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , ,"2,039.00","-546,592.00","-1,401,000.00","-9,163,678.00","-2,946,256.00","-2,829,397.00","-1,579,539.00","-6,245,124.00","-1,563,497.00","-1,762,320.00","-1,949,275.00","-2,255,405.00","-2,222,462.00","-2,380,199.00","-2,179,223.00","-2,492,150.00","-4,220,342.00", 
ADO,Anteo Diagnostics Limited,Annual Balance Sheet - Total Equity, , , , , , , , , ,"7,854,309.00","7,314,683.00","10,199,317.00","6,372,825.00","3,455,730.00","2,107,897.00","526,706.00","1,591,757.00","1,549,861.00","3,010,212.00","1,032,600.00","1,394,366.00","6,891,174.00","4,772,565.00","2,775,766.00","7,101,335.00","5,346,863.00", 
ADO,Anteo Diagnostics Limited,Annual Balance Sheet - Total Assets, , , , , , , , , ,"7,865,442.00","7,932,728.00","11,527,497.00","7,971,025.00","5,037,306.00","3,434,580.00","732,065.00","1,908,617.00","1,958,564.00","3,472,095.00","1,332,129.00","1,723,206.00","7,285,267.00","5,211,398.00","3,275,348.00","7,666,936.00","6,043,268.00", 
ADR,Adherium Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , , , , , , ,0.00%, 
ADR,Adherium Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , , , , , , ,--, 
ADR,Adherium Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , , , , , , ,0.00, 
ADR,Adherium Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , , , , , , ,"34,528,000.00", 
ADR,Adherium Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , , , , , , ,"37,153,000.00", 
AFP,AFT Pharmaceuticals Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , , , , , , , ,-47.00%
AFP,AFT Pharmaceuticals Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , , , , , , , ,"57,670,270.00"
AFP,AFT Pharmaceuticals Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , , , , , , , ,"-11,952,252.00"
AFP,AFT Pharmaceuticals Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , , , , , , , ,"25,432,432.00"
AFP,AFT Pharmaceuticals Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , , , , , , , ,"58,832,432.00"
AGX,Agenix Limited,Annual Ratio Analysis - ROE,-42.32%,-39.94%,-170.24%,-99.38%,0.45%,-19.74%,-98.40%,-23.81%,-14.77%,8.20%,2.96%,12.13%,4.73%,4.68%,-27.61%,-90.90%,-96.88%,-59.20%,-324.18%,"1,432.45%",87.06%,-136.24%,-130.56%,"-1,544.79%",-139.87%,-91.18%, 
AGX,Agenix Limited,Annual Profit and Loss - Operating Revenue,"81,000.00","387,000.00","629,000.00","480,000.00","706,000.00","745,000.00","3,504,715.00","4,395,733.00","4,718,933.00","18,230,788.00","26,158,907.00","29,254,351.00","37,490,000.00","33,604,000.00","31,952,000.00","22,179,000.00","560,000.00","342,000.00","247,000.00","717,000.00","37,666.00",--,0.00,"3,745.00","25,382.00",0.00, 
AGX,Agenix Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-1,940,000.00","-701,000.00","-869,000.00","-642,000.00","-290,000.00","-347,000.00","-1,849,053.00","-768,579.00","-4,421,147.00","1,074,289.00","4,923,828.00","4,200,596.00","161,000.00","-811,000.00","-14,336,000.00","-11,988,000.00","-3,721,000.00","-4,778,000.00","-23,283,000.00","-7,954,000.00","2,478,187.00","-2,707,451.00","-1,355,204.00","-3,258,469.00","786,160.00","-1,083,446.00", 
AGX,Agenix Limited,Annual Balance Sheet - Total Equity,"1,744,000.00","1,755,000.00","168,000.00","646,000.00","1,339,000.00","1,758,000.00","1,879,148.00","3,227,532.00","14,683,598.00","15,421,587.00","21,649,963.00","34,384,972.00","34,696,000.00","33,968,000.00","20,282,000.00","8,710,000.00","14,211,000.00","19,752,000.00","7,137,000.00","-490,000.00","2,846,399.00","1,987,201.00","1,038,009.00","210,933.00","1,387,079.00","848,719.00", 
AGX,Agenix Limited,Annual Balance Sheet - Total Assets,"2,452,000.00","2,753,000.00","7,729,000.00","7,324,000.00","7,932,000.00","2,153,000.00","4,681,471.00","4,163,720.00","34,113,819.00","33,534,906.00","33,122,832.00","44,038,165.00","45,613,000.00","45,781,000.00","35,616,000.00","24,589,000.00","23,654,000.00","33,803,000.00","13,579,000.00","2,649,000.00","5,802,446.00","2,836,753.00","1,207,316.00","725,379.00","2,092,299.00","1,694,819.00", 
AHZ,Admedus Ltd,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , ,-12.97%,-46.46%,-39.87%,-104.18%,-93.52%,-99.48%,-96.90%,-14.32%,-43.99%,-14.28%,-26.34%,-69.71%, 
AHZ,Admedus Ltd,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , ,--,--,0.00,0.00,0.00,0.00,0.00,"6,749,716.00","6,435,653.00","7,402,988.00","7,900,095.00","10,133,460.00", 
AHZ,Admedus Ltd,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , ,"-650,347.00","-1,767,760.00","-1,177,080.00","-2,237,442.00","-1,275,942.00","-1,131,386.00","-1,312,566.00","-1,953,648.00","-10,222,135.00","-2,418,497.00","-8,207,715.00","-26,799,970.00", 
AHZ,Admedus Ltd,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , ,"5,012,432.00","3,805,141.00","3,372,319.00","2,338,684.00","1,388,617.00","1,098,045.00","1,239,267.00","13,638,433.00","10,433,447.00","15,075,074.00","37,166,875.00","38,558,482.00", 
AHZ,Admedus Ltd,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , ,"5,067,931.00","3,826,752.00","3,923,693.00","2,583,739.00","1,563,980.00","1,301,215.00","1,398,206.00","14,748,179.00","11,197,704.00","16,563,796.00","39,761,373.00","41,260,466.00", 
AJJ,Asian American Medical Group Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , ,-57.60%,-435.39%,647.12%,128.97%,58.52%,54.90%,2.93%,-47.23%,13.02%, 
AJJ,Asian American Medical Group Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , ,"884,047.00","876,320.00","17,708,458.00","16,933,988.00","16,123,928.00","18,598,739.00","16,957,237.00","13,640,150.00","19,287,616.00", 
AJJ,Asian American Medical Group Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , ,"-781,209.00","-1,612,046.00","1,935,289.00","1,933,475.00","1,196,931.00","1,942,200.00","202,984.00","-2,135,444.00","553,232.00", 
AJJ,Asian American Medical Group Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , ,"1,356,377.00","370,251.00","1,794,022.00","1,499,138.00","2,141,063.00","3,581,986.00","6,928,720.00","4,521,330.00","8,393,344.00", 
AJJ,Asian American Medical Group Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , ,"1,751,235.00","834,240.00","7,766,030.00","5,367,945.00","5,923,949.00","7,648,880.00","10,827,702.00","7,052,434.00","15,036,712.00", 
ALC,Alcidion Group Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , ,0.00%,-28.09%,-123.03%,-28.59%,-3.69%,-7.43%, 
ALC,Alcidion Group Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , ,--,--,"107,621.00","110,245.00",0.00,--, 
ALC,Alcidion Group Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , ,0.00,"-721,657.00","-3,108,021.00","-1,193,789.00","-148,588.00","-278,421.00", 
ALC,Alcidion Group Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , ,"5,715,533.00","5,138,102.00","2,526,150.00","4,175,336.00","4,026,748.00","3,748,327.00", 
ALC,Alcidion Group Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , ,"5,745,640.00","5,357,353.00","2,658,559.00","4,201,734.00","4,041,074.00","3,763,186.00", 
ALT,Analytica Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , ,-117.86%,-865.06%,-182.06%,-126.20%,-279.21%,-173.28%,-37.62%,-171.20%,-681.14%,-133.75%,"-1,394.99%", 
ALT,Analytica Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , ,"619,672.00","194,251.00","249,807.00",0.00,0.00,"1,800.00","6,100.00","4,880.00","498,081.00",0.00,"73,824.00", 
ALT,Analytica Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , ,"-3,614,447.00","-3,076,454.00","-589,740.00","-829,457.00","-1,901,780.00","-1,287,837.00","-203,176.00","-2,222,009.00","-1,135,751.00","-3,176,008.00","-5,315,604.00", 
ALT,Analytica Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , ,"3,066,839.00","355,641.00","323,934.00","657,235.00","681,132.00","743,224.00","540,012.00","1,297,909.00","166,743.00","2,374,522.00","381,049.00", 
ALT,Analytica Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , ,"3,290,538.00","448,075.00","510,523.00","1,140,607.00","1,197,749.00","834,519.00","989,346.00","1,486,412.00","422,800.00","2,824,921.00","1,080,043.00", 
AMT,Allegra Orthopaedics Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , ,0.00%,1.92%,-12.12%,-11.97%,-63.10%,-4.29%,-11.61%,-7.22%,-20.42%, 
AMT,Allegra Orthopaedics Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , ,--,"6,815,141.00","6,187,581.00","7,307,000.00","7,195,000.00","8,511,000.00","7,156,000.00","7,966,000.00","7,316,662.00", 
AMT,Allegra Orthopaedics Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , ,0.00,"180,005.00","-1,024,695.00","-896,000.00","-3,265,000.00","-173,000.00","-571,000.00","-64,000.00","-855,056.00", 
AMT,Allegra Orthopaedics Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , ,"8,355,000.00","9,362,992.00","8,454,149.00","7,485,000.00","4,247,000.00","4,035,000.00","4,203,000.00","4,169,000.00","4,186,474.00", 
AMT,Allegra Orthopaedics Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , ,"10,425,000.00","11,579,727.00","10,833,365.00","10,613,000.00","8,585,000.00","11,607,000.00","10,757,000.00","8,034,000.00","7,279,538.00", 
ANN,Ansell Limited,Annual Ratio Analysis - ROE,24.26%,17.61%,10.63%,11.82%,13.12%,14.53%,7.98%,9.70%,10.85%,12.38%,10.69%,7.33%,8.05%,6.72%,9.03%,15.38%,18.15%,16.71%,19.24%,19.44%,18.35%,18.48%,18.40%,16.75%,13.94%,17.65%, 
ANN,Ansell Limited,Annual Profit and Loss - Operating Revenue,"5,048,000,000.00","4,921,605,000.00","5,806,156,000.00","6,304,624,000.00","6,966,823,000.00","7,306,248,000.00","6,470,796,000.00","5,782,905,856.00","5,983,499,776.00","6,150,000,128.00","5,725,800,000.00","4,156,800,000.00","2,222,800,000.00","1,293,600,000.00","1,113,300,000.00","1,096,200,000.00","1,138,200,000.00","1,239,200,000.00","1,244,700,000.00","1,352,100,000.00","1,230,600,000.00","1,219,800,000.00","1,218,300,000.00","1,340,000,000.00","1,688,110,403.00","2,142,057,291.00", 
ANN,Ansell Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"342,712,000.00","219,882,000.00","217,728,000.00","266,255,000.00","308,532,000.00","103,239,000.00","-126,518,000.00","184,928,000.00","23,800,000.00","111,500,000.00","-82,400,000.00","-135,800,000.00","-113,000,000.00","52,500,000.00","72,600,000.00","13,100,000.00","118,700,000.00","104,100,000.00","105,600,000.00","126,400,000.00","122,700,000.00","125,900,000.00","133,000,000.00","140,800,000.00","47,133,757.00","246,223,958.00", 
ANN,Ansell Limited,Annual Balance Sheet - Total Equity,"1,277,904,000.00","1,384,551,000.00","2,051,826,000.00","2,191,010,000.00","2,368,696,000.00","2,256,841,000.00","1,792,562,000.00","1,846,799,048.00","1,691,700,000.00","1,634,300,000.00","1,499,900,000.00","1,066,200,000.00","876,000,000.00","844,500,000.00","811,800,000.00","602,800,000.00","653,700,000.00","613,600,000.00","546,000,000.00","639,100,000.00","664,600,000.00","677,600,000.00","720,800,000.00","833,300,000.00","1,210,721,868.00","1,519,010,416.00", 
ANN,Ansell Limited,Annual Balance Sheet - Total Assets,"4,251,534,000.00","4,644,539,000.00","5,984,286,000.00","6,450,252,000.00","6,744,805,000.00","6,957,719,000.00","5,944,840,000.00","5,592,879,040.00","5,342,300,032.00","5,218,900,064.00","5,085,700,000.00","3,476,200,000.00","1,832,700,000.00","1,578,800,000.00","1,499,400,000.00","1,199,200,000.00","1,308,000,000.00","1,250,100,000.00","1,156,500,000.00","1,312,100,000.00","1,297,600,000.00","1,216,300,000.00","1,348,300,000.00","1,835,400,000.00","2,505,201,698.00","3,094,270,833.00", 
ANP,Antisense Therapeutics Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , ,-1.97%,-46.89%,-52.50%,-26.90%,-57.67%,-62.12%,-80.37%,-33.73%,-67.47%,-254.81%,-89.86%,-34.21%,-52.83%,-144.39%,9.97%, 
ANP,Antisense Therapeutics Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , ,--,0.00,0.00,0.00,0.00,0.00,"-3,408.00","6,399,000.00",0.00,0.00,0.00,0.00,0.00,0.00,"3,863,988.00", 
ANP,Antisense Therapeutics Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , ,"-393,739.00","-6,321,006.00","-6,107,898.00","-4,609,624.00","-6,265,839.00","-5,462,401.00","-4,835,963.00","-2,136,886.00","-2,649,727.00","-3,424,875.00","-1,813,550.00","-1,801,278.00","-2,454,842.00","-3,013,272.00","706,918.00", 
ANP,Antisense Therapeutics Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , ,"20,033,762.00","13,481,712.00","11,617,746.00","17,132,983.00","10,864,344.00","8,793,236.00","6,017,376.00","6,334,646.00","3,927,502.00","1,344,099.00","2,018,122.00","5,265,844.00","4,647,055.00","2,086,891.00","7,091,598.00", 
ANP,Antisense Therapeutics Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , ,"20,088,222.00","15,334,216.00","11,982,149.00","18,151,131.00","11,222,068.00","9,116,265.00","8,049,769.00","9,865,525.00","4,989,230.00","1,815,525.00","2,435,861.00","5,689,132.00","5,201,156.00","2,656,021.00","7,673,038.00", 
ANR,Anatara Lifesciences Ltd,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , , , , , ,0.00%,-32.75%, 
ANR,Anatara Lifesciences Ltd,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , , , , , ,--,0.00, 
ANR,Anatara Lifesciences Ltd,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , , , , , ,0.00,"-1,795,228.00", 
ANR,Anatara Lifesciences Ltd,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , , , , , ,"7,226,054.00","5,480,816.00", 
ANR,Anatara Lifesciences Ltd,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , , , , , ,"7,453,671.00","5,627,794.00", 
APH,Ascent Pharmahealth Ltd,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , ,-2.84%,-11.85%,-14.94%,7.00%,2.96%,8.79%,10.43%, , , , , , 
APH,Ascent Pharmahealth Ltd,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , ,--,--,"1,795,000.00","54,575,000.00","40,383,000.00","106,854,000.00","137,757,000.00", , , , , , 
APH,Ascent Pharmahealth Ltd,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , ,"-985,427.00","-3,672,693.00","-5,601,000.00","-17,961,000.00","1,532,000.00","9,177,000.00","11,962,000.00", , , , , , 
APH,Ascent Pharmahealth Ltd,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , ,"34,678,810.00","30,992,306.00","37,484,000.00","72,810,000.00","103,464,000.00","104,404,000.00","114,721,000.00", , , , , , 
APH,Ascent Pharmahealth Ltd,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , ,"34,830,053.00","31,253,547.00","40,782,000.00","102,659,000.00","139,116,000.00","142,071,000.00","157,252,000.00", , , , , , 
API,Australian Pharmaceutical Industries Limited,Annual Ratio Analysis - ROE, , , , , , , ,15.44%,11.65%,11.94%,13.71%,11.11%,13.01%,10.44%,9.66%,6.70%,10.39%,-1.92%,3.63%,4.28%,3.83%,-3.55%,2.77%,4.16%,-23.06%,8.53%, 
API,Australian Pharmaceutical Industries Limited,Annual Profit and Loss - Operating Revenue, , , , , , , ,"855,542,976.00","1,001,209,024.00","1,132,806,016.00","1,237,141,000.00","1,645,457,000.00","1,907,774,000.00","2,473,191,000.00","2,942,170,000.00","3,411,241,000.00","2,582,144,000.00","940,303,000.00","3,238,879,000.00","3,549,734,000.00","3,713,312,000.00","3,425,890,000.00","3,215,234,000.00","3,186,143,000.00","3,345,946,000.00","3,457,400,000.00", 
API,Australian Pharmaceutical Industries Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , ,"23,940,000.00","18,645,000.00","25,970,000.00","26,578,000.00","28,586,000.00","34,657,000.00","23,567,000.00","18,444,000.00","29,721,000.00","20,374,000.00","-2,598,000.00","15,213,000.00","18,598,000.00","22,646,000.00","-23,310,000.00","30,283,000.00","24,292,000.00","-90,771,000.00","43,126,000.00", 
API,Australian Pharmaceutical Industries Limited,Annual Balance Sheet - Total Equity, , , , , , , ,"155,176,000.00","160,019,000.00","174,413,992.00","154,644,000.00","257,300,000.00","266,402,000.00","343,186,000.00","338,408,000.00","443,614,000.00","428,897,000.00","406,935,000.00","418,964,000.00","434,527,000.00","591,175,000.00","554,367,000.00","568,308,000.00","584,120,000.00","480,737,000.00","505,402,000.00", 
API,Australian Pharmaceutical Industries Limited,Annual Balance Sheet - Total Assets, , , , , , , ,"275,055,000.00","316,921,000.00","357,962,992.00","383,070,000.00","542,276,000.00","657,341,000.00","772,781,000.00","822,605,000.00","1,115,090,000.00","873,280,000.00","908,283,000.00","999,255,000.00","1,047,244,000.00","1,484,943,000.00","1,390,904,000.00","1,373,371,000.00","1,375,954,000.00","1,289,066,000.00","1,342,548,000.00", 
AVE,Aevum Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , ,-0.04%,6.25%,4.48%,10.39%,10.45%,10.48%,-4.59%,1.14%, , , , , , 
AVE,Aevum Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , ,"10,815,000.00","12,499,000.00","12,478,000.00","14,692,000.00","15,537,000.00","13,307,000.00","14,828,000.00","21,936,000.00", , , , , , 
AVE,Aevum Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , ,"-28,000.00","5,043,000.00","4,454,000.00","13,369,000.00","22,931,000.00","28,545,000.00","-12,204,000.00","28,604,000.00", , , , , , 
AVE,Aevum Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , ,"68,703,000.00","80,672,000.00","127,112,000.00","128,656,000.00","219,509,000.00","272,247,000.00","265,625,000.00","359,481,000.00", , , , , , 
AVE,Aevum Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , ,"132,971,000.00","149,880,000.00","250,471,000.00","274,168,000.00","621,845,000.00","809,370,000.00","828,279,000.00","1,227,924,000.00", , , , , , 
AVH,Avita Medical Ltd,Annual Ratio Analysis - ROE, , , ,-4.81%,-3.85%,-8.04%,-14.45%,-128.74%,-51.00%,-26.67%,-29.46%,-24.66%,-18.73%,-31.25%,-57.57%,-82.42%,-79.70%,-116.42%,-89.99%,-59.70%,-60.68%,-25.08%,-88.00%,-77.41%,-93.14%,-168.55%, 
AVH,Avita Medical Ltd,Annual Profit and Loss - Operating Revenue, , , ,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,"346,473.00","522,859.00","556,504.00","1,436,891.00","1,190,469.00","932,581.00","1,256,588.00","2,430,147.00","2,702,219.00","3,120,984.00","3,352,268.00","2,814,990.00","2,683,133.00","2,750,176.00", 
AVH,Avita Medical Ltd,Annual Profit and Loss - Reported NPAT After Abnorma, , , ,"-333,000.00","-2,498,000.00","-1,727,000.00","231,652.00","-3,519,806.00","-923,381.00","-1,241,305.00","-2,932,839.00","-2,529,112.00","-2,688,501.00","-1,983,430.00","-7,129,289.00","-14,156,687.00","-11,973,869.00","-15,065,061.00","-12,188,280.00","-5,128,292.00","-5,889,363.00","-1,796,920.00","-7,671,682.00","-8,092,939.00","-5,147,391.00","-7,107,496.00", 
AVH,Avita Medical Ltd,Annual Balance Sheet - Total Equity, , , ,"9,667,000.00","7,499,000.00","6,022,000.00","6,253,774.00","2,733,968.00","1,810,587.00","4,654,569.00","9,661,767.00","8,882,655.00","14,703,496.00","12,692,981.00","12,383,365.00","17,176,702.00","15,023,589.00","12,940,765.00","13,543,855.00","8,589,881.00","4,678,054.00","16,050,495.00","8,553,977.00","10,455,310.00","5,526,622.00","4,216,884.00", 
AVH,Avita Medical Ltd,Annual Balance Sheet - Total Assets, , , ,"10,231,000.00","7,810,000.00","6,137,000.00","6,316,252.00","2,763,173.00","1,843,096.00","4,788,612.00","9,727,236.00","9,909,377.00","15,262,355.00","13,425,192.00","13,114,639.00","19,002,091.00","17,623,673.00","14,198,988.00","16,206,113.00","9,829,464.00","9,243,405.00","17,486,837.00","10,706,070.00","12,908,631.00","7,312,839.00","5,443,166.00", 
AVS,Avastra Sleep Centres Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , ,-80.04%,-23.03%,-23.88%,-79.55%,-10.18%,-17.58%, , , , , , , , 
AVS,Avastra Sleep Centres Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , ,0.00,0.00,"302,456.00",0.00,"13,021,000.00","37,296,000.00", , , , , , , , 
AVS,Avastra Sleep Centres Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , ,"-534,521.00","-1,863,420.00","-1,559,819.00","-3,000,218.00","-2,035,000.00","-4,125,000.00", , , , , , , , 
AVS,Avastra Sleep Centres Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , ,"667,791.00","8,092,078.00","6,532,259.00","3,771,478.00","19,983,000.00","23,459,000.00", , , , , , , , 
AVS,Avastra Sleep Centres Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , ,"667,791.00","8,157,368.00","6,605,076.00","3,944,758.00","46,696,000.00","53,076,000.00", , , , , , , , 
AVT,AVT Plasma Limited,Annual Ratio Analysis - ROE, , , , ,24.13%,17.45%,-29.74%,-60.84%,-160.63%,-20.01%,-27.79%,-248.03%,-368.15%,-273.38%,677.40%, , , , , , , , , , , , 
AVT,AVT Plasma Limited,Annual Profit and Loss - Operating Revenue, , , , ,"15,564,000.00","20,889,000.00","13,643,053.00","15,751,760.00","2,728,028.00",--,--,--,--,--,"7,190.00", , , , , , , , , , , , 
AVT,AVT Plasma Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , ,"4,431,000.00","4,267,000.00","-9,193,383.00","-15,283,893.00","7,034,930.00","-1,406,856.00","-2,352,000.00","-7,980,126.00","-986,715.00","-4,679,268.00","-2,151,344.00", , , , , , , , , , , , 
AVT,AVT Plasma Limited,Annual Balance Sheet - Total Equity, , , , ,"18,318,000.00","22,686,000.00","12,057,996.00","-2,179,205.00","4,711,504.00","7,032,452.00","8,464,860.00","1,254,734.00","268,019.00","1,711,654.00","-317,590.00", , , , , , , , , , , , 
AVT,AVT Plasma Limited,Annual Balance Sheet - Total Assets, , , , ,"33,387,000.00","42,272,000.00","42,227,477.00","42,318,329.00","4,764,125.00","7,387,158.00","8,674,337.00","1,972,332.00","383,264.00","2,429,654.00","232,292.00", , , , , , , , , , , , 
AVX,Avexa Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , ,-64.12%,-105.38%,-16.67%,-64.71%,-84.66%,-64.53%,-16.70%,-20.63%,-21.99%,-25.25%,-25.26%, 
AVX,Avexa Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , ,"669,000.00",--,0.00,"891,000.00",0.00,"398,000.00",0.00,0.00,0.00,"295,000.00",0.00, 
AVX,Avexa Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , ,"-13,536,000.00","-17,830,000.00","-15,218,000.00","-36,093,000.00","-36,218,000.00","-41,488,000.00","-4,402,000.00","-3,513,000.00","-2,977,000.00","-2,897,000.00","-6,610,000.00", 
AVX,Avexa Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , ,"21,112,000.00","16,920,000.00","91,290,000.00","55,776,000.00","42,783,000.00","24,369,000.00","26,355,000.00","17,029,000.00","13,539,000.00","11,471,000.00","6,374,000.00", 
AVX,Avexa Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , ,"21,993,000.00","20,585,000.00","93,978,000.00","64,783,000.00","45,777,000.00","25,478,000.00","26,828,000.00","17,620,000.00","14,013,000.00","11,923,000.00","6,651,000.00", 
AXN,Axon Instruments Inc.,Annual Ratio Analysis - ROE, , , , , , , ,4.63%,1.91%,2.38%,5.78%,1.44%,-20.18%,2.42%, , , , , , , , , , , , , 
AXN,Axon Instruments Inc.,Annual Profit and Loss - Operating Revenue, , , , , , , ,"17,900,013.00","22,671,024.00","24,986,758.00","51,480,456.00","69,934,772.00","48,507,629.00","44,638,484.00", , , , , , , , , , , , , 
AXN,Axon Instruments Inc.,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , ,"519,209.00","503,241.00","1,059,940.00","5,486,129.00","1,468,920.00","-16,690,483.00","1,432,146.00", , , , , , , , , , , , , 
AXN,Axon Instruments Inc.,Annual Balance Sheet - Total Equity, , , , , , , ,"11,223,177.00","26,306,874.00","25,718,329.00","94,929,799.00","102,312,081.00","74,424,878.00","59,072,024.00", , , , , , , , , , , , , 
AXN,Axon Instruments Inc.,Annual Balance Sheet - Total Assets, , , , , , , ,"11,223,064.00","26,306,874.00","40,396,179.00","107,053,346.00","112,725,062.00","85,022,423.00","68,781,726.00", , , , , , , , , , , , , 
AXP,"AirXpanders, Inc.",Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , , , , , ,0.00%,-65.48%, 
AXP,"AirXpanders, Inc.",Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , , , , , ,--,"292,608.00", 
AXP,"AirXpanders, Inc.",Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , , , , , ,0.00,"-11,161,345.00", 
AXP,"AirXpanders, Inc.",Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , , , , , ,"36,738,000.00","17,045,215.00", 
AXP,"AirXpanders, Inc.",Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , , , , , ,"42,216,000.00","20,949,589.00", 
AYX,Austofix Group Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , ,0.00%,-39.08%,-18.61%,-8.96%,-14.81%, , , , , 
AYX,Austofix Group Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , ,--,"1,398,858.00","1,539,922.00","2,648,021.00","1,603,305.00", , , , , 
AYX,Austofix Group Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , ,0.00,"-1,891,923.00","-719,739.00","-341,312.00","-580,461.00", , , , , 
AYX,Austofix Group Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , ,"8,605,143.00","4,581,874.00","3,868,104.00","3,808,126.00","3,919,640.00", , , , , 
AYX,Austofix Group Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , ,"9,710,216.00","6,039,080.00","5,150,652.00","7,015,830.00","8,123,128.00", , , , , 
AZV,Azure Healthcare Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , ,0.00%,9.28%,17.72%,4.82%,6.10%,-33.69%,-58.04%,-2.31%,3.86%,9.08%,26.81%,6.96%, 
AZV,Azure Healthcare Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , ,--,"10,055,000.00","21,988,000.00","39,963,000.00","47,616,000.00","46,808,000.00","43,021,000.00","16,767,000.00","18,197,000.00","21,794,000.00","31,308,000.00","34,950,000.00", 
AZV,Azure Healthcare Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , ,0.00,"879,000.00","2,205,000.00","1,715,000.00","2,349,000.00","-8,864,000.00","-9,681,000.00","-11,050,000.00","744,000.00","1,040,000.00","3,865,000.00","1,093,000.00", 
AZV,Azure Healthcare Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , ,"7,374,193.00","9,477,000.00","12,441,000.00","35,283,000.00","35,724,000.00","26,547,000.00","16,679,000.00","6,749,000.00","9,464,000.00","10,635,000.00","14,374,000.00","15,537,000.00", 
AZV,Azure Healthcare Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , ,"8,562,869.00","11,607,000.00","18,760,000.00","44,671,000.00","48,441,000.00","39,062,000.00","28,491,000.00","12,602,000.00","15,351,000.00","16,724,000.00","21,298,000.00","23,393,000.00", 
BDM,BioDiem Ltd,Annual Ratio Analysis - ROE, , , , , , , , , , , , , ,9.83%,-33.24%,-56.67%,-106.10%,-143.56%,-82.40%,-37.96%,-81.60%,-104.81%,-67.26%,-216.98%, , , 
BDM,BioDiem Ltd,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , ,"5,262,198.00",--,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00, , , 
BDM,BioDiem Ltd,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , ,"1,422,481.00","-3,233,256.00","-4,264,383.00","-2,847,618.00","-3,851,867.00","-4,470,506.00","-1,513,742.00","-3,391,630.00","-2,618,933.00","-1,009,384.00","-2,316,160.00", , , 
BDM,BioDiem Ltd,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , ,"14,478,118.00","9,726,075.00","5,461,692.00","2,683,887.00","2,683,051.00","5,425,190.00","3,987,394.00","4,156,418.00","2,498,730.00","1,500,768.00","1,067,446.00", , , 
BDM,BioDiem Ltd,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , ,"14,682,487.00","9,903,583.00","5,832,168.00","2,921,022.00","2,997,451.00","5,676,976.00","4,061,829.00","4,320,521.00","2,683,211.00","1,760,628.00","1,355,551.00", , , 
BGN,BresaGen Limited,Annual Ratio Analysis - ROE, , , , , , ,--,--,-13.45%,-212.54%,-15.83%,-14.96%,-37.22%,-54.43%,-146.04%,-351.11%,-7.70%, , , , , , , , , , 
BGN,BresaGen Limited,Annual Profit and Loss - Operating Revenue, , , , , , ,"3,493,000.00","3,225,000.00","3,227,000.00","613,838.00","909,000.00","3,172,000.00","2,220,000.00","2,626,000.00","2,386,000.00","1,887,000.00","5,563,000.00", , , , , , , , , , 
BGN,BresaGen Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , ,"-1,383,000.00","-1,816,000.00","-2,492,000.00","-2,194,939.00","-3,342,000.00","-6,469,000.00","-11,861,000.00","-13,946,000.00","-10,658,000.00","-8,093,000.00","-291,000.00", , , , , , , , , , 
BGN,BresaGen Limited,Annual Balance Sheet - Total Equity, , , , , , ,--,--,"18,523,000.00","1,032,729.00","21,116,000.00","43,231,000.00","31,866,000.00","17,956,000.00","7,298,000.00","2,305,000.00","3,779,000.00", , , , , , , , , , 
BGN,BresaGen Limited,Annual Balance Sheet - Total Assets, , , , , , ,--,--,"13,282,000.00","6,478,652.00","22,532,000.00","44,732,000.00","34,472,000.00","27,791,000.00","17,928,000.00","12,285,000.00","12,095,000.00", , , , , , , , , , 
BIT,Biotron Limited,Annual Ratio Analysis - ROE, , , , , , , , , , ,0.00%,-12.69%,-19.65%,-47.36%,-94.90%,-82.66%,-48.91%,-238.49%,-102.10%,-211.06%,-109.01%,-79.47%,-28.76%,-86.05%,-222.11%,-65.73%, 
BIT,Biotron Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , ,--,"13,060.00","62,740.00",--,0.00,0.00,"794,862.00","402,457.00",0.00,0.00,--,0.00,0.00,0.00,0.00,0.00, 
BIT,Biotron Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , ,0.00,"-1,279,663.00","-1,667,894.00","-2,728,701.00","-2,805,115.00","-1,883,575.00","-2,198,973.00","-3,234,004.00","-1,882,093.00","-1,776,099.00","-1,872,244.00","-1,907,527.00","-2,378,052.00","-3,850,745.00","-3,085,814.00","-2,723,221.00", 
BIT,Biotron Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , ,"42,221,000.00","10,080,657.00","8,489,713.00","5,761,012.00","2,955,897.00","2,278,730.00","4,495,848.00","1,356,015.00","1,843,377.00","841,506.00","1,717,558.00","2,400,300.00","8,269,547.00","4,475,110.00","1,389,296.00","4,143,026.00", 
BIT,Biotron Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , ,"42,221,000.00","10,192,106.00","8,632,608.00","5,909,088.00","3,109,230.00","2,428,608.00","4,813,956.00","1,519,038.00","2,267,322.00","1,063,838.00","1,857,845.00","2,644,620.00","8,461,726.00","4,866,189.00","1,863,940.00","4,616,202.00", 
BLT,Benitec Biopharma Limited,Annual Ratio Analysis - ROE, , , , , , , ,-33.53%,-50.83%,-65.01%,-241.12%,-154.89%,-7.43%,-116.87%,-32.31%,-58.53%,-789.36%,-55.12%,-204.32%,-215.07%,378.34%,-55.22%,-154.44%,-309.94%,-20.99%,-48.20%, 
BLT,Benitec Biopharma Limited,Annual Profit and Loss - Operating Revenue, , , , , , , ,--,"115,673.00","602,391.00","681,136.00","239,968.00","333,938.00","673,029.00","91,559.00","923,200.00","3,690,112.00","402,589.00",0.00,0.00,0.00,0.00,0.00,0.00,"276,824.00","307,000.00", 
BLT,Benitec Biopharma Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , ,"-793,760.00","-848,469.00","-2,105,226.00","-1,110,000.00","-1,539,561.00","-1,124,036.00","-8,229,667.00","-7,827,227.00","-14,562,565.00","-7,676,840.00","-2,746,753.00","-2,774,690.00","-2,470,671.00","-4,640,671.00","-3,534,874.00","-4,112,617.00","-3,487,960.00","-7,039,109.00","-11,509,000.00", 
BLT,Benitec Biopharma Limited,Annual Balance Sheet - Total Equity, , , , , , , ,"2,367,661.00","1,669,192.00","1,574,211.00","460,361.00","993,995.00","15,132,693.00","6,903,026.00","24,226,535.00","24,879,189.00","62,637.00","3,643,393.00","1,358,035.00","1,148,784.00","-696,674.00","5,204,348.00","2,662,914.00","640,340.00","33,540,522.00","23,878,000.00", 
BLT,Benitec Biopharma Limited,Annual Balance Sheet - Total Assets, , , , , , , ,"2,538,195.00","1,792,822.00","2,379,621.00","2,456,012.00","2,380,398.00","17,227,965.00","14,325,483.00","26,942,104.00","28,455,577.00","2,285,384.00","5,216,052.00","2,020,228.00","1,997,948.00","1,037,162.00","6,865,358.00","3,251,206.00","1,750,710.00","34,495,202.00","25,520,000.00", 
BNC,Bioniche Life Sciences Inc,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , ,0.00%,-70.06%,-153.59%,269.42%, , , 
BNC,Bioniche Life Sciences Inc,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , ,--,"26,341,322.00","28,516,357.00","84,544.00", , , 
BNC,Bioniche Life Sciences Inc,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , ,0.00,"-14,761,767.00","-23,137,555.00","-31,387,771.00", , , 
BNC,Bioniche Life Sciences Inc,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , ,"39,991,087.00","21,071,325.00","15,064,090.00","-12,931,230.00", , , 
BNC,Bioniche Life Sciences Inc,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , ,"88,612,967.00","67,029,550.00","78,584,273.00","63,411,691.00", , , 
BNO,Bionomics Limited,Annual Ratio Analysis - ROE, , , , , , , , , ,61.83%,-28.03%,-32.19%,-43.05%,-67.62%,-40.02%,-43.38%,-49.30%,-24.01%,-22.22%,-36.71%,-32.26%,-32.60%,-12.11%,-24.15%,7.15%,-54.71%, 
BNO,Bionomics Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , ,0.00,--,0.00,"1,611,599.00","1,028,243.00",0.00,"295,552.00","652,375.00","817,295.00","1,125,995.00","3,610,495.00","2,993,308.00","3,183,179.00","1,126,113.00","1,637,207.00","19,142,065.00","6,629,113.00", 
BNO,Bionomics Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , ,"-337,000.00","-1,418,874.00","-3,279,252.00","-3,489,730.00","-4,540,955.00","-3,574,582.00","-4,632,314.00","-5,396,950.00","-5,449,798.00","-4,783,917.00","-6,862,299.00","-8,214,082.00","-9,356,497.00","-3,136,238.00","-10,001,350.00","3,206,616.00","-16,949,405.00", 
BNO,Bionomics Limited,Annual Balance Sheet - Total Equity, , , , , , , , , ,"-545,000.00","5,062,021.00","10,186,951.00","9,988,858.00","6,715,090.00","8,930,891.00","10,679,038.00","10,946,278.00","22,698,596.00","21,527,425.00","18,694,568.00","25,465,888.00","28,699,180.00","25,899,117.00","41,406,983.00","44,818,607.00","31,965,825.00", 
BNO,Bionomics Limited,Annual Balance Sheet - Total Assets, , , , , , , , , ,"213,000.00","5,307,946.00","10,829,271.00","15,838,595.00","12,570,687.00","14,961,612.00","17,049,593.00","19,714,759.00","30,820,997.00","28,313,400.00","24,724,686.00","31,514,471.00","34,308,899.00","31,102,188.00","53,611,092.00","65,060,617.00","69,131,715.00", 
BOT,Botanix Pharmaceuticals Ltd,Annual Ratio Analysis - ROE,0.51%,10.06%,10.28%,7.58%,19.03%,15.88%,11.20%,-25.78%,-37.54%,-94.83%,-30.10%,-6.20%,-31.04%,-52.80%,-26.53%,-84.27%,-125.11%,-117.96%,-219.68%,-346.74%,219.59%,68.11%,67.19%,73.96%,-50.41%,-42.92%, 
BOT,Botanix Pharmaceuticals Ltd,Annual Profit and Loss - Operating Revenue,"21,000,000.00","25,515,000.00","26,824,000.00","33,084,000.00","45,027,000.00","66,645,000.00","41,329,000.00","35,061,000.00","34,895,000.00","25,377,000.00","9,143,000.00",0.00,"369,379.00","925,374.00","457,505.00",0.00,0.00,--,--,--,--,--,--,--,0.00,--, 
BOT,Botanix Pharmaceuticals Ltd,Annual Profit and Loss - Reported NPAT After Abnorma,"-210,000.00","961,000.00","-1,766,000.00","1,875,000.00","5,155,000.00","6,125,000.00","4,244,000.00","-12,806,000.00","-17,155,000.00","-7,581,000.00","-3,172,000.00","-353,018.00","-1,409,920.00","-1,398,571.00","-958,586.00","-29,766,350.00","-2,782,476.00","-3,416,963.00","-2,825,253.00","-3,043,463.00","-3,945,207.00","-1,519,744.00","-1,568,030.00","-1,849,884.00","-1,131,036.00","-1,014,541.00", 
BOT,Botanix Pharmaceuticals Ltd,Annual Balance Sheet - Total Equity,"11,961,000.00","12,875,000.00","11,406,000.00","18,346,000.00","26,044,000.00","38,440,000.00","37,913,000.00","32,046,000.00","15,752,000.00","8,084,000.00","5,150,000.00","5,694,532.00","4,047,275.00","2,648,704.00","2,244,515.00","3,456,604.00","2,223,949.00","2,896,755.00","1,286,083.00","877,740.00","-1,796,608.00","-2,231,289.00","-2,333,643.00","-2,501,176.00","2,243,523.00","1,228,982.00", 
BOT,Botanix Pharmaceuticals Ltd,Annual Balance Sheet - Total Assets,"25,584,000.00","27,413,000.00","25,921,000.00","38,030,000.00","48,565,000.00","68,158,000.00","57,046,000.00","50,262,000.00","30,362,000.00","16,149,000.00","5,268,000.00","5,863,868.00","4,505,153.00","2,937,994.00","2,426,130.00","3,679,849.00","2,507,843.00","3,500,229.00","2,367,918.00","2,016,714.00","58,595.00","42,549.00","17,857.00","8,158.00","2,553,369.00","1,320,565.00", 
BPH,BPH Energy Ltd,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , ,-24.81%,-22.35%,-33.85%,-35.23%,-225.56%,-7.45%,-0.43%,-1.51%,-1.18%,-1.10%,7.06%, 
BPH,BPH Energy Ltd,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , ,--,"10,000.00","436,183.00",0.00,"134,335.00","164,645.00","138,525.00",0.00,0.00,0.00,--, 
BPH,BPH Energy Ltd,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , ,"-727,639.00","-986,613.00","-1,339,391.00","-1,178,893.00","-2,240,611.00","-234,457.00","-267,884.00","-764,478.00","-594,908.00","-1,266,079.00","-26,490,513.00", 
BPH,BPH Energy Ltd,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , ,"2,932,527.00","4,413,773.00","3,802,187.00","3,338,480.00","716,488.00","15,697,202.00","50,893,918.00","48,789,149.00","48,197,297.00","46,947,298.00","20,739,418.00", 
BPH,BPH Energy Ltd,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , ,"2,960,739.00","5,032,042.00","4,634,886.00","4,058,522.00","1,515,626.00","16,637,216.00","56,329,812.00","54,192,811.00","53,328,510.00","52,018,922.00","22,485,897.00", 
BRC,Brain Resource Limited,Annual Ratio Analysis - ROE, , , , , , , , , , ,0.00%,-4.76%,-22.90%,-19.42%,-16.39%,-14.00%,-14.59%,-16.60%,-20.49%,36.17%,15.96%,1.70%,-8.57%,-8.34%,-11.60%,-11.58%, 
BRC,Brain Resource Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , ,--,--,0.00,"246,188.00","505,459.00","1,376,040.00","1,316,519.00","2,386,393.00","3,249,020.00","6,318,696.00","7,618,121.00","5,534,104.00","3,719,554.00","3,225,663.00","2,531,438.00","2,637,973.00", 
BRC,Brain Resource Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , ,0.00,"-30,155.00","-1,351,996.00","-1,326,032.00","-1,498,646.00","-1,122,980.00","-1,438,283.00","-1,454,578.00","-1,505,014.00","4,195,463.00","2,213,505.00","269,487.00","388,425.00","-1,459,681.00","-1,997,880.00","-2,595,316.00", 
BRC,Brain Resource Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , ,"6,344,256.00","1,268,141.00","5,904,679.00","6,828,647.00","9,142,027.00","8,019,054.00","9,855,965.00","8,761,738.00","7,343,958.00","11,598,690.00","13,867,300.00","15,840,227.00","17,939,531.00","17,511,850.00","17,227,845.00","22,421,206.00", 
BRC,Brain Resource Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , ,"6,344,256.00","2,256,546.00","6,348,142.00","7,104,798.00","9,472,968.00","8,702,044.00","10,471,240.00","28,532,506.00","26,640,515.00","29,475,798.00","28,658,010.00","29,187,233.00","35,874,637.00","33,315,436.00","32,666,458.00","38,051,296.00", 
BTA,Biota Holdings Limited,Annual Ratio Analysis - ROE,-13.21%,-5.07%,2.03%,-1.86%,3.60%,-8.84%,-9.49%,-16.34%,-15.95%,-16.35%,6.25%,-1.64%,-27.03%,-42.12%,-33.93%,-55.95%,-24.11%,28.21%,-10.25%,18.74%,11.78%,-39.76%,-32.24%, , , , 
BTA,Biota Holdings Limited,Annual Profit and Loss - Operating Revenue,0.00,"276,000.00","1,465,000.00","328,000.00","2,528,000.00","194,000.00","57,000.00",0.00,"24,000.00","303,000.00","1,728,000.00",0.00,"8,464,000.00","3,449,000.00","5,286,000.00","1,811,000.00","6,420,000.00","13,534,000.00","15,549,000.00","25,239,000.00","1,362,000.00","627,000.00","10,699,000.00", , , , 
BTA,Biota Holdings Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-304,000.00","-111,000.00","-1,679,000.00","-279,000.00","-31,827,000.00","-1,643,000.00","-2,155,000.00","-4,101,000.00","-6,460,000.00","-5,966,000.00","2,519,000.00","-718,000.00","-9,338,000.00","-11,002,000.00","-8,112,000.00","-14,831,000.00","-11,306,000.00","20,180,000.00","-6,489,000.00","38,181,000.00","16,235,000.00","-28,090,000.00","-18,814,000.00", , , , 
BTA,Biota Holdings Limited,Annual Balance Sheet - Total Equity,"2,301,000.00","2,190,000.00","5,892,000.00","10,760,000.00","9,487,000.00","18,040,000.00","22,707,000.00","25,099,000.00","40,507,000.00","36,484,000.00","40,275,000.00","40,288,000.00","30,950,000.00","21,588,000.00","21,620,000.00","26,036,000.00","46,898,000.00","71,535,000.00","63,300,000.00","97,032,000.00","104,896,000.00","76,856,000.00","58,353,000.00", , , , 
BTA,Biota Holdings Limited,Annual Balance Sheet - Total Assets,"2,768,000.00","2,626,000.00","7,079,000.00","11,083,000.00","21,905,000.00","18,669,000.00","23,276,000.00","25,557,000.00","41,214,000.00","37,469,000.00","43,761,000.00","41,441,000.00","35,097,000.00","25,226,000.00","26,175,000.00","30,427,000.00","57,559,000.00","92,454,000.00","89,258,000.00","111,629,000.00","122,167,000.00","83,561,000.00","68,084,000.00", , , , 
BXN,Bioxyne Limited,Annual Ratio Analysis - ROE, , , , , , , , , , ,-11.47%,-34.45%,-112.83%,-527.39%,-341.97%,"-2,103.51%",-457.39%,-806.40%,213.63%,-488.83%,65.00%,0.85%,-4.64%,"2,937.95%",24.37%,15.66%, 
BXN,Bioxyne Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , ,--,--,"261,472.00","1,408,449.00","1,090,995.00","1,388,812.00","1,684,644.00","785,996.00","674,563.00","1,103,288.00","751,897.00","984,982.00","123,275.00","880,497.00","2,305,227.00","1,492,109.00", 
BXN,Bioxyne Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , ,"-1,426,259.00","-3,109,026.00","-4,803,987.00","-5,103,987.00","-4,337,044.00","-3,933,058.00","-1,877,981.00","-1,763,157.00","-1,331,146.00","-210,906.00","80,144.00","1,054.00","-1,784,131.00","-6,191,113.00","1,190,827.00","201,039.00", 
BXN,Bioxyne Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , ,"12,431,420.00","9,024,579.00","4,257,592.00","967,783.00","1,175,273.00","186,976.00","410,583.00","218,646.00","-623,122.00","43,145.00","123,289.00","124,343.00","5,887,883.00","-210,729.00","1,071,915.00","1,283,666.00", 
BXN,Bioxyne Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , ,"12,542,934.00","9,563,655.00","4,897,525.00","1,980,479.00","2,378,749.00","1,301,182.00","1,073,320.00","610,132.00","482,420.00","485,629.00","298,583.00","220,733.00","6,910,089.00","702,220.00","1,499,172.00","1,513,037.00", 
CAJ,Capitol Health Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , ,-95.89%,-144.42%,0.79%,-7.48%,3.66%,4.76%,8.72%,10.64%,18.73%,12.60%, 
CAJ,Capitol Health Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , ,"154,551.00","1,512,114.00","13,413,336.00","28,284,354.00","35,405,104.00","45,530,139.00","51,541,024.00","61,618,316.00","88,761,236.00","110,220,107.00", 
CAJ,Capitol Health Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , ,"-391,153.00","-966,327.00","214,521.00","-1,018,218.00","705,232.00","962,009.00","2,134,225.00","3,627,361.00","7,232,870.00","3,863,653.00", 
CAJ,Capitol Health Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , ,"1,631,749.00","669,120.00","18,681,976.00","17,663,858.00","19,255,855.00","20,211,755.00","24,464,973.00","34,105,286.00","38,664,771.00","93,883,665.00", 
CAJ,Capitol Health Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , ,"2,825,053.00","2,038,543.00","29,898,244.00","27,298,943.00","32,184,694.00","33,713,232.00","37,013,828.00","57,219,667.00","62,168,150.00","191,524,690.00", 
CDY,Cellmid Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , ,-50.06%,-297.12%,-436.76%,-451.44%,-47.03%,-111.37%,-93.63%,-28.65%,-26.02%,-88.43%, 
CDY,Cellmid Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , ,0.00,0.00,0.00,0.00,0.00,"31,418.00","141,199.00","542,055.00","2,196,613.00","1,842,804.00", 
CDY,Cellmid Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , ,"-2,760,092.00","-4,554,782.00","-2,688,804.00","-3,334,546.00","-1,339,948.00","-2,269,637.00","-1,972,483.00","-1,541,307.00","-1,480,836.00","-3,337,348.00", 
CDY,Cellmid Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , ,"5,513,521.00","1,532,962.00","615,630.00","738,649.00","2,848,939.00","2,037,968.00","2,089,484.00","5,305,157.00","5,663,726.00","3,773,909.00", 
CDY,Cellmid Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , ,"6,114,679.00","4,715,095.00","2,601,433.00","1,222,453.00","3,218,251.00","2,821,872.00","2,518,262.00","5,993,719.00","6,454,425.00","6,147,547.00", 
CGS,Cogstate Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , ,-20.82%,-38.19%,-67.89%,-51.77%,-104.39%,-38.77%,28.96%,23.32%,-13.43%,23.99%,-22.22%,-29.88%,-28.65%, 
CGS,Cogstate Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , ,"302,378.00","192,094.00","1,025,770.00","2,075,939.00","2,499,856.00","3,783,487.00","8,387,185.00","9,484,958.00","8,133,258.00","12,014,411.00","12,462,756.00","12,265,432.00","16,073,369.00", 
CGS,Cogstate Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , ,"-1,311,795.00","-1,833,827.00","-2,224,148.00","-1,602,918.00","-1,653,257.00","-746,496.00","1,429,634.00","1,637,615.00","-846,206.00","2,451,962.00","-1,957,233.00","-3,888,395.00","-5,062,222.00", 
CGS,Cogstate Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , ,"6,299,513.00","6,054,606.00","3,830,458.00","3,096,056.00","1,583,702.00","1,925,329.00","4,936,178.00","7,020,957.00","6,303,131.00","10,222,314.00","8,809,317.00","13,015,259.00","10,114,938.00", 
CGS,Cogstate Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , ,"6,586,814.00","6,279,175.00","4,390,180.00","3,811,751.00","2,357,175.00","2,777,954.00","6,473,111.00","8,644,286.00","7,858,207.00","11,906,401.00","11,054,227.00","15,113,013.00","14,305,081.00", 
CLS,CL Asset Holdings Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , ,99.99%,0.48%,0.54%,0.75%,-1.90%,2.19%,-0.39%,-1.82%,0.98%, , , , 
CLS,CL Asset Holdings Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , ,"96,175.00","1,973,087.00",17.00,"2,476,214.00","900,070.00","15,566,812.00","17,136,991.00","13,848,153.00","23,572,199.00", , , , 
CLS,CL Asset Holdings Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , ,"-22,434.00","112,364.00","129,870.00","179,503.00","-448,341.00","-3,229,670.00","-119,509.00","-347,501.00","225,568.00", , , , 
CLS,CL Asset Holdings Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , ,"-22,437.00","23,258,912.00","23,876,925.00","24,057,628.00","23,610,487.00","20,587,017.00","20,467,508.00","20,120,057.00","20,345,625.00", , , , 
CLS,CL Asset Holdings Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , ,"5,213,772.00","23,584,996.00","23,950,141.00","24,620,625.00","24,133,845.00","21,327,661.00","21,527,551.00","20,648,872.00","22,193,652.00", , , , 
CLV,Clover Corporation Limited,Annual Ratio Analysis - ROE, , , , , , , ,--,--,--,-17.28%,-21.90%,-19.80%,2.06%,6.60%,3.51%,2.05%,2.79%,15.34%,10.90%,-3.77%,16.40%,18.70%,18.75%,3.21%,0.34%, 
CLV,Clover Corporation Limited,Annual Profit and Loss - Operating Revenue, , , , , , , ,"4,794,000.00","7,832,000.00","9,338,000.00","8,066,000.00","8,840,000.00","9,678,000.00","11,444,000.00","17,230,000.00","14,359,000.00","17,394,000.00","16,536,000.00","21,619,000.00","21,121,000.00","34,937,000.00","35,635,000.00","38,387,000.00","44,098,000.00","27,190,000.00","29,921,000.00", 
CLV,Clover Corporation Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , ,"-684,000.00","-65,000.00","-154,000.00","-299,000.00","-4,845,000.00","-5,572,000.00","604,000.00","1,503,000.00","938,000.00","678,000.00","907,000.00","4,375,000.00","3,082,000.00","-967,000.00","4,603,000.00","4,371,000.00","6,078,000.00","967,000.00","100,000.00", 
CLV,Clover Corporation Limited,Annual Balance Sheet - Total Equity, , , , , , , ,--,--,--,"26,862,000.00","22,126,000.00","16,554,000.00","17,358,000.00","19,013,000.00","22,225,000.00","22,761,000.00","23,668,000.00","26,957,000.00","28,274,000.00","25,627,000.00","28,070,000.00","29,900,000.00","32,409,000.00","30,134,000.00","29,388,000.00", 
CLV,Clover Corporation Limited,Annual Balance Sheet - Total Assets, , , , , , , ,--,--,--,"28,670,000.00","26,240,000.00","20,648,000.00","20,938,000.00","22,203,000.00","24,594,000.00","25,398,000.00","26,367,000.00","31,468,000.00","31,581,000.00","31,746,000.00","32,340,000.00","38,573,000.00","41,484,000.00","39,498,000.00","36,560,000.00", 
CMP,Compumedics Limited,Annual Ratio Analysis - ROE, , , , , , , , ,--,--,-0.32%,6.13%,-6.28%,-6.48%,17.19%,-41.70%,-23.75%,1.78%,8.89%,23.76%,3.39%,0.64%,-30.70%,-17.83%,9.92%,17.48%, 
CMP,Compumedics Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , ,"7,443,000.00","9,033,000.00","9,001,000.00","16,639,451.00","19,747,259.00","32,056,143.00","33,963,418.00","38,157,067.00","38,757,000.00","36,787,000.00","38,576,000.00","38,970,000.00","32,361,000.00","31,262,000.00","27,915,000.00","27,150,000.00","29,068,000.00","33,495,000.00", 
CMP,Compumedics Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , ,"788,000.00","1,215,000.00","-95,000.00","1,971,000.00","-1,897,773.00","-18,556,660.00","2,396,683.00","-3,897,660.00","-1,595,000.00","123,000.00","756,000.00","2,727,000.00","414,000.00","81,000.00","-2,829,000.00","-1,489,000.00","909,000.00","1,970,000.00", 
CMP,Compumedics Limited,Annual Balance Sheet - Total Equity, , , , , , , , ,--,--,"30,067,000.00","32,163,292.00","30,226,035.00","11,675,217.00","13,945,095.00","9,347,435.00","6,717,000.00","6,914,000.00","8,507,000.00","11,479,000.00","12,196,000.00","12,755,000.00","9,215,000.00","8,353,000.00","9,162,000.00","11,268,000.00", 
CMP,Compumedics Limited,Annual Balance Sheet - Total Assets, , , , , , , , ,--,--,"34,459,000.00","39,197,402.00","43,624,137.00","23,762,401.00","24,509,206.00","24,549,453.00","22,175,000.00","19,251,000.00","20,142,000.00","21,458,000.00","21,811,000.00","23,104,000.00","19,875,000.00","19,087,000.00","19,522,000.00","21,675,000.00", 
CMQ,Chemeq Limited,Annual Ratio Analysis - ROE, , , , , , , ,--,-5.35%,-89.55%,-24.09%,-33.46%,-43.09%,-33.80%,-15.56%,-193.47%,"-2,316.68%", , , , , , , , , , 
CMQ,Chemeq Limited,Annual Profit and Loss - Operating Revenue, , , , , , , ,--,"1,159.00",0.00,--,"2,069.00",0.00,30.00,--,"154,000.00","1,785,000.00", , , , , , , , , , 
CMQ,Chemeq Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , ,"-245,394.00","-191,716.00","-420,953.00","-1,350,757.00","-1,432,502.00","-3,540,337.00","-7,272,893.00","-9,954,809.00","-60,670,000.00","-31,808,000.00", , , , , , , , , , 
CMQ,Chemeq Limited,Annual Balance Sheet - Total Equity, , , , , , , ,--,"3,585,909.00","470,086.00","5,607,207.00","4,280,708.00","8,215,997.00","21,447,998.00","63,979,138.00","31,359,000.00","1,373,000.00", , , , , , , , , , 
CMQ,Chemeq Limited,Annual Balance Sheet - Total Assets, , , , , , , ,--,"3,348,968.00","515,325.00","5,849,334.00","4,689,400.00","8,872,404.00","28,571,177.00","75,824,147.00","74,388,000.00","65,298,000.00", , , , , , , , , , 
COH,Cochlear Limited,Annual Ratio Analysis - ROE, , , , , , ,58.86%,46.38%,41.39%,47.95%,57.33%,56.18%,57.96%,48.64%,35.45%,36.19%,38.56%,38.39%,36.08%,35.84%,35.40%,34.94%,41.09%,37.14%,28.47%,41.04%, 
COH,Cochlear Limited,Annual Profit and Loss - Operating Revenue, , , , , , ,"72,275,000.00","71,913,000.00","91,698,000.00","127,181,000.00","144,158,000.00","220,111,000.00","255,511,000.00","288,576,000.00","252,487,000.00","318,063,000.00","431,567,000.00","542,886,000.00","580,442,000.00","711,827,000.00","696,151,000.00","738,365,000.00","704,555,000.00","715,030,000.00","804,936,000.00","925,630,000.00", 
COH,Cochlear Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , ,"10,863,000.00","10,809,000.00","13,285,000.00","16,327,000.00","20,167,000.00","31,178,000.00","40,110,000.00","58,213,000.00","36,134,000.00","53,352,000.00","78,225,000.00","97,676,000.00","115,234,000.00","130,540,000.00","155,152,000.00","180,114,000.00","56,803,000.00","132,563,000.00","93,709,000.00","145,840,000.00", 
COH,Cochlear Limited,Annual Balance Sheet - Total Equity, , , , , , ,"18,456,000.00","23,307,000.00","32,095,000.00","34,050,000.00","42,829,000.00","55,495,000.00","75,416,000.00","119,687,000.00","145,529,000.00","165,870,000.00","209,778,000.00","260,809,000.00","319,341,000.00","364,234,000.00","438,308,000.00","503,283,000.00","384,880,000.00","356,913,000.00","329,205,000.00","355,386,000.00", 
COH,Cochlear Limited,Annual Balance Sheet - Total Assets, , , , , , ,"48,242,000.00","51,287,000.00","69,113,000.00","82,939,000.00","93,771,000.00","129,048,000.00","160,428,000.00","230,579,000.00","264,539,000.00","505,747,000.00","545,924,000.00","585,737,000.00","607,916,000.00","679,373,000.00","751,719,000.00","741,047,000.00","702,542,000.00","764,501,000.00","789,036,000.00","869,056,000.00", 
CSL,CSL Limited,Annual Ratio Analysis - ROE, , , ,8.81%,6.73%,7.41%,8.49%,9.68%,10.48%,11.42%,6.86%,8.93%,9.72%,5.49%,3.69%,14.31%,17.63%,22.98%,25.01%,18.67%,24.98%,25.81%,28.66%,40.45%,41.33%,49.40%, 
CSL,CSL Limited,Annual Profit and Loss - Operating Revenue, , , ,"167,696,000.00","192,996,000.00","250,430,000.00","281,102,016.00","305,003,008.00","353,491,008.00","413,471,008.00","450,598,000.00","843,308,000.00","1,336,412,000.00","1,303,034,000.00","1,654,349,000.00","2,755,792,000.00","2,848,908,000.00","3,172,397,000.00","3,556,662,000.00","4,640,278,000.00","4,473,926,000.00","4,196,456,000.00","4,444,300,000.00","5,357,520,215.00","5,663,269,639.00","7,107,552,083.00", 
CSL,CSL Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , ,"13,841,000.00","18,046,000.00","24,542,000.00","28,995,000.00","35,152,000.00","44,854,000.00","47,382,000.00","54,402,000.00","78,241,000.00","123,808,000.00","70,423,000.00","219,625,000.00","546,518,000.00","117,357,000.00","539,299,000.00","701,802,000.00","1,145,932,000.00","1,052,901,000.00","940,601,000.00","982,600,000.00","1,311,374,663.00","1,387,473,460.00","1,795,572,916.00", 
CSL,CSL Limited,Annual Balance Sheet - Total Equity, , , ,"156,827,000.00","316,576,000.00","331,248,000.00","341,556,000.00","363,044,000.00","390,262,000.00","414,921,992.00","793,580,000.00","875,958,000.00","1,273,131,000.00","1,282,698,000.00","2,074,042,000.00","2,074,512,000.00","1,989,804,000.00","2,268,849,000.00","2,806,125,000.00","5,462,895,000.00","4,215,194,000.00","3,644,360,000.00","3,428,300,000.00","3,241,832,884.00","3,356,687,898.00","3,576,692,708.00", 
CSL,CSL Limited,Annual Balance Sheet - Total Assets, , , ,"229,155,000.00","427,907,000.00","472,339,000.00","474,685,992.00","511,117,992.00","523,762,000.00","561,538,000.00","946,479,000.00","1,771,810,000.00","2,312,122,000.00","2,219,538,000.00","3,875,383,000.00","3,874,296,000.00","4,186,085,000.00","4,199,694,000.00","4,694,964,000.00","7,366,815,000.00","5,711,044,000.00","5,067,997,000.00","5,819,300,000.00","6,442,587,601.00","6,664,225,053.00","8,334,635,416.00", 
CST,Cellestis Limited,Annual Ratio Analysis - ROE, , , , , , , , , , ,0.00%,-5.80%,-19.40%,-27.72%,-44.04%,-17.25%,-24.63%,-17.41%,14.61%,37.03%,30.22%, , , , , , 
CST,Cellestis Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , ,--,"26,408.00","203,380.00","449,076.00","971,603.00","1,897,665.00","5,279,000.00","10,654,000.00","18,829,000.00","34,461,000.00","40,383,000.00", , , , , , 
CST,Cellestis Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , ,-8.00,"-293,000.00","-1,640,539.00","-2,374,941.00","-2,648,992.00","-3,068,638.00","-3,622,000.00","-2,277,000.00","2,256,000.00","8,232,000.00","8,253,000.00", , , , , , 
CST,Cellestis Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , ,"10,431,992.00","10,102,927.00","8,456,493.00","8,566,686.00","6,014,992.00","17,793,471.00","14,705,000.00","13,082,000.00","15,443,000.00","22,231,000.00","27,312,000.00", , , , , , 
CST,Cellestis Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , ,"10,454,409.00","10,279,445.00","8,655,833.00","8,973,968.00","6,473,232.00","19,114,692.00","16,749,000.00","15,852,000.00","19,592,000.00","29,589,000.00","35,656,000.00", , , , , , 
CTE,Cryosite Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , ,-25.46%,-36.23%,-42.24%,-31.26%,-25.03%,3.60%,24.70%,10.35%,0.17%,0.11%,7.13%,18.66%,19.95%,8.24%,12.84%, 
CTE,Cryosite Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , ,"2,427.00","460,919.00","1,902,666.00","2,092,836.00","2,955,056.00","4,097,100.00","4,722,572.00","6,467,582.00","6,158,392.00","5,968,601.00","6,432,973.00","7,757,568.00","8,497,803.00","9,171,014.00","9,594,375.00", 
CTE,Cryosite Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , ,"-984,991.00","-1,224,325.00","-1,170,000.00","-950,038.00","-620,311.00","101,374.00","922,744.00","447,059.00","7,249.00","4,612.00","334,305.00","1,022,479.00","1,249,961.00","505,602.00","455,170.00", 
CTE,Cryosite Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , ,"3,868,363.00","3,889,894.00","2,769,834.00","3,038,890.00","2,477,872.00","2,813,290.00","3,735,965.00","4,321,088.00","4,340,310.00","4,354,687.00","4,691,383.00","5,480,664.00","6,264,228.00","6,135,137.00","3,544,435.00", 
CTE,Cryosite Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , ,"4,048,063.00","4,358,889.00","3,524,617.00","4,402,858.00","4,661,088.00","5,113,844.00","6,397,666.00","7,248,518.00","7,354,556.00","7,682,293.00","8,625,134.00","9,770,324.00","11,362,227.00","11,633,480.00","9,122,755.00", 
CUV,Clinuvel Pharmaceuticals Limited,Annual Ratio Analysis - ROE, , , , , , , , , , ,-2.44%,-11.58%,-30.47%,-52.81%,-85.72%,-147.96%,-76.98%,-14.03%,-28.29%,-41.49%,-43.60%,-75.72%,-72.83%,-50.72%,-35.82%,-92.94%, 
CUV,Clinuvel Pharmaceuticals Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , ,--,--,--,--,--,"124,622.00","754,846.00","283,308.00",--,0.00,0.00,"1,041,021.00","722,801.00","1,552,998.00","2,200,092.00","2,911,553.00", 
CUV,Clinuvel Pharmaceuticals Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , ,"-374,150.00","-1,557,582.00","-3,141,224.00","-3,976,770.00","-7,589,730.00","-11,029,031.00","-10,768,981.00","-9,176,123.00","-14,655,791.00","-15,372,907.00","-11,521,040.00","-11,409,089.00","-9,767,228.00","-6,802,823.00","-5,525,889.00","-10,414,376.00", 
CUV,Clinuvel Pharmaceuticals Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , ,"15,317,497.00","13,450,758.00","10,309,534.00","7,530,715.00","8,854,501.00","7,454,262.00","13,988,832.00","65,391,816.00","51,814,516.00","37,051,184.00","26,426,163.00","16,408,101.00","13,637,336.00","13,839,290.00","15,427,732.00","11,205,291.00", 
CUV,Clinuvel Pharmaceuticals Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , ,"15,441,036.00","13,769,023.00","10,520,362.00","8,066,166.00","10,246,943.00","10,055,643.00","17,070,859.00","67,824,745.00","54,970,758.00","41,613,762.00","29,506,783.00","20,165,457.00","15,995,277.00","15,814,791.00","17,153,568.00","13,643,875.00", 
CXD,CathRx Ltd,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , ,0.00%,-25.00%,-89.56%,-44.94%,-109.35%,-63.39%,-109.10%,-462.28%, , , , 
CXD,CathRx Ltd,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , ,--,0.00,0.00,"1,727.00","137,378.00","524,235.00","53,531.00","20,616.00", , , , 
CXD,CathRx Ltd,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , ,0.00,"-2,989,178.00","-5,816,560.00","-10,059,916.00","-13,398,285.00","-10,556,907.00","-8,947,978.00","-8,688,192.00", , , , 
CXD,CathRx Ltd,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , ,"14,570,992.00","11,956,376.00","6,494,915.00","22,383,418.00","12,252,547.00","16,654,818.00","8,201,351.00","1,447,126.00", , , , 
CXD,CathRx Ltd,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , ,"14,794,035.00","12,511,236.00","7,056,557.00","23,923,485.00","14,217,651.00","18,268,230.00","9,840,927.00","3,911,857.00", , , , 
CXS,ChemGenex Pharmaceuticals Ltd,Annual Ratio Analysis - ROE,-54.43%,4.25%,80.86%,21.59%,-16.27%,-6.26%,-5.23%,-5.29%,-11.38%,-38.46%,-32.39%,-65.63%,"1,918.39%",-48.85%,-34.85%,-19.24%,-33.45%,-29.35%,-70.85%,-35.18%,-33.98%, , , , , , 
CXS,ChemGenex Pharmaceuticals Ltd,Annual Profit and Loss - Operating Revenue,0.00,0.00,0.00,0.00,"781,000.00",0.00,0.00,0.00,0.00,"1,436,750.00","2,054,210.00","3,898,401.00","4,402,634.00","4,997,247.00","3,490,459.00","3,631,397.00","1,676,297.00","1,266,210.00",0.00,"990,132.00","17,806,000.00", , , , , , 
CXS,ChemGenex Pharmaceuticals Ltd,Annual Profit and Loss - Reported NPAT After Abnorma,"-5,237,000.00","-4,753,000.00","10,880,000.00","-1,845,000.00","8,030,000.00","3,770,000.00","8,827,739.00","-258,091.00","-5,828,000.00","-12,775,806.00","-9,034,000.00","-3,417,971.00","-7,465,913.00","-1,887,154.00","-5,139,077.00","-4,693,269.00","-10,369,719.00","-11,700,919.00","-6,419,926.00","-25,943,758.00","-6,018,000.00", , , , , , 
CXS,ChemGenex Pharmaceuticals Ltd,Annual Balance Sheet - Total Equity,"-7,621,000.00","-12,374,000.00","-1,494,000.00","-3,339,000.00","4,691,000.00","8,461,000.00","17,289,153.00","24,115,857.00","18,288,000.00","5,513,130.00","13,499,733.00","6,925,209.00","-389,175.00","3,862,864.00","14,745,081.00","24,387,320.00","31,004,909.00","39,869,598.00","24,509,366.00","73,751,454.00","69,206,000.00", , , , , , 
CXS,ChemGenex Pharmaceuticals Ltd,Annual Balance Sheet - Total Assets,"5,778,000.00","842,000.00","3,466,000.00","2,418,000.00","7,806,000.00","12,203,000.00","21,700,293.00","24,333,604.00","18,689,000.00","7,645,356.00","14,320,931.00","8,304,397.00","4,338,539.00","4,310,132.00","16,866,401.00","25,727,496.00","32,965,251.00","42,761,109.00","27,944,777.00","77,044,777.00","71,948,000.00", , , , , , 
CYC,Cyclopharm Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , ,0.00%,10.27%,13.46%,14.68%,3.27%,-6.55%,-6.69%,-147.17%,18.25%,20.52%, 
CYC,Cyclopharm Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , ,--,"11,128,224.00","10,888,269.00","13,112,420.00","9,464,605.00","10,314,506.00","10,743,824.00","11,882,134.00","12,046,797.00","12,582,519.00", 
CYC,Cyclopharm Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , ,0.00,"1,131,239.00","1,757,062.00","2,044,490.00","450,106.00","-956,220.00","-1,044,127.00","-9,640,117.00","4,065,563.00","4,793,047.00", 
CYC,Cyclopharm Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , ,"11,339,680.00","7,342,144.00","13,055,556.00","13,928,641.00","13,766,154.00","14,604,799.00","15,608,433.00","6,550,493.00","7,756,160.00","13,102,243.00", 
CYC,Cyclopharm Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , ,"20,994,769.00","10,977,549.00","18,579,649.00","19,644,411.00","22,141,899.00","21,293,213.00","21,656,363.00","11,899,167.00","10,961,317.00","16,540,917.00", 
CYP,Cynata Therapeutics Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , ,0.00%,-92.05%,-150.76%,-227.05%,-263.91%,-180.65%,-55.74%,-30.85%,-42.42%, 
CYP,Cynata Therapeutics Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , ,--,"350,565.00",0.00,"113,879.00","222,936.00","162,452.00","33,964.00",0.00,0.00, 
CYP,Cynata Therapeutics Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , ,0.00,"-2,034,852.00","-1,450,271.00","-2,116,125.00","-2,564,979.00","-1,542,307.00","-915,701.00","-3,039,663.00","-3,712,077.00", 
CYP,Cynata Therapeutics Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , ,"3,409,742.00","2,210,670.00","961,980.00","932,005.00","971,930.00","853,753.00","1,642,843.00","9,854,632.00","8,749,959.00", 
CYP,Cynata Therapeutics Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , ,"3,556,905.00","2,327,549.00","1,420,237.00","1,248,816.00","1,217,855.00","1,016,839.00","1,792,543.00","9,925,928.00","9,125,352.00", 
CYT,Cytopia Limited,Annual Ratio Analysis - ROE, , , , , , , , , ,-10.97%,-15.22%,-18.47%,-30.16%,-38.07%,-31.87%,-22.93%,-22.38%,-35.47%,-67.13%,-130.20%, , , , , , , 
CYT,Cytopia Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , ,--,0.00,"18,204.00",0.00,0.00,0.00,"3,748,346.00",0.00,"4,404,517.00",0.00,0.00, , , , , , , 
CYT,Cytopia Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , ,"-769,054.00","-2,138,000.00","-3,167,317.00","-3,872,900.00","-4,846,590.00","-4,583,218.00","-5,118,905.00","-4,412,360.00","-4,947,260.00","-7,603,000.00","-6,515,767.00", , , , , , , 
CYT,Cytopia Limited,Annual Balance Sheet - Total Equity, , , , , , , , , ,"8,085,540.00","12,489,285.00","16,534,642.00","12,745,818.00","11,544,778.00","13,530,312.00","22,322,898.00","19,719,112.00","13,949,164.00","11,325,000.00","5,004,376.00", , , , , , , 
CYT,Cytopia Limited,Annual Balance Sheet - Total Assets, , , , , , , , , ,"8,676,171.00","12,575,290.00","16,977,310.00","13,315,111.00","12,272,063.00","14,253,119.00","23,039,964.00","26,021,001.00","17,967,899.00","14,566,000.00","6,342,020.00", , , , , , , 
DNX,DenX Limited,Annual Ratio Analysis - ROE,11.10%,16.44%,-14.03%,-16.40%,4.04%,4.31%,3.95%,15.88%,0.59%,3.64%,4.54%,1.01%,-0.96%,-22.73%,-29.15%,-29.93%, , , , , , , , , , , 
DNX,DenX Limited,Annual Profit and Loss - Operating Revenue,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,"1,241,000.00",0.00,"2,717,000.00","2,947,000.00",0.00, , , , , , , , , , , 
DNX,DenX Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"4,454,000.00","-1,725,000.00","-6,375,000.00","-6,176,000.00","900,000.00","1,032,000.00","1,210,000.00","5,715,000.00","204,000.00","1,287,000.00","1,680,000.00","379,000.00","-305,000.00","-8,899,000.00","-9,848,000.00","-8,547,000.00", , , , , , , , , , , 
DNX,DenX Limited,Annual Balance Sheet - Total Equity,"41,616,000.00","40,417,000.00","33,094,000.00","28,452,000.00","25,613,000.00","28,902,000.00","30,628,000.00","35,995,000.00","34,332,000.00","35,350,000.00","37,030,000.00","37,409,000.00","31,863,000.00","39,145,000.00","33,787,000.00","28,557,000.00", , , , , , , , , , , 
DNX,DenX Limited,Annual Balance Sheet - Total Assets,"113,476,000.00","81,332,000.00","48,741,000.00","37,220,000.00","26,481,000.00","29,449,000.00","31,096,000.00","36,970,000.00","34,716,000.00","35,562,000.00","37,188,000.00","38,078,000.00","33,567,000.00","43,007,000.00","36,602,000.00","31,821,000.00", , , , , , , , , , , 
DVC,DCA Group Limited,Annual Ratio Analysis - ROE,5.32%,3.45%,5.78%,4.89%,5.50%,9.86%,9.30%,9.20%,8.63%,13.02%,11.52%,7.50%,6.81%,4.04%,3.73%,1.46%,5.88%, , , , , , , , , , 
DVC,DCA Group Limited,Annual Profit and Loss - Operating Revenue,"15,683,000.00","14,147,000.00","15,652,000.00","14,602,000.00","16,193,000.00","18,211,000.00","15,811,000.00","15,580,000.00","15,421,000.00","16,780,000.00","30,307,000.00","44,197,000.00","43,789,000.00","209,637,000.00","320,216,000.00","691,895,000.00","936,073,000.00", , , , , , , , , , 
DVC,DCA Group Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"620,000.00","454,000.00","-655,000.00","766,000.00","1,309,000.00","2,847,000.00","3,816,000.00","3,880,000.00","3,947,000.00","3,911,000.00","14,680,000.00","7,567,000.00","11,705,000.00","15,725,000.00","18,129,000.00","17,530,000.00","80,939,000.00", , , , , , , , , , 
DVC,DCA Group Limited,Annual Balance Sheet - Total Equity,"12,917,000.00","13,159,000.00","11,930,000.00","15,662,000.00","23,816,000.00","28,887,000.00","41,015,000.00","42,160,000.00","45,713,000.00","46,256,000.00","57,092,000.00","92,198,000.00","123,361,000.00","332,531,000.00","425,008,000.00","925,193,000.00","1,250,216,000.00", , , , , , , , , , 
DVC,DCA Group Limited,Annual Balance Sheet - Total Assets,"20,155,000.00","19,704,000.00","24,150,000.00","29,002,000.00","32,727,000.00","57,385,000.00","66,963,000.00","64,283,000.00","70,458,000.00","69,445,000.00","96,254,000.00","175,122,000.00","192,080,000.00","605,977,000.00","709,364,000.00","1,884,277,000.00","2,368,358,000.00", , , , , , , , , , 
DVL,Dorsavi Ltd,Annual Ratio Analysis - ROE, , , , , ,0.01%,4.02%,5.27%,0.98%, , , , , , , , , , , , , , ,0.00%,-24.36%,-121.45%, 
DVL,Dorsavi Ltd,Annual Profit and Loss - Operating Revenue, , , , , ,0.00,0.00,0.00,0.00, , , , , , , , , , , , , , ,--,"529,000.00","1,476,973.00", 
DVL,Dorsavi Ltd,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , ,"2,000.00","725,461.00","1,104,788.00","228,143.00", , , , , , , , , , , , , , ,0.00,"-3,562,000.00","-8,036,161.00", 
DVL,Dorsavi Ltd,Annual Balance Sheet - Total Equity, , , , , ,"14,927,000.00","18,048,988.00","20,956,228.00","23,380,694.00", , , , , , , , , , , , , , ,"18,492,815.00","14,620,000.00","6,616,716.00", 
DVL,Dorsavi Ltd,Annual Balance Sheet - Total Assets, , , , , ,"14,949,000.00","18,107,147.00","21,026,242.00","23,599,618.00", , , , , , , , , , , , , , ,"18,875,881.00","15,339,000.00","8,017,330.00", 
DXB,Dimerix Limited,Annual Ratio Analysis - ROE,-3.41%,1.63%,-0.10%,-3.12%,-7.58%,-7.13%,-6.68%,-7.18%,11.90%,11.20%,-5.58%,-401.98%,-261.47%,176.44%,396.85%,-11.51%,-112.18%,-171.17%,-352.86%,-140.10%,-22.29%,0.36%,-32.72%,-30.29%,-44.78%,-20.87%, 
DXB,Dimerix Limited,Annual Profit and Loss - Operating Revenue,"114,000.00","9,000.00",0.00,0.00,0.00,0.00,0.00,0.00,"4,017,426.00","10,731,454.00","8,090,419.00","5,343,004.00","4,090,520.00","2,487,216.00","2,704,726.00","1,369,138.00",564.00,"655,993.00","756,957.00",--,0.00,"73,068.00",0.00,0.00,0.00,0.00, 
DXB,Dimerix Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-119,000.00","-344,000.00","-1,000.00","-65,000.00","-137,000.00","-123,000.00","-123,497.00","-140,533.00","598,173.00","646,298.00","-516,948.00","-4,349,865.00","-739,658.00","-945,668.00","-676,149.00","-595,797.00","-11,161,018.00","-2,421,661.00","-3,557,390.00","-4,128,738.00","-347,767.00","5,656.00","-386,070.00","-517,098.00","-527,978.00","-679,539.00", 
DXB,Dimerix Limited,Annual Balance Sheet - Total Equity,"1,409,000.00","1,046,000.00","1,044,000.00","1,410,000.00","1,741,000.00","1,724,000.00","1,849,772.00","1,957,517.00","5,025,864.00","5,771,871.00","5,240,203.00","640,427.00","282,886.00","-565,025.00","-170,377.00","10,280,504.00","2,694,481.00","1,414,772.00","1,008,159.00","341,976.00","1,560,180.00","1,565,836.00","1,179,766.00","1,707,138.00","1,179,160.00","2,777,090.00", 
DXB,Dimerix Limited,Annual Balance Sheet - Total Assets,"1,727,000.00","1,149,000.00","1,161,000.00","1,636,000.00","2,033,000.00","1,981,000.00","2,243,534.00","2,260,732.00","9,689,631.00","9,121,446.00","7,901,573.00","2,278,158.00","1,890,609.00","1,216,200.00","1,827,671.00","10,521,001.00","3,038,236.00","4,071,529.00","2,448,607.00","385,333.00","1,606,528.00","1,593,823.00","1,214,290.00","1,753,446.00","1,213,655.00","2,968,733.00", 
EBO,EBOS Group Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , , , , , ,9.40%,10.08%, 
EBO,EBOS Group Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , , , , , ,"5,757,234,000.00","5,372,835,133.00", 
EBO,EBOS Group Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , , , , , ,"92,069,000.00","93,802,904.00", 
EBO,EBOS Group Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , , , , , ,"979,039,000.00","930,607,402.00", 
EBO,EBOS Group Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , , , , , ,"2,309,293,000.00","2,257,887,373.00", 
EGX,EvoGenix Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , ,-49.20%,-42.35%, , , , , , , , , , 
EGX,EvoGenix Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , ,"528,451.00","440,089.00", , , , , , , , , , 
EGX,EvoGenix Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , ,"-2,862,278.00","-4,271,886.00", , , , , , , , , , 
EGX,EvoGenix Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , ,"5,817,841.00","10,087,777.00", , , , , , , , , , 
EGX,EvoGenix Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , ,"7,295,745.00","10,851,392.00", , , , , , , , , , 
EHE,Estia Health Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , , , , , ,0.00%,1.46%, 
EHE,Estia Health Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , , , , , ,--,"283,542,492.00", 
EHE,Estia Health Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , , , , , ,0.00,"-22,523,276.00", 
EHE,Estia Health Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , , , , , ,"577,100,000.00","563,913,936.00", 
EHE,Estia Health Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , , , , , ,"887,800,000.00","1,146,757,426.00", 
ELX,Ellex Medical Lasers Limited,Annual Ratio Analysis - ROE,-52.91%,-29.47%,-72.20%,-92.18%,-73.57%,-14.87%,-8.03%,-16.41%,-69.03%,-81.77%,-110.46%,-58.55%,10.11%,5.34%,-0.68%,-3.80%,10.51%,9.86%,9.94%,-0.83%,11.56%,-2.19%,2.87%,-2.65%,2.13%,4.22%, 
ELX,Ellex Medical Lasers Limited,Annual Profit and Loss - Operating Revenue,"708,000.00","337,000.00","178,000.00","79,000.00","117,000.00","7,000.00","7,534.00","12,152.00","3,775.00","1,802.00","6,839.00",160.00,"27,354,000.00","26,063,000.00","24,665,000.00","28,351,000.00","34,691,000.00","45,502,000.00","51,181,000.00","59,254,000.00","48,553,000.00","43,373,000.00","47,503,000.00","42,804,000.00","54,378,000.00","62,679,000.00", 
ELX,Ellex Medical Lasers Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-2,741,000.00","-323,000.00","-535,000.00","-448,000.00","-206,000.00","-179,000.00","-137,782.00","-269,339.00","-670,353.00","-728,249.00","-368,000.00","-462,497.00","3,281,000.00","1,632,000.00","-206,000.00","-1,102,000.00","3,693,000.00","4,368,000.00","4,834,000.00","-22,615,000.00","3,760,000.00","-700,000.00","1,050,000.00","-816,000.00","788,000.00","1,680,000.00", 
ELX,Ellex Medical Lasers Limited,Annual Balance Sheet - Total Equity,"928,000.00","1,096,000.00","741,000.00","486,000.00","280,000.00","1,204,000.00","1,715,230.00","1,641,492.00","971,139.00","519,016.00","333,160.00","789,861.00","30,806,000.00","30,590,000.00","30,478,000.00","28,990,000.00","35,144,000.00","43,380,000.00","47,941,000.00","30,051,000.00","33,187,000.00","30,322,000.00","32,058,000.00","30,829,000.00","36,950,000.00","39,794,000.00", 
ELX,Ellex Medical Lasers Limited,Annual Balance Sheet - Total Assets,"1,392,000.00","1,198,000.00","844,000.00","545,000.00","305,000.00","1,226,000.00","1,762,088.00","1,732,554.00","1,014,872.00","567,063.00","534,072.00","1,145,661.00","38,769,000.00","37,075,000.00","38,314,000.00","39,055,000.00","46,476,000.00","63,687,000.00","71,941,000.00","50,905,000.00","51,578,000.00","48,382,000.00","44,932,000.00","47,346,000.00","54,228,000.00","58,980,000.00", 
EPL,Eyecare Partners Limited,Annual Ratio Analysis - ROE,28.85%,-18.46%,-13.10%,-12.34%,8.44%,-5.46%,-27.80%,0.14%,4.72%,20.89%,-57.81%, , , , , ,11.87%,40.47%,6.93%,4.78%,2.34%,3.26%, , , , , 
EPL,Eyecare Partners Limited,Annual Profit and Loss - Operating Revenue,0.00,0.00,0.00,"6,529,000.00","18,609,000.00","34,977,000.00","40,085,720.00","32,494,230.00","31,798,000.00","20,580,000.00","21,415,000.00", , , , , ,--,--,"16,287,000.00","27,787,000.00","30,160,000.00","27,855,000.00", , , , , 
EPL,Eyecare Partners Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"457,000.00","-146,000.00","-119,000.00","-652,000.00","1,428,000.00","-2,318,000.00","-9,981,613.00","9,583.00","-3,493,000.00","2,486,000.00","-5,825,000.00", , , , , ,"-167,735.00","-160,093.00","1,816,000.00","1,384,000.00","-4,372,000.00","827,000.00", , , , , 
EPL,Eyecare Partners Limited,Annual Balance Sheet - Total Equity,"936,000.00","791,000.00","672,000.00","2,909,000.00","16,918,000.00","16,738,000.00","6,756,117.00","6,765,700.00","10,028,000.00","12,701,000.00","6,876,000.00", , , , , ,"-235,457.00","-395,550.00","26,194,000.00","28,981,000.00","24,523,000.00","25,331,000.00", , , , , 
EPL,Eyecare Partners Limited,Annual Balance Sheet - Total Assets,"984,000.00","801,000.00","682,000.00","8,341,000.00","34,521,000.00","40,383,000.00","30,581,155.00","29,644,450.00","33,899,000.00","35,744,000.00","33,450,000.00", , , , , ,"4,991.00","1,224,648.00","28,028,000.00","39,380,000.00","33,770,000.00","33,334,000.00", , , , , 
FFC,Farmaforce Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , , , , , ,0.00%, , 
FFC,Farmaforce Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , , , , , ,--, , 
FFC,Farmaforce Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , , , , , ,0.00, , 
FFC,Farmaforce Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , , , , , ,"7,503,317.00", , 
FFC,Farmaforce Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , , , , , ,"7,596,632.00", , 
FHM,Freehill Mining Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , ,-36.52%,-75.41%,-323.28%,-151.92%,-37.83%,-40.90%,-104.09%,-82.33%,402.29%,116.11%,"-1,639.24%",88.16%,23.99%,38.67%,264.00%, 
FHM,Freehill Mining Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , ,"4,000.00","486,542.00","251,976.00","100,589.00","560,961.00","663,825.00","1,104,648.00","1,006,160.00","292,820.00",--,--,--,--,--,0.00, 
FHM,Freehill Mining Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , ,"-2,464,572.00","-3,794,742.00","-3,843,530.00","-1,018,501.00","-463,909.00","-589,964.00","-989,550.00","-498,672.00","-1,135,287.00","-1,240,937.00","-508,123.00","-343,197.00","-272,492.00","-386,056.00","819,513.00", 
FHM,Freehill Mining Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , ,"6,749,249.00","5,031,950.00","1,188,920.00","670,417.00","1,226,265.00","1,442,427.00","950,707.00","605,680.00","-282,204.00","-832,725.00","35,185.00","-308,012.00","-580,504.00","-966,560.00","-73,127.00", 
FHM,Freehill Mining Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , ,"8,402,797.00","6,861,500.00","1,709,072.00","948,006.00","1,433,097.00","1,697,244.00","1,170,752.00","922,745.00","281,296.00","298,544.00","586,585.00","500,416.00","478,499.00","60,143.00","30,497.00", 
FIT,Fitgenes Limited,Annual Ratio Analysis - ROE, , , , , , , , ,0.00%,7.43%,--, , ,4.42%,-13.61%,-129.34%,-12.65%,-52.40%,-111.76%,-149.72%,-25.02%,-997.59%,272.63%,85.92%, , , 
FIT,Fitgenes Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , ,--,--,--, , ,"1,892,866.00","5,595,814.00","7,946,540.00","8,144,435.00","19,609,452.00","18,642,299.00","27,175,003.00","12,582,122.00","488,635.00",--,--, , , 
FIT,Fitgenes Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , ,0.00,"13,830,000.00",0.00, , ,"173,431.00","-767,539.00","-4,473,670.00","-1,075,363.00","-3,105,658.00","-2,630,420.00","-880,024.00","-382,900.00","-990,414.00","-599,361.00","-476,107.00", , , 
FIT,Fitgenes Limited,Annual Balance Sheet - Total Equity, , , , , , , , ,"170,171,000.00","186,077,000.00",0.00, , ,"3,759,970.00","5,733,330.00","3,441,383.00","8,633,681.00","7,200,215.00","3,359,448.00","3,203,097.00","2,796,926.00","379,517.00","-219,844.00","-554,136.00", , , 
FIT,Fitgenes Limited,Annual Balance Sheet - Total Assets, , , , , , , , ,"29,964,000.00","269,026,992.00",0.00, , ,"4,442,375.00","8,055,761.00","4,789,428.00","10,534,446.00","15,579,246.00","17,855,424.00","16,073,540.00","13,792,439.00","544,588.00","88,623.00","63,168.00", , , 
FNC,Foundation Healthcare Limited,Annual Ratio Analysis - ROE,-109.55%,51.44%,4.01%,-220.66%,-198.67%,"-2,850.00%",22.21%,-153.88%,-232.10%, ,-10.42%,-17.90%, , , , , , , , , , , , , , , 
FNC,Foundation Healthcare Limited,Annual Profit and Loss - Operating Revenue,0.00,0.00,0.00,0.00,"529,000.00","464,000.00","826,123.00","226,635.00","17,324,140.00", ,"4,345,000.00","71,486,000.00", , , , , , , , , , , , , , , 
FNC,Foundation Healthcare Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-1,296,000.00","609,000.00","339,000.00","-618,000.00","-453,000.00","-440,000.00","-30,871,624.00","-21,538,124.00","-17,960,456.00", ,"-6,216,000.00","-28,336,000.00", , , , , , , , , , , , , , , 
FNC,Foundation Healthcare Limited,Annual Balance Sheet - Total Equity,"1,183,000.00","1,184,000.00","1,523,000.00","905,000.00","452,000.00","12,000.00","20,393,630.00","11,148,384.00","4,621,452.00", ,"29,744,000.00","161,566,000.00", , , , , , , , , , , , , , , 
FNC,Foundation Healthcare Limited,Annual Balance Sheet - Total Assets,"2,057,000.00","2,284,000.00","2,200,000.00","1,162,000.00","746,000.00","416,000.00","24,162,406.00","19,166,310.00","11,184,994.00", ,"42,893,000.00","286,826,000.00", , , , , , , , , , , , , , , 
FPH,Fisher & Paykel Healthcare Corporation Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , ,46.39%,53.76%,37.81%,28.60%,31.98%,34.30%,29.77%,18.03%,30.46%,24.43%,20.41%,18.41%,20.70%,23.90%,24.02%,26.48%
FPH,Fisher & Paykel Healthcare Corporation Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , ,"159,126,990.00","177,340,117.00","191,119,054.00","187,304,741.00","221,917,909.00","247,476,068.00","308,790,450.00","299,356,234.00","401,451,959.00","367,884,540.00","344,764,705.00","367,790,386.00","406,972,079.00","533,347,715.00","631,694,948.00","737,380,180.00"
FPH,Fisher & Paykel Healthcare Corporation Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , ,"8,009,736.00","39,817,986.00","66,816,973.00","47,680,439.00","56,511,135.00","59,799,145.00","50,932,802.00","30,523,492.00","51,457,747.00","55,506,392.00","38,577,941.00","50,520,094.00","61,820,442.00","91,035,550.00","111,008,337.00","129,211,711.00"
FPH,Fisher & Paykel Healthcare Corporation Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , ,"125,500,453.00","142,204,848.00","176,717,991.00","166,688,458.00","176,726,486.00","174,352,991.00","171,099,911.00","169,303,452.00","168,927,567.00","227,170,864.00","230,361,029.00","274,351,457.00","298,644,897.00","380,941,750.00","462,177,538.00","487,990,090.00"
FPH,Fisher & Paykel Healthcare Corporation Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , ,"195,301,592.00","178,152,560.00","209,652,644.00","195,408,821.00","211,954,721.00","228,606,837.00","242,853,227.00","286,983,646.00","342,101,041.00","368,120,108.00","380,594,117.00","450,791,174.00","496,306,964.00","591,243,785.00","657,004,413.00","690,813,513.00"
FTT,Factor Therapeutics Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , ,-0.25%,-8.18%,-24.20%,-35.61%,-25.69%,-129.43%,-121.28%,-43.90%,-31.35%,-64.67%,-41.09%,-40.51%,-84.19%, 
FTT,Factor Therapeutics Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , ,--,0.00,"5,873.00","9,611.00","37,144.00","80,732.00","252,948.00","229,484.00","232,024.00","336,637.00",0.00,--,0.00, 
FTT,Factor Therapeutics Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , ,"-8,878.00","-181,281.00","-926,847.00","-1,861,242.00","-1,710,280.00","-4,865,418.00","-4,473,196.00","-3,486,399.00","-5,340,548.00","-6,769,382.00","-5,740,094.00","-6,829,591.00","-11,218,514.00", 
FTT,Factor Therapeutics Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , ,"3,497,712.00","3,325,709.00","3,829,662.00","5,227,194.00","6,658,310.00","3,759,058.00","3,688,189.00","7,942,395.00","17,033,436.00","10,466,891.00","13,968,238.00","16,859,743.00","13,325,214.00", 
FTT,Factor Therapeutics Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , ,"3,517,712.00","3,383,016.00","4,024,671.00","5,439,014.00","7,298,398.00","6,224,288.00","4,136,418.00","8,498,279.00","22,807,934.00","12,932,253.00","15,794,992.00","18,832,690.00","15,206,043.00", 
GBI,Genera Biosystems Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , ,0.00%,-109.84%,-23.14%,-32.94%,-42.46%,-36.41%,-53.31%,-79.86%,-102.92%, 
GBI,Genera Biosystems Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , ,--,0.00,"36,500.00","39,500.00","55,300.00","231,448.00","46,568.00","204,730.00","344,728.00", 
GBI,Genera Biosystems Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , ,0.00,"-3,239,917.00","-1,614,506.00","-2,486,813.00","-2,934,769.00","-2,087,566.00","-2,262,872.00","-2,461,958.00","-2,789,474.00", 
GBI,Genera Biosystems Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , ,"6,528,938.00","5,899,532.00","6,977,378.00","7,549,351.00","6,911,184.00","5,733,233.00","4,244,670.00","3,082,748.00","2,710,210.00", 
GBI,Genera Biosystems Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , ,"7,531,537.00","6,924,146.00","8,193,746.00","8,858,534.00","8,234,083.00","6,808,340.00","5,241,692.00","5,192,131.00","6,390,050.00", 
GEN,Genesis Research & Development Corporation Limited,Annual Ratio Analysis - ROE, , , , , , , , ,-94.19%,-442.18%,1.24%,-15.73%,-26.77%,-46.68%,-101.32%,-111.78%,34.33%,-58.49%,-559.49%,-68.43%,"1,469.40%",78.32%,31.02%, , , , 
GEN,Genesis Research & Development Corporation Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , ,0.00,0.00,0.00,"10,770,170.00","9,986,991.00","7,412,722.00",--,0.00,--,--,"24,257.00","468,674.00","645,357.00",0.00,"19,828.00", , , , 
GEN,Genesis Research & Development Corporation Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , ,"-3,439,204.00","-5,697,665.00","574,356.00","-7,778,230.00","-9,927,522.00","-11,113,833.00","-12,640,760.00","-6,663,553.00","2,974,322.00","-672,890.00","-6,302,802.00","-628,136.00","-1,494,951.00","-368,200.00","-187,975.00", , , , 
GEN,Genesis Research & Development Corporation Limited,Annual Balance Sheet - Total Equity, , , , , , , , ,"3,651,522.00","1,288,548.00","46,302,033.00","41,116,176.00","37,086,972.00","23,808,732.00","12,475,539.00","5,961,143.00","8,664,407.00","7,666,020.00","978,670.00","917,921.00","-101,738.00","-470,140.00","-605,964.00", , , , 
GEN,Genesis Research & Development Corporation Limited,Annual Balance Sheet - Total Assets, , , , , , , , ,"5,307,945.00","6,022,790.00","55,942,167.00","47,371,163.00","42,415,907.00","25,624,289.00","13,631,161.00","6,612,180.00","9,194,900.00","8,369,737.00","1,457,967.00","1,249,797.00","269,531.00","81,399.00","22,208.00", , , , 
GGL1,Gribbles Group Limited (The),Annual Ratio Analysis - ROE, , , , , , , , , , ,2.52%,0.59%,2.13%,3.52%,-6.73%, , , , , , , , , , , , 
GGL1,Gribbles Group Limited (The),Annual Profit and Loss - Operating Revenue, , , , , , , , , , ,"6,996,000.00","32,061,000.00","183,806,000.00","232,066,000.00","254,566,000.00", , , , , , , , , , , , 
GGL1,Gribbles Group Limited (The),Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , ,"533,000.00","-9,215,000.00","1,146,000.00","10,682,000.00","-51,622,000.00", , , , , , , , , , , , 
GGL1,Gribbles Group Limited (The),Annual Balance Sheet - Total Equity, , , , , , , , , , ,"104,503,000.00","288,461,000.00","292,576,000.00","292,492,000.00","247,005,000.00", , , , , , , , , , , , 
GGL1,Gribbles Group Limited (The),Annual Balance Sheet - Total Assets, , , , , , , , , , ,"110,009,000.00","402,295,000.00","440,251,000.00","461,410,000.00","445,114,000.00", , , , , , , , , , , , 
GIA,Giaconda Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , ,-16.84%,-18.35%,-150.54%,-27.47%,27.68%, , , , , , 
GIA,Giaconda Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , ,"35,740.00","3,000.00",0.00,"5,280.00",0.00, , , , , , 
GIA,Giaconda Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , ,"-942,768.00","-1,011,253.00","-2,821,415.00","-1,092,712.00","-1,307,633.00", , , , , , 
GIA,Giaconda Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , ,"5,597,204.00","4,909,498.00","1,874,141.00","781,429.00","-415,767.00", , , , , , 
GIA,Giaconda Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , ,"6,275,766.00","5,724,105.00","3,092,215.00","1,936,241.00","772,476.00", , , , , , 
GID,"GI Dynamics, Inc",Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , ,0.00%,-40.21%,-64.22%,-57.03%,-96.07%,-192.58%, 
GID,"GI Dynamics, Inc",Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , ,--,"230,405.00","643,297.00","2,520,116.00","3,447,939.00","1,801,259.00", 
GID,"GI Dynamics, Inc",Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , ,0.00,"-25,953,131.00","-25,795,454.00","-39,760,840.00","-58,772,250.00","-48,126,197.00", 
GID,"GI Dynamics, Inc",Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , ,"86,828,000.00","64,544,111.00","40,165,639.00","69,719,490.00","61,177,761.00","24,990,418.00", 
GID,"GI Dynamics, Inc",Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , ,"89,703,000.00","70,801,496.00","47,077,234.00","77,475,413.00","72,543,282.00","29,813,851.00", 
GLH,Global Health Limited,Annual Ratio Analysis - ROE, , , , , , , , ,--,1.16%,2.03%,-152.49%,-16.91%,-4.36%,9.01%,16.03%,-134.07%,232.50%,58.18%,-68.76%,197.12%,-50.86%,380.37%,81.82%,51.32%,28.15%, 
GLH,Global Health Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , ,"2,801,322.00","3,335,291.00","670,073.00","5,337,319.00","6,105,485.00","6,688,296.00","6,398,796.00","8,991,374.00","5,170,021.00","5,456,256.00","6,355,736.00","6,383,312.00","4,679,060.00","5,175,547.00","5,025,679.00","4,498,430.00","4,768,901.00","3,954,336.00", 
GLH,Global Health Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , ,"-74,687.00","136,305.00","242,999.00","-7,941,925.00","-1,319,462.00","-695,498.00","457,459.00","987,572.00","-2,529,410.00","-3,446,595.00","-542,226.00","-301,306.00","-812,789.00","-230,821.00","-657,797.00","1,096,848.00","1,443,513.00","1,059,907.00", 
GLH,Global Health Limited,Annual Balance Sheet - Total Equity, , , , , , , , ,--,"11,745,000.00","11,957,004.00","5,190,232.00","4,768,281.00","4,581,809.00","5,075,374.00","6,071,537.00","1,702,326.00","-1,557,953.00","-1,005,370.00","297,418.00","-556,582.00","301,210.00","-310,234.00","1,203,045.00","2,675,052.00","3,628,006.00", 
GLH,Global Health Limited,Annual Balance Sheet - Total Assets, , , , , , , , ,--,"12,840,562.00","13,999,792.00","8,555,177.00","8,012,521.00","7,919,927.00","9,147,952.00","12,306,731.00","5,079,796.00","1,718,697.00","2,089,373.00","3,425,832.00","1,708,065.00","2,490,100.00","2,282,222.00","3,712,846.00","4,973,267.00","6,023,339.00", 
GOD,Global Doctor Limited,Annual Ratio Analysis - ROE,4.46%,-35.61%,-7.70%,-17.38%,-79.05%,-43.21%,-16.35%,-10.01%,-29.90%,-12.97%,-199.62%,-424.22%, , , , , , , , , , , , , , , 
GOD,Global Doctor Limited,Annual Profit and Loss - Operating Revenue,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,--,--,"157,017.00","1,887,735.00", , , , , , , , , , , , , , , 
GOD,Global Doctor Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-144,000.00","-646,000.00","-686,000.00","-1,652,000.00","-2,104,000.00","-177,000.00","1,845,432.00","-1,988,354.00","-502,486.00","-551,835.00","-4,970,000.00","-4,263,677.00", , , , , , , , , , , , , , , 
GOD,Global Doctor Limited,Annual Balance Sheet - Total Equity,"2,444,000.00","1,814,000.00","2,464,000.00","1,726,000.00","482,000.00","405,000.00","2,745,079.00","756,725.00","550,039.00","4,254,849.00","2,489,201.00","1,005,065.00", , , , , , , , , , , , , , , 
GOD,Global Doctor Limited,Annual Balance Sheet - Total Assets,"2,476,000.00","1,839,000.00","3,079,000.00","1,883,000.00","542,000.00","447,000.00","2,792,600.00","786,142.00","1,072,900.00","4,365,948.00","4,042,574.00","2,850,387.00", , , , , , , , , , , , , , , 
GRO,GroPep Limited,Annual Ratio Analysis - ROE, , , , , , , , ,--,-3.82%,1.58%,0.18%,-9.89%,-4.81%,5.47%,25.22%,10.59%, , , , , , , , , , 
GRO,GroPep Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , ,"2,155,646.00","2,066,654.00","6,317,866.00","7,063,000.00","8,953,000.00","8,793,000.00","10,939,000.00","14,868,000.00","14,325,000.00", , , , , , , , , , 
GRO,GroPep Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , ,"255,067.00","-665,912.00","48,715.00","35,000.00","-6,894,000.00","-2,546,000.00","1,018,000.00","6,472,000.00","3,188,000.00", , , , , , , , , , 
GRO,GroPep Limited,Annual Balance Sheet - Total Equity, , , , , , , , ,--,"17,416,048.00","3,086,328.00","19,032,000.00","19,722,000.00","17,228,000.00","18,601,000.00","25,663,000.00","30,112,000.00", , , , , , , , , , 
GRO,GroPep Limited,Annual Balance Sheet - Total Assets, , , , , , , , ,--,"20,653,728.00","9,823,073.00","20,987,000.00","31,070,000.00","20,058,000.00","23,096,000.00","29,340,000.00","32,796,000.00", , , , , , , , , , 
GSS,Genetic Signatures Limited,Annual Ratio Analysis - ROE, , , ,1.32%,-4.28%,-71.80%, , , , , , , , , , , , , , , , , , ,0.00%,-37.68%, 
GSS,Genetic Signatures Limited,Annual Profit and Loss - Operating Revenue, , , ,0.00,0.00,0.00, , , , , , , , , , , , , , , , , , ,--,"1,043,269.00", 
GSS,Genetic Signatures Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , ,"229,000.00","-1,092,000.00","-5,753,000.00", , , , , , , , , , , , , , , , , , ,0.00,"-2,659,120.00", 
GSS,Genetic Signatures Limited,Annual Balance Sheet - Total Equity, , , ,"302,000.00","13,424,000.00","7,671,000.00", , , , , , , , , , , , , , , , , , ,"16,177,239.00","7,056,969.00", 
GSS,Genetic Signatures Limited,Annual Balance Sheet - Total Assets, , , ,"302,000.00","13,771,000.00","13,727,000.00", , , , , , , , , , , , , , , , , , ,"16,547,714.00","7,800,112.00", 
GTG,Genetic Technologies Limited,Annual Ratio Analysis - ROE,-134.05%,-185.11%,-14.98%,-21.30%,-18.23%,-29.17%,-6.93%,-5.52%,-5.27%,-0.91%,5.21%,-8.93%,-28.37%,-15.19%,-31.38%,-28.45%,-26.34%,-16.68%,-26.38%,-57.50%,-146.01%,13.44%,-73.00%,-164.93%,-554.04%,-53.84%, 
GTG,Genetic Technologies Limited,Annual Profit and Loss - Operating Revenue,"1,739,000.00","152,000.00","467,000.00","368,000.00","132,000.00","98,000.00",0.00,"197,910.00","206,487.00","287,810.00",800.00,"5,022,826.00","1,620,831.00","8,496,890.00","3,147,587.00","8,962,441.00","9,235,469.00","12,146,330.00","13,829,016.00","5,382,182.00","5,805,558.00","4,594,960.00","3,691,215.00","3,377,183.00","4,564,280.00","2,011,918.00", 
GTG,Genetic Technologies Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-848,000.00","-1,736,000.00","-721,000.00","-1,415,000.00","-1,478,000.00","-3,122,000.00","-533,211.00","-489,653.00","-3,614,390.00","-3,306,335.00","-2,809,410.00","-3,443,603.00","-8,888,430.00","-4,325,345.00","-10,467,207.00","-10,420,232.00","-7,908,123.00","-4,345,702.00","-5,451,638.00","-7,858,321.00","-9,355,209.00","901,341.00","-5,296,828.00","-9,349,483.00","-10,134,469.00","-8,810,170.00", 
GTG,Genetic Technologies Limited,Annual Balance Sheet - Total Equity,"514,000.00","685,000.00","4,813,000.00","6,643,000.00","8,108,000.00","7,775,000.00","7,696,630.00","16,707,515.00","13,093,125.00","9,731,336.00","7,577,124.00","38,067,754.00","31,136,174.00","27,276,860.00","34,224,047.00","36,959,339.00","30,242,139.00","26,102,809.00","20,785,073.00","14,112,045.00","5,717,696.00","6,813,995.00","14,402,642.00","5,758,287.00","1,827,519.00","18,959,248.00", 
GTG,Genetic Technologies Limited,Annual Balance Sheet - Total Assets,"1,507,000.00","837,000.00","5,620,000.00","6,928,000.00","8,422,000.00","8,310,000.00","7,715,653.00","16,891,696.00","13,221,096.00","9,791,802.00","8,847,013.00","39,685,822.00","33,000,907.00","30,245,002.00","38,880,305.00","43,475,157.00","33,716,907.00","29,449,027.00","24,094,578.00","17,977,731.00","8,279,572.00","8,922,354.00","16,441,751.00","8,319,527.00","6,729,199.00","20,719,732.00", 
HCN,Health Communication Network Limited,Annual Ratio Analysis - ROE, , , , , , , ,--,--,-10.86%,-21.47%,-157.93%,-783.19%,67.86%,78.59%, , , , , , , , , , , , 
HCN,Health Communication Network Limited,Annual Profit and Loss - Operating Revenue, , , , , , , ,"10,423,000.00","12,832,000.00","13,448,000.00","16,141,892.00","31,604,479.00","34,252,105.00","29,485,000.00","28,901,000.00", , , , , , , , , , , , 
HCN,Health Communication Network Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , ,"-1,757,000.00","-1,235,000.00","-2,393,000.00","-7,809,584.00","-28,569,846.00","-10,500,955.00","1,678,000.00","4,079,000.00", , , , , , , , , , , , 
HCN,Health Communication Network Limited,Annual Balance Sheet - Total Equity, , , , , , , ,--,--,"22,033,000.00","36,374,513.00","8,597,831.00","375,007.00","2,083,000.00","5,025,000.00", , , , , , , , , , , , 
HCN,Health Communication Network Limited,Annual Balance Sheet - Total Assets, , , , , , , ,--,--,"28,425,000.00","49,693,449.00","26,742,668.00","21,931,873.00","23,263,000.00","24,176,000.00", , , , , , , , , , , , 
HIN,"HeartWare International, Inc.",Annual Ratio Analysis - ROE, , , , , , , , , , , , , , ,0.00%,-19.89%,-38.98%,-75.08%,-88.82%,-35.94%,-17.52%,-43.42%,-128.60%, , , , 
HIN,"HeartWare International, Inc.",Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , ,--,--,--,--,"478,924.00","26,950,365.00","54,279,664.00","81,492,713.00","106,820,107.00", , , , 
HIN,"HeartWare International, Inc.",Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , ,0.00,"-14,683,862.00","-25,461,888.00","-26,376,647.00","-34,300,838.00","-23,312,362.00","-28,925,415.00","-54,209,334.00","-84,474,191.00", , , , 
HIN,"HeartWare International, Inc.",Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , ,"76,062,000.00","59,073,860.00","65,316,184.00","35,129,605.00","38,619,450.00","79,142,563.00","165,073,653.00","124,836,549.00","65,688,559.00", , , , 
HIN,"HeartWare International, Inc.",Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , ,"78,577,000.00","62,128,866.00","68,814,846.00","38,624,725.00","43,790,713.00","86,914,017.00","263,285,352.00","237,034,265.00","198,862,673.00", , , , 
HSO,Healthscope Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , , , , ,0.00%, ,4.49%, 
HSO,Healthscope Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , , , , ,--, ,"2,094,247,000.00", 
HSO,Healthscope Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , , , , ,0.00, ,"140,848,000.00", 
HSO,Healthscope Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , , , , ,"2,183,400,000.00", ,"2,305,746,000.00", 
HSO,Healthscope Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , , , , ,"3,627,900,000.00", ,"3,981,076,000.00", 
HSP,Healthscope Ltd,Annual Ratio Analysis - ROE, , , ,12.16%,3.64%,6.29%,4.59%,4.11%,5.37%,14.06%,8.61%,8.72%,12.05%,9.35%,11.38%,3.31%,7.38%,8.48%,8.83%,9.74%,8.91%, , ,0.00%, , , 
HSP,Healthscope Ltd,Annual Profit and Loss - Operating Revenue, , , ,"28,392,000.00","36,500,000.00","92,016,000.00","112,949,000.00","113,602,000.00","107,678,000.00","103,670,000.00","111,457,000.00","128,043,000.00","175,936,000.00","242,092,000.00","354,399,000.00","521,312,000.00","1,100,768,000.00","1,369,685,000.00","1,465,718,000.00","1,629,727,000.00","1,823,251,000.00", , ,--, , , 
HSP,Healthscope Ltd,Annual Profit and Loss - Reported NPAT After Abnorma, , , ,"1,782,000.00","3,106,000.00","6,038,000.00","-4,726,000.00","-21,624,000.00","3,554,000.00","-11,634,000.00","5,941,000.00","6,520,000.00","10,549,000.00","12,646,000.00","18,149,000.00","23,290,000.00","54,920,000.00","84,280,000.00","64,438,000.00","72,290,000.00","99,282,000.00", , ,0.00, , , 
HSP,Healthscope Ltd,Annual Balance Sheet - Total Equity, , , ,"14,654,000.00","94,003,000.00","96,009,000.00","86,215,000.00","64,591,000.00","66,198,000.00","54,564,000.00","60,505,000.00","64,765,000.00","83,014,000.00","123,989,000.00","136,985,000.00","442,513,000.00","731,223,000.00","806,471,000.00","848,082,000.00","905,316,000.00","1,199,286,000.00", , ,--, , , 
HSP,Healthscope Ltd,Annual Balance Sheet - Total Assets, , , ,"52,212,000.00","151,018,000.00","163,610,000.00","149,828,000.00","112,807,000.00","107,004,000.00","121,064,000.00","113,865,000.00","118,782,000.00","195,043,000.00","238,155,000.00","271,015,000.00","906,641,000.00","1,547,712,000.00","1,622,968,000.00","1,727,586,000.00","1,895,594,000.00","2,272,036,000.00", , ,--, , , 
HXL,Hexima Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , ,-8.98%,-39.10%,-26.10%, , , , , , 
HXL,Hexima Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , ,0.00,0.00,0.00, , , , , , 
HXL,Hexima Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , ,"-3,029,909.00","-11,276,023.00","-6,118,978.00", , , , , , 
HXL,Hexima Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , ,"33,748,698.00","28,837,495.00","23,447,105.00", , , , , , 
HXL,Hexima Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , ,"36,664,990.00","31,418,364.00","26,078,260.00", , , , , , 
HZL,HZ Lim Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , ,0.00%,31.37%,19.28%,15.20%,13.40%,7.49%, , , , , 
HZL,HZ Lim Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , ,--,"12,242,675.00","62,071,714.00","100,195,000.00","107,461,000.00","80,046,000.00", , , , , 
HZL,HZ Lim Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , ,0.00,"1,702,514.00","2,695,489.00","2,987,000.00","4,394,000.00","2,968,000.00", , , , , 
HZL,HZ Lim Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , ,"4,005,200.00","5,427,696.00","13,978,163.00","19,648,000.00","32,783,000.00","39,635,000.00", , , , , 
HZL,HZ Lim Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , ,"6,023,200.00","10,987,332.00","61,413,637.00","64,726,000.00","84,172,000.00","88,681,000.00", , , , , 
ICS,ICSGlobal Limited,Annual Ratio Analysis - ROE, , , , , , , ,--,--,43.88%,-13.83%,-261.78%,-219.87%,-171.62%,-262.37%,-378.75%,-305.90%,-75.07%,-30.46%,-65.51%,12.29%,-5.16%,8.58%,9.38%,14.04%,17.63%, 
ICS,ICSGlobal Limited,Annual Profit and Loss - Operating Revenue, , , , , , , ,"595,000.00","3,208,000.00","13,726,000.00","6,821,078.00","1,595,857.00","731,966.00","338,331.00","317,741.00","348,597.00","431,825.00","1,129,600.00","1,562,024.00","3,684,064.00","1,213,360.00","1,687,928.00","1,964,292.00","2,221,221.00","2,929,561.00","3,848,649.00", 
ICS,ICSGlobal Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , ,0.00,0.00,"2,238,000.00","-1,030,800.00","-5,671,519.00","-3,344,633.00","-2,995,266.00","-2,559,882.00","-2,479,495.00","-2,789,133.00","-2,574,724.00","-1,786,600.00","-2,951,751.00","-3,525,835.00","203,650.00","448,169.00","532,403.00","624,662.00","1,003,640.00", 
ICS,ICSGlobal Limited,Annual Balance Sheet - Total Equity, , , , , , , ,--,--,"5,100,000.00","7,456,025.00","1,784,506.00","1,521,156.00","1,745,268.00","975,675.00","654,650.00","911,789.00","3,429,653.00","5,865,806.00","4,505,463.00","2,715,893.00","3,234,852.00","3,679,011.00","4,093,038.00","4,382,195.00","5,080,842.00", 
ICS,ICSGlobal Limited,Annual Balance Sheet - Total Assets, , , , , , , ,--,--,"3,879,000.00","8,240,575.00","2,353,638.00","1,922,793.00","2,213,363.00","1,415,238.00","1,257,128.00","1,461,195.00","4,028,988.00","6,531,275.00","6,743,057.00","2,972,484.00","3,887,648.00","4,209,661.00","4,761,380.00","5,506,471.00","6,802,184.00", 
IDT,IDT Australia Limited,Annual Ratio Analysis - ROE,3.38%,-23.52%,8.44%,16.08%,6.72%,6.88%,9.81%,11.05%,14.13%,24.97%,28.67%,18.06%,18.15%,15.99%,15.27%,15.34%,12.59%,17.99%,21.64%,18.75%,-5.23%,-0.79%,-6.53%,-20.57%,-25.93%,-7.63%, 
IDT,IDT Australia Limited,Annual Profit and Loss - Operating Revenue,"5,283,000.00","3,820,000.00","3,953,000.00","4,451,000.00","4,768,000.00","5,658,000.00","7,534,296.00","8,152,869.00","9,568,542.00","12,274,954.00","14,534,472.00","18,760,805.00","20,876,225.00","25,532,000.00","25,234,000.00","26,546,000.00","24,811,000.00","26,298,000.00","30,871,000.00","26,423,000.00","11,825,000.00","12,770,000.00","9,808,000.00","10,593,000.00","13,171,000.00","15,703,000.00", 
IDT,IDT Australia Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"88,000.00","-840,000.00","199,000.00","390,000.00","333,000.00","343,000.00","512,966.00","631,434.00","891,913.00","1,863,424.00","3,005,152.00","3,696,650.00","4,222,107.00","4,223,000.00","4,260,000.00","4,471,000.00","3,613,000.00","5,467,000.00","7,110,000.00","6,416,000.00","-1,577,000.00","-236,000.00","-1,837,000.00","-5,354,000.00","-6,626,000.00","-2,992,000.00", 
IDT,IDT Australia Limited,Annual Balance Sheet - Total Equity,"2,600,000.00","1,760,000.00","2,357,000.00","2,426,000.00","4,959,000.00","4,985,000.00","5,231,525.00","5,714,879.00","6,310,632.00","7,463,272.00","10,483,474.00","20,471,400.00","23,259,721.00","26,412,000.00","27,890,000.00","29,148,000.00","28,692,000.00","30,390,000.00","32,861,000.00","34,212,000.00","30,142,000.00","29,972,000.00","28,135,000.00","26,029,000.00","25,551,000.00","39,205,000.00", 
IDT,IDT Australia Limited,Annual Balance Sheet - Total Assets,"4,387,000.00","3,221,000.00","3,394,000.00","3,546,000.00","6,035,000.00","7,767,000.00","10,244,491.00","10,943,947.00","12,412,263.00","14,558,883.00","18,463,805.00","28,225,418.00","32,813,992.00","34,243,000.00","36,560,000.00","37,280,000.00","35,376,000.00","36,916,000.00","42,341,000.00","39,460,000.00","33,091,000.00","32,451,000.00","31,775,000.00","30,706,000.00","28,295,000.00","43,200,000.00", 
IDX,Integral Diagnostics Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , ,6.40%,-5.24%, , , , , , , , , , , , ,0.00%, 
IDX,Integral Diagnostics Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , ,--,--, , , , , , , , , , , , ,--, 
IDX,Integral Diagnostics Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , ,"1,021,253.00","-776,484.00", , , , , , , , , , , , ,0.00, 
IDX,Integral Diagnostics Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , ,"15,964,851.00","14,824,890.00", , , , , , , , , , , , ,"68,000,000.00", 
IDX,Integral Diagnostics Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , ,"16,091,076.00","15,151,512.00", , , , , , , , , , , , ,"159,100,000.00", 
IIL,Innate Immunotherapeutics Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , , , , ,0.00%,-61.33%,-107.61%,-123.48%
IIL,Innate Immunotherapeutics Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , , , , ,--,0.00,"30,309.00",0.00
IIL,Innate Immunotherapeutics Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , , , , ,0.00,"-4,495,458.00","-5,236,578.00","-4,943,000.00"
IIL,Innate Immunotherapeutics Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , , , , ,"11,235,000.00","9,772,478.00","4,866,037.00","4,003,000.00"
IIL,Innate Immunotherapeutics Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , , , , ,"11,426,000.00","10,176,209.00","5,318,933.00","5,034,000.00"
IMC,Immuron Limited,Annual Ratio Analysis - ROE, , , , , , , , , ,-12.71%,-22.37%,-20.78%,-26.87%,-25.37%,-28.83%,-19.21%,-68.74%,-170.86%,-270.00%,"1,419.89%",-56.66%,-149.80%,-112.08%,"-2,441.01%",-37.49%,-103.21%, 
IMC,Immuron Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , ,"181,200.00","55,400.00","488,232.00","1,981,753.00","3,285,611.00","3,677,553.00","4,867,597.00","4,002,371.00","4,249,324.00","292,904.00","524,102.00","461,890.00","213,951.00","449,012.00","149,755.00","1,044,142.00","1,123,707.00", 
IMC,Immuron Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , ,"-690,957.00","-993,546.00","-1,553,517.00","-1,699,112.00","-1,279,584.00","-1,162,035.00","-1,333,389.00","-3,559,931.00","-3,281,236.00","-2,858,337.00","-2,317,814.00","-1,905,807.00","-2,595,179.00","-2,297,520.00","-3,539,117.00","-2,544,550.00","-3,447,951.00", 
IMC,Immuron Limited,Annual Balance Sheet - Total Equity, , , , , , , , , ,"5,435,464.00","4,441,918.00","7,475,121.00","6,322,947.00","5,043,363.00","4,031,328.00","6,940,452.00","5,178,647.00","1,920,473.00","1,087,316.00","-184,871.00","3,363,291.00","1,732,379.00","2,049,981.00","144,986.00","6,786,945.00","3,340,839.00", 
IMC,Immuron Limited,Annual Balance Sheet - Total Assets, , , , , , , , , ,"5,653,814.00","4,502,854.00","7,831,401.00","6,576,789.00","5,954,709.00","4,909,765.00","8,054,905.00","6,625,251.00","3,295,978.00","1,899,952.00","493,029.00","3,798,394.00","2,660,215.00","3,638,286.00","2,526,632.00","7,632,245.00","4,548,649.00", 
IMI,IM Medical Ltd,Annual Ratio Analysis - ROE, , , , , , , ,-3.06%,-3.10%,-11.09%,-10.50%,-50.63%,-117.41%,156.62%,-66.99%,-224.90%,-119.75%,-102.45%,-287.81%,-297.35%,"-2,576.84%",-247.13%,-111.82%,-171.01%,-737.30%,111.16%, 
IMI,IM Medical Ltd,Annual Profit and Loss - Operating Revenue, , , , , , , ,--,0.00,0.00,"313,389.00","1,073,696.00","1,464,388.00","440,595.00",0.00,"31,966.00","569,351.00","1,105,142.00","955,743.00","90,738.00","85,168.00","5,915.00","5,493.00",--,--,--, 
IMI,IM Medical Ltd,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , ,"-225,081.00","-510,830.00","-2,018,486.00","-1,257,000.00","-4,087,548.00","-4,701,985.00","-4,955,829.00","491,639.00","-3,137,155.00","-3,192,485.00","-3,187,099.00","-5,468,358.00","-2,451,565.00","-1,686,566.00","-4,068,842.00","-883,813.00","-446,489.00","-404,293.00","-523,762.00", 
IMI,IM Medical Ltd,Annual Balance Sheet - Total Equity, , , , , , , ,"7,355,053.00","6,854,223.00","1,696,783.00","12,081,646.00","8,073,073.00","4,004,809.00","-948,205.00","696,048.00","1,394,935.00","2,665,950.00","3,110,851.00","1,899,968.00","824,471.00","65,451.00","592,893.00","672,221.00","226,007.00","54,834.00","-471,188.00", 
IMI,IM Medical Ltd,Annual Balance Sheet - Total Assets, , , , , , , ,"7,430,563.00","6,931,837.00","1,718,148.00","12,815,589.00","9,027,945.00","4,776,389.00","9,688.00","792,711.00","1,629,570.00","3,450,559.00","3,710,834.00","2,646,095.00","1,069,975.00","456,920.00","2,736,884.00","754,406.00","262,540.00","100,254.00","73,715.00", 
IMU,Imugene Limited,Annual Ratio Analysis - ROE, , , ,4.75%,-12.21%,-20.10%,-28.93%,-35.53%,-63.12%,-74.45%,-159.04%,"1,783.98%",59.70%,-7.67%,-38.95%,-20.74%,-33.85%,-49.03%,-40.92%,12.21%,-40.49%,9.88%,-97.28%,-82.67%,-31.43%,-28.02%, 
IMU,Imugene Limited,Annual Profit and Loss - Operating Revenue, , , ,0.00,0.00,"188,000.00","278,000.00","385,000.00","463,000.00","385,000.00","338,694.00","114,239.00","1,291,796.00",0.00,0.00,0.00,0.00,"1,572.00",0.00,0.00,0.00,"4,454,056.00","235,912.00",0.00,0.00,0.00, 
IMU,Imugene Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , ,"243,000.00","-875,000.00","-2,135,000.00","-4,244,000.00","-2,182,000.00","-4,546,000.00","-4,930,000.00","-4,419,408.00","-4,041,485.00","-782,385.00","-2,044,118.00","-2,115,675.00","-1,794,208.00","-2,187,219.00","-2,304,263.00","-1,910,925.00","650,286.00","-1,535,041.00","415,539.00","-3,133,433.00","-1,559,566.00","-2,115,964.00","-2,440,789.00", 
IMU,Imugene Limited,Annual Balance Sheet - Total Equity, , , ,"5,111,000.00","11,186,000.00","10,621,000.00","8,122,000.00","7,452,000.00","6,755,000.00","5,995,000.00","2,778,850.00","-226,543.00","792,831.00","7,443,323.00","5,431,668.00","8,652,660.00","6,462,381.00","4,699,818.00","4,670,062.00","5,326,348.00","3,791,307.00","4,206,846.00","1,073,413.00","1,886,466.00","6,732,242.00","7,732,003.00", 
IMU,Imugene Limited,Annual Balance Sheet - Total Assets, , , ,"5,698,000.00","11,313,000.00","11,926,000.00","9,249,000.00","8,693,000.00","7,891,000.00","6,893,000.00","3,681,938.00","2,440,544.00","844,390.00","8,144,089.00","6,015,962.00","9,064,183.00","7,268,421.00","5,260,368.00","5,163,427.00","5,763,066.00","4,098,681.00","4,687,123.00","1,318,387.00","2,584,495.00","8,631,475.00","9,114,718.00", 
IPD,ImpediMed Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , ,0.00%,-79.30%,-139.34%,-51.29%,-71.66%,-71.30%,-79.89%,-58.64%,-42.47%, 
IPD,ImpediMed Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , ,--,"3,493,512.00","2,994,291.00","3,639,000.00","3,887,000.00","2,952,000.00","2,733,000.00","3,521,000.00","4,844,000.00", 
IPD,ImpediMed Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , ,0.00,"-9,754,128.00","-14,027,655.00","-11,402,000.00","-14,822,000.00","-12,342,000.00","-8,464,000.00","-7,935,000.00","-14,797,000.00", 
IPD,ImpediMed Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , ,"19,403,537.00","12,300,369.00","10,067,104.00","22,230,000.00","20,683,000.00","17,310,000.00","10,594,000.00","13,532,000.00","34,837,000.00", 
IPD,ImpediMed Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , ,"21,788,942.00","14,515,036.00","13,097,976.00","24,910,000.00","22,805,000.00","19,614,000.00","11,864,000.00","14,958,000.00","37,917,000.00", 
IPN,Independent Practitioner Network Ltd,Annual Ratio Analysis - ROE, , , , , , , , , ,-0.72%,-3.68%,-3.56%,-23.82%,-0.97%,-17.26%,2.96%,17.41%,30.09%,15.29%, , , , , , , , 
IPN,Independent Practitioner Network Ltd,Annual Profit and Loss - Operating Revenue, , , , , , , , , ,"293,550.00","4,471,540.00","12,248,949.00","14,688,704.00","72,573,000.00","71,509,000.00","73,794,000.00","66,343,000.00","74,196,000.00","99,211,000.00", , , , , , , , 
IPN,Independent Practitioner Network Ltd,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , ,"-56,375.00","-290,524.00","-515,832.00","-2,799,037.00","-36,470,000.00","-11,927,000.00","-219,000.00","5,328,000.00","14,018,000.00","8,736,000.00", , , , , , , , 
IPN,Independent Practitioner Network Ltd,Annual Balance Sheet - Total Equity, , , , , , , , , ,"7,801,142.00","7,899,765.00","14,479,977.00","11,748,727.00","28,741,000.00","23,903,000.00","23,684,000.00","32,632,000.00","47,940,000.00","57,140,000.00", , , , , , , , 
IPN,Independent Practitioner Network Ltd,Annual Balance Sheet - Total Assets, , , , , , , , , ,"4,476,102.00","11,935,911.00","16,817,625.00","14,128,963.00","61,811,000.00","51,757,000.00","64,401,000.00","60,450,000.00","98,152,000.00","147,657,000.00", , , , , , , , 
ISF,iSOFT Group Limited,Annual Ratio Analysis - ROE, , , , , , , ,--,--,1.26%,-8.53%,-27.91%,-104.63%,-35.49%,-2.44%,19.02%,15.37%,14.38%,2.46%,4.75%,-141.95%, , , , , , 
ISF,iSOFT Group Limited,Annual Profit and Loss - Operating Revenue, , , , , , , ,"6,771,000.00","9,281,000.00","10,922,000.00","11,224,000.00","17,032,000.00","21,126,000.00","15,885,000.00","20,319,000.00","39,403,000.00","57,955,000.00","74,102,000.00","358,003,000.00","540,124,000.00","433,705,000.00", , , , , , 
ISF,iSOFT Group Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , ,"197,000.00","654,000.00","924,000.00","-6,329,000.00","-17,181,000.00","-49,387,000.00","-487,000.00","439,000.00","10,720,000.00","15,266,000.00","23,029,000.00","14,655,000.00","34,731,000.00","-382,914,000.00", , , , , , 
ISF,iSOFT Group Limited,Annual Balance Sheet - Total Equity, , , , , , , ,--,--,"73,275,000.00","74,218,000.00","61,561,000.00","17,394,000.00","17,759,000.00","19,541,000.00","52,153,000.00","117,945,000.00","156,871,000.00","586,074,000.00","738,870,000.00","264,458,000.00", , , , , , 
ISF,iSOFT Group Limited,Annual Balance Sheet - Total Assets, , , , , , , ,--,--,"78,194,000.00","81,756,000.00","77,133,000.00","32,204,000.00","26,749,000.00","28,422,000.00","70,413,000.00","167,868,000.00","335,657,000.00","1,291,348,000.00","1,301,189,000.00","757,526,000.00", , , , , , 
ITD,ITL Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , ,2.17%,-4.39%,11.23%,4.56%,3.59%,-0.41%,-10.51%,6.25%,21.48%,22.76%,20.22%,17.86%, 
ITD,ITL Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , ,"17,147,046.00","23,974,002.00","31,068,211.00","35,086,672.00","38,283,372.00","43,733,315.00","41,076,000.00","40,879,000.00","28,283,000.00","24,885,000.00","25,864,000.00","28,330,000.00", 
ITD,ITL Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , ,"-2,032,501.00","-139,043.00","3,257,385.00","1,742,917.00","763,633.00","-3,481,751.00","-12,861,000.00","940,000.00","1,323,000.00","2,458,000.00","2,021,000.00","2,121,000.00", 
ITD,ITL Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , ,"24,961,554.00","25,111,916.00","29,006,704.00","38,256,431.00","38,916,719.00","35,747,181.00","14,610,000.00","15,048,000.00","12,807,000.00","10,799,000.00","9,995,000.00","11,879,000.00", 
ITD,ITL Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , ,"32,082,079.00","30,266,019.00","41,545,750.00","53,011,759.00","57,415,794.00","54,866,842.00","36,082,000.00","26,191,000.00","16,494,000.00","15,043,000.00","17,209,000.00","21,823,000.00", 
IVQ,Invitrocue Limited,Annual Ratio Analysis - ROE, , , , , ,11.46%,-8.43%,7.44%,-23.15%,139.54%,95.09%,62.01%,29.46%,-141.03%,234.15%,-11.81%,939.07%,84.85%,56.57%,-153.56%,-11.36%,3.65%,2.49%,111.11%,77.22%,294.19%, 
IVQ,Invitrocue Limited,Annual Profit and Loss - Operating Revenue, , , , , ,"46,548,000.00","36,891,264.00","65,735,924.00","63,405,724.00","31,246,668.00","49,624,809.00","65,426,000.00","88,040,000.00","32,754,000.00","33,903,000.00","32,125,000.00","29,748,000.00","15,681,000.00","11,302,000.00","41,670.00",0.00,--,0.00,0.00,--,0.00, 
IVQ,Invitrocue Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , ,"3,051,000.00","-918,161.00","1,720,097.00","-5,754,909.00","-45,770,554.00","10,054,455.00","9,409,000.00","7,006,000.00","-17,935,000.00","-40,932,000.00","-929,000.00","-10,527,000.00","-10,864,000.00","-16,435,000.00","12,325,409.00","431,203.00","-165,807.00","268,473.00","3,839,027.00","-580,805.00","-66,387.00", 
IVQ,Invitrocue Limited,Annual Balance Sheet - Total Equity, , , , , ,"26,612,000.00","24,299,428.00","30,027,399.00","28,291,448.00","-16,000,048.00","5,545,770.00","15,174,000.00","23,781,000.00","5,981,000.00","-16,029,000.00","7,869,000.00","-1,121,000.00","-12,804,000.00","-29,052,000.00","-4,809,594.00","-4,378,391.00","-4,544,198.00","-4,275,725.00","-150,698.00","-591,503.00","-176,510.00", 
IVQ,Invitrocue Limited,Annual Balance Sheet - Total Assets, , , , , ,"47,245,000.00","41,866,977.00","65,170,050.00","73,135,671.00","26,604,090.00","33,575,429.00","40,894,000.00","54,500,000.00","43,050,000.00","34,527,000.00","27,301,000.00","20,218,000.00","17,942,000.00","15,373,000.00","122,476.00",90.00,"11,448.00","1,382.00","14,302.00","71,424.00","74,138.00", 
IVX,Invion Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , ,0.00%,351.42%,638.53%,-92.15%,-46.89%,-67.76%,-190.10%, 
IVX,Invion Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , ,--,0.00,0.00,0.00,0.00,0.00,0.00, 
IVX,Invion Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , ,0.00,"-16,787,189.00","-13,679,994.00","-5,540,923.00","-5,174,080.00","-6,883,937.00","-13,041,233.00", 
IVX,Invion Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , ,"12,138,420.00","-4,776,893.00","-2,142,416.00","6,013,240.00","11,035,582.00","10,159,077.00","6,860,171.00", 
IVX,Invion Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , ,"24,317,189.00","4,487,629.00","4,729,684.00","6,828,763.00","16,249,871.00","14,730,618.00","16,099,289.00", 
JHC,Japara Healthcare Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , , , , ,0.00%,-1.14%,5.32%, 
JHC,Japara Healthcare Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , , , , ,--,"48,437,000.00","278,262,000.00", 
JHC,Japara Healthcare Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , , , , ,0.00,"-2,938,000.00","28,839,000.00", 
JHC,Japara Healthcare Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , , , , ,"509,700,000.00","513,987,000.00","530,039,000.00", 
JHC,Japara Healthcare Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , , , , ,"781,200,000.00","799,960,000.00","915,799,000.00", 
JHL,Jayex Healthcare Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , , , , , , ,-24.33%, 
JHL,Jayex Healthcare Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , , , , , , ,"1,181,000.00", 
JHL,Jayex Healthcare Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , , , , , , ,"-2,902,000.00", 
JHL,Jayex Healthcare Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , , , , , , ,"15,748,797.00", 
JHL,Jayex Healthcare Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , , , , , , ,"25,948,086.00", 
KKT,Konekt Limited,Annual Ratio Analysis - ROE,-36.59%,-22.99%,-24.77%,4.63%,-36.92%,-2.47%,2.87%,-18.94%,-19.81%,-88.60%,-38.13%,-27.83%,-387.89%,372.84%,-33.20%,-11.56%,-15.98%,-17.29%,-56.09%,34.55%,51.95%,2.76%,7.57%,-2.33%,11.44%,14.48%, 
KKT,Konekt Limited,Annual Profit and Loss - Operating Revenue,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,"1,536,963.00","621,826.00","792,689.00","11,665,726.00","29,218,598.00","30,109,392.00","27,267,460.00","26,955,829.00","32,283,503.00","35,971,000.00","34,135,000.00","32,890,000.00","30,518,000.00","32,796,000.00","35,050,000.00", 
KKT,Konekt Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-693,000.00","-354,000.00","-443,000.00","2,597,000.00","5,574,000.00","-358,000.00","440,221.00","-1,086,504.00","-948,172.00","-868,023.00","-2,115,276.00","-2,102,857.00","-6,010,022.00","-2,405,106.00","-11,139,622.00","-1,340,115.00","-1,468,340.00","-1,526,469.00","-7,228,980.00","1,174,095.00","3,880,000.00","205,000.00","610,000.00","-184,000.00","1,020,000.00","1,478,000.00", 
KKT,Konekt Limited,Annual Balance Sheet - Total Equity,"1,894,000.00","1,540,000.00","3,033,000.00","10,247,000.00","17,275,000.00","15,963,000.00","15,977,661.00","5,735,081.00","4,786,909.00","3,918,886.00","5,547,892.00","7,555,060.00","1,549,405.00","-671,079.00","7,029,190.00","11,591,397.00","9,188,116.00","8,828,005.00","1,798,813.00","3,397,798.00","7,469,000.00","7,434,000.00","8,055,000.00","7,886,000.00","8,916,000.00","10,204,000.00", 
KKT,Konekt Limited,Annual Balance Sheet - Total Assets,"1,925,000.00","1,547,000.00","3,565,000.00","10,290,000.00","18,589,000.00","16,024,000.00","17,837,672.00","5,916,565.00","4,822,861.00","3,925,861.00","6,226,412.00","10,518,623.00","6,618,825.00","443,847.00","11,666,943.00","22,118,321.00","13,572,833.00","13,125,843.00","9,165,538.00","9,714,622.00","12,214,000.00","11,680,000.00","12,149,000.00","11,641,000.00","13,448,000.00","15,504,000.00", 
LBT,LBT Innovations Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , ,0.00%, ,-10.59%,-7.51%,2.55%,10.14%,-8.63%,-9.39%,-27.84%,-24.22%,-4.33%, 
LBT,LBT Innovations Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , ,--, ,"3,394,097.00","1,868,000.00","1,992,000.00","3,457,000.00","500,000.00","842,000.00","4,339,000.00","3,877,000.00","1,922,000.00", 
LBT,LBT Innovations Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , ,0.00, ,"965,338.00","722,000.00","337,000.00","1,488,000.00","-1,162,000.00","-1,156,000.00","531,000.00","292,000.00","321,000.00", 
LBT,LBT Innovations Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , ,"4,678,434.00", ,"12,137,608.00","12,886,000.00","13,237,000.00","14,678,000.00","13,468,000.00","12,312,000.00","12,850,000.00","13,564,000.00","15,684,000.00", 
LBT,LBT Innovations Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , ,"4,894,127.00", ,"16,657,109.00","19,585,000.00","19,837,000.00","21,152,000.00","19,822,000.00","18,381,000.00","18,757,000.00","22,448,000.00","24,574,000.00", 
LCT,Living Cell Technologies Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , ,--,162.79%,-194.46%,-391.12%,-427.26%,-58.94%,-110.79%,-90.94%,-100.52%,39.55%,-22.48%,-80.40%,-137.38%, 
LCT,Living Cell Technologies Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , ,0.00,"72,714.00","65,412.00","1,307.00","18,292.00","51,946.00","186,463.00","517,087.00","176,538.00","3,708,000.00","7,580,000.00","7,394,130.00","611,955.00", 
LCT,Living Cell Technologies Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , ,"-3,609.00","-10,307,766.00","-6,097,309.00","-6,819,611.00","-5,987,322.00","-6,794,037.00","-6,123,562.00","-5,674,059.00","-6,795,708.00","5,676,000.00","-2,979,000.00","-6,778,896.00","-7,043,402.00", 
LCT,Living Cell Technologies Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , ,--,"-1,325,415.00","3,135,554.00","1,743,610.00","1,401,328.00","11,527,248.00","5,527,390.00","6,239,622.00","6,760,236.00","14,353,000.00","13,252,000.00","8,431,577.00","5,126,863.00", 
LCT,Living Cell Technologies Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , ,--,"1,309,448.00","3,944,714.00","4,258,164.00","3,817,446.00","12,241,442.00","6,500,029.00","6,943,366.00","7,471,632.00","15,523,000.00","14,218,000.00","9,664,604.00","5,464,515.00", 
LHC,Lifehealthcare Group Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , , , , ,0.00%,16.53%,8.70%, 
LHC,Lifehealthcare Group Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , , , , ,--,"87,230,000.00","99,309,000.00", 
LHC,Lifehealthcare Group Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , , , , ,0.00,"20,517,000.00","3,744,000.00", 
LHC,Lifehealthcare Group Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , , , , ,"34,300,000.00","43,664,000.00","43,043,000.00", 
LHC,Lifehealthcare Group Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , , , , ,"74,800,000.00","83,604,000.00","95,465,000.00", 
LIP,Lipa Pharmaceuticals Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , ,--,--,56.90%,29.78%,16.01%,13.09%, , , , , , , , , 
LIP,Lipa Pharmaceuticals Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , ,"33,338,000.00","53,791,000.00","77,826,579.00","82,352,000.00","77,894,000.00","87,990,000.00", , , , , , , , , 
LIP,Lipa Pharmaceuticals Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , ,0.00,0.00,"9,541,663.00","10,143,000.00","5,868,000.00","5,109,000.00", , , , , , , , , 
LIP,Lipa Pharmaceuticals Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , ,--,--,"16,770,442.00","34,065,000.00","36,642,000.00","39,016,000.00", , , , , , , , , 
LIP,Lipa Pharmaceuticals Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , ,--,--,"49,960,625.00","70,969,000.00","81,875,000.00","86,150,000.00", , , , , , , , , 
M7T,Mach7 Technologies Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , ,0.00%,-84.85%,-21.07%,-122.96%,-450.72%,76.27%,-25.51%,-30.10%,-200.38%,-56.13%,-48.12%, 
M7T,Mach7 Technologies Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , ,--,"69,000.00","857,000.00","4,777,000.00","2,132,626.00","55,735.00","15,766.00",--,0.00,--,"143,878.00", 
M7T,Mach7 Technologies Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , ,0.00,"-1,523,000.00","-1,519,000.00","-4,418,000.00","-3,874,198.00","-4,488,342.00","1,367,566.00","-423,674.00","-938,813.00","-302,272.00","-6,909,809.00", 
M7T,Mach7 Technologies Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , ,"2,545,451.00","1,795,000.00","7,210,000.00","3,593,000.00","-87,240.00","-4,436,566.00","1,831,000.00","1,407,326.00","468,513.00","538,506.00","3,096,688.00", 
M7T,Mach7 Technologies Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , ,"2,557,119.00","2,062,000.00","8,335,000.00","5,932,000.00","4,831,147.00","832,619.00","1,867,888.00","1,485,407.00","688,906.00","624,305.00","3,688,958.00", 
MDC,Medlab Clinical Limited,Annual Ratio Analysis - ROE,2.02%,-100.16%,5.19%,21.43%,40.33%,26.24%,18.72%,17.78%,18.73%,23.93%,38.41%,-7.86%,7.02%, , , , , , , , , , , ,0.00%, , 
MDC,Medlab Clinical Limited,Annual Profit and Loss - Operating Revenue,"708,182,016.00","715,060,992.00","409,908,000.00","238,454,000.00","379,491,008.00","315,985,984.00","321,756,992.00","355,028,992.00","387,256,000.00","449,048,992.00","509,628,000.00","208,912,000.00","551,960,000.00", , , , , , , , , , , ,--, , 
MDC,Medlab Clinical Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"1,855,000.00","-71,762,000.00","158,000.00","-2,463,000.00","-3,409,000.00","25,448,000.00","8,758,000.00","11,174,000.00","15,055,000.00","21,071,000.00","19,013,000.00","-3,932,000.00","5,729,000.00", , , , , , , , , , , ,0.00, , 
MDC,Medlab Clinical Limited,Annual Balance Sheet - Total Equity,"74,460,992.00","22,236,016.00","26,963,000.00","21,193,000.00","13,344,000.00","46,140,000.00","51,504,000.00","62,855,000.00","76,251,000.00","84,682,000.00","100,017,000.00","101,194,000.00","97,150,000.00", , , , , , , , , , , ,"10,458,130.00", , 
MDC,Medlab Clinical Limited,Annual Balance Sheet - Total Assets,"340,845,000.00","211,817,000.00","88,879,000.00","118,617,000.00","134,882,000.00","150,975,000.00","159,220,000.00","177,684,000.00","202,208,000.00","210,309,000.00","244,886,000.00","249,784,000.00","255,560,000.00", , , , , , , , , , , ,"11,033,603.00", , 
MDE,MedAire Inc,Annual Ratio Analysis - ROE, , , , , , , , , , , ,0.00%,-66.78%,-38.82%,-45.01%,-14.58%,-85.56%,69.32%, , , , , , , , , 
MDE,MedAire Inc,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , ,--,"11,011,234.00","23,281,437.00","32,707,798.00","38,658,008.00","38,099,975.00","34,788,580.00", , , , , , , , , 
MDE,MedAire Inc,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , ,0.00,"-539,000.00","-1,427,784.00","-1,428,220.00","-538,228.00","-2,022,422.00","3,232,942.00", , , , , , , , , 
MDE,MedAire Inc,Annual Balance Sheet - Total Equity, , , , , , , , , , , ,"4,381,000.00","1,191,073.00","4,191,036.00","3,173,329.00","3,692,558.00","2,363,610.00","4,664,032.00", , , , , , , , , 
MDE,MedAire Inc,Annual Balance Sheet - Total Assets, , , , , , , , , , , ,"12,826,000.00","5,808,357.00","17,815,922.00","16,779,473.00","17,218,382.00","17,682,828.00","18,972,215.00", , , , , , , , , 
MDG,Medtech Global Limited,Annual Ratio Analysis - ROE,-66.26%,-51.55%,-28.20%,-22.53%,-19.58%,-4.62%,-13.90%,6.81%,-10.30%,-50.93%,-2.23%,-82.21%,-15.77%,-42.84%,-54.57%,-66.44%,-7.29%,-1.64%,-34.23%,-14.07%,-2.15%,1.27%,-0.79%,-6.90%,-61.56%,-35.05%,-111.52%
MDG,Medtech Global Limited,Annual Profit and Loss - Operating Revenue,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,"1,676,210.00","1,450,328.00","2,485,755.00","1,497,474.00","1,749,103.00","1,617,500.00","4,564,340.00","8,347,455.00","9,001,376.00","9,302,964.00","10,872,225.00","9,616,907.00","11,801,246.00","16,613,024.00","17,606,632.00","19,800,000.00"
MDG,Medtech Global Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-606,000.00","-585,000.00","-823,000.00","-953,000.00","-450,000.00","-330,000.00","-320,980.00","356,870.00","-699,387.00","-1,724,351.00","-929,724.00","-14,690,000.00","-2,465,069.00","-8,461,954.00","-3,134,869.00","-2,260,280.00","-358,114.00","-315,132.00","-4,944,999.00","-1,808,720.00","-269,960.00","161,224.00","-107,184.00","-856,787.00","-4,135,234.00","-1,999,778.00","-2,325,000.00"
MDG,Medtech Global Limited,Annual Balance Sheet - Total Equity,"892,000.00","997,000.00","1,674,000.00","1,798,000.00","2,298,000.00","1,968,000.00","2,156,461.00","5,238,954.00","6,789,566.00","2,031,753.00","32,509,745.00","17,861,332.00","15,649,340.00","8,127,493.00","5,609,271.00","3,348,991.00","4,824,691.00","19,159,290.00","14,367,693.00","12,851,400.00","12,574,711.00","12,729,312.00","12,630,946.00","12,000,951.00","7,749,205.00","5,998,917.00","1,962,000.00"
MDG,Medtech Global Limited,Annual Balance Sheet - Total Assets,"936,000.00","1,023,000.00","1,702,000.00","1,854,000.00","2,369,000.00","2,043,000.00","2,212,567.00","5,459,477.00","7,617,645.00","2,109,778.00","32,947,451.00","18,579,187.00","16,129,876.00","8,602,821.00","7,640,003.00","4,784,855.00","6,392,787.00","22,008,303.00","17,552,508.00","16,025,428.00","14,860,366.00","16,093,851.00","15,709,818.00","16,413,960.00","13,170,869.00","11,827,672.00","8,920,000.00"
MDR,MedAdvisor Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , ,0.00%,-4.47%,-35.73%,-33.73%,"-3,583.50%",624.02%, 
MDR,MedAdvisor Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , ,--,--,--,--,0.00,--, 
MDR,MedAdvisor Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , ,0.00,"-70,229.00","-993,412.00","-3,747,017.00","-11,144,067.00","-666,965.00", 
MDR,MedAdvisor Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , ,"3,177,612.00","3,139,470.00","2,780,558.00","11,109,810.00","310,983.00","-106,882.00", 
MDR,MedAdvisor Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , ,"3,177,612.00","3,407,738.00","3,288,384.00","11,906,175.00","705,497.00","197,699.00", 
MDV,Medivac Limited,Annual Ratio Analysis - ROE, , , ,51.28%,33.08%,9.70%,-56.30%,-52.58%,10.11%,351.42%,31.57%,-76.66%,364.90%,188.36%,-17.56%,-90.07%,"-1,340.00%",307.43%,-52.88%,-29.65%,-49.58%,-36.26%,-35.98%,"4,549.05%", , , 
MDV,Medivac Limited,Annual Profit and Loss - Operating Revenue, , , ,"38,531,000.00","57,589,000.00","88,268,000.00","72,816,000.00","83,293,000.00","86,407,000.00","87,718,000.00","81,181,000.00","87,155,000.00","79,698,000.00","9,768,000.00","9,000.00","459,000.00","675,000.00","850,791.00","607,552.00","1,018,010.00","201,251.00","191,779.00","91,502.00","741,700.00", , , 
MDV,Medivac Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , ,"1,484,000.00","3,189,000.00","500,000.00","-4,602,000.00","-2,945,000.00","670,000.00","-7,247,000.00","2,187,000.00","-3,193,000.00","-5,657,000.00","-4,144,000.00","-2,466,000.00","-7,092,000.00","-8,375,000.00","-2,863,117.00","-1,991,596.00","-1,120,433.00","-2,529,505.00","-2,321,574.00","-3,486,209.00","-4,748,870.00", , , 
MDV,Medivac Limited,Annual Balance Sheet - Total Equity, , , ,"2,884,000.00","9,699,000.00","9,604,000.00","4,217,000.00","2,893,000.00","6,629,000.00","-704,000.00","6,944,000.00","4,159,000.00","-1,520,000.00","-2,200,000.00","14,041,000.00","7,874,000.00","625,000.00","-931,316.00","3,766,179.00","3,778,246.00","5,101,792.00","5,418,692.00","3,310,423.00","-38,762.00", , , 
MDV,Medivac Limited,Annual Balance Sheet - Total Assets, , , ,"12,339,000.00","28,005,000.00","33,884,000.00","24,721,000.00","31,605,000.00","32,350,000.00","22,524,000.00","27,484,000.00","30,325,000.00","22,325,000.00",--,"15,226,000.00","9,087,000.00","2,345,000.00","1,433,134.00","5,482,571.00","5,861,210.00","6,287,490.00","6,167,175.00","4,647,538.00","1,775,633.00", , , 
MEB,Medibio Limited,Annual Ratio Analysis - ROE, , , , , , , , , , ,-1.43%,-27.19%,-61.97%,-39.49%,-31.97%,-33.39%,-34.44%,-75.98%,-82.06%,-123.33%,-247.50%,-273.46%,-136.11%,-43.21%,-15.80%,-39.68%, 
MEB,Medibio Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , ,--,"140,719.00","155,375.00","57,590.00","36,755.00","113,053.00","17,159.00","8,356.00",0.00,--,"1,456.00","294,042.00","52,397.00","19,230.00",0.00,0.00, 
MEB,Medibio Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , ,"-108,092.00","-1,882,228.00","-4,482,733.00","-3,381,332.00","-2,282,838.00","-1,828,453.00","-777,877.00","-1,429,844.00","-4,657,171.00","-3,035,460.00","-3,301,454.00","-3,220,121.00","-3,326,955.00","-1,096,713.00","-428,332.00","-7,921,702.00", 
MEB,Medibio Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , ,"7,552,912.00","6,047,687.00","6,051,096.00","5,150,325.00","4,857,705.00","4,436,495.00","2,258,400.00","1,881,778.00","5,675,610.00","2,461,300.00","1,097,552.00","1,177,537.00","2,444,327.00","2,538,153.00","2,710,271.00","9,111,081.00", 
MEB,Medibio Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , ,"8,142,538.00","6,999,481.00","6,963,638.00","5,437,908.00","5,134,661.00","4,676,083.00","2,442,382.00","2,061,596.00","6,172,678.00","2,723,535.00","1,408,569.00","3,276,813.00","5,476,283.00","5,418,911.00","5,042,517.00","15,184,514.00", 
MEM,Memphasys Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , ,-274.83%,-499.04%,687.96%,25.63%,-3.79%,-71.54%,-147.92%,160.03%,-306.55%, 
MEM,Memphasys Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , ,"660,000.00","1,311,678.00","1,625,743.00","1,589,911.00","1,081,093.00","1,780,350.00","918,654.00","850,855.00","189,630.00", 
MEM,Memphasys Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , ,"-4,947,000.00","-5,496,190.00","-2,741,323.00","3,291,709.00","-6,321,097.00","-6,308,215.00","-1,841,920.00","-3,842,140.00","-2,645,684.00", 
MEM,Memphasys Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , ,"1,800,000.00","1,101,357.00","-398,471.00","12,843,038.00","6,995,083.00","4,562,379.00","6,990,106.00","-992,848.00","746,591.00", 
MEM,Memphasys Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , ,"4,463,000.00","5,055,784.00","5,756,596.00","17,717,066.00","10,571,264.00","8,951,867.00","13,632,034.00","7,102,391.00","6,844,468.00", 
MEQ,Metlifecare Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , , , , , ,8.69%,13.39%, 
MEQ,Metlifecare Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , , , , , ,"90,856,000.00","84,334,159.00", 
MEQ,Metlifecare Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , , , , , ,"68,776,000.00","108,604,568.00", 
MEQ,Metlifecare Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , , , , , ,"791,803,000.00","807,012,573.00", 
MEQ,Metlifecare Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , , , , , ,"2,009,684,000.00","1,972,217,991.00", 
MGZ,Medigard Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , ,0.00%,-6.20%,-11.59%,-29.52%,-13.10%,-99.67%,-91.37%,-87.72%,-72.35%,-60.12%,-140.83%,333.62%,85.66%, 
MGZ,Medigard Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , ,--,0.00,"15,997.00",0.00,0.00,"115,629.00",0.00,0.00,0.00,0.00,--,--,--, 
MGZ,Medigard Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , ,0.00,"-201,888.00","-338,110.00","-669,393.00","-264,957.00","-1,258,995.00","-761,323.00","-400,158.00","-638,390.00","-331,276.00","-322,223.00","-326,743.00","-585,260.00", 
MGZ,Medigard Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , ,"4,879,984.00","3,255,296.00","2,917,186.00","2,267,743.00","2,021,986.00","1,263,215.00","833,255.00","456,191.00","882,304.00","551,028.00","228,805.00","-97,938.00","-683,198.00", 
MGZ,Medigard Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , ,"4,888,288.00","3,301,275.00","2,957,359.00","2,313,764.00","2,072,276.00","1,327,795.00","1,023,347.00","604,683.00","933,452.00","576,165.00","252,147.00","138,619.00","268,133.00", 
MIA,MIA Group Limited,Annual Ratio Analysis - ROE, , , , , , , , ,--,0.00%,6.53%,6.66%,6.37%,4.16%,4.29%, , , , , , , , , , , , 
MIA,MIA Group Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , ,"157,000,000.00","172,700,000.00","170,442,000.00","203,913,000.00","345,757,000.00","388,488,000.00","380,549,000.00", , , , , , , , , , , , 
MIA,MIA Group Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , ,0.00,0.00,"15,843,000.00","17,843,000.00","25,814,000.00","-25,599,000.00","18,308,000.00", , , , , , , , , , , , 
MIA,MIA Group Limited,Annual Balance Sheet - Total Equity, , , , , , , , ,--,"175,785,000.00","143,565,000.00","266,456,000.00","391,155,000.00","338,731,000.00","340,736,000.00", , , , , , , , , , , , 
MIA,MIA Group Limited,Annual Balance Sheet - Total Assets, , , , , , , , ,--,"306,509,000.00","277,507,000.00","397,777,000.00","677,504,000.00","658,567,000.00","649,237,000.00", , , , , , , , , , , , 
MLA,Medical Australia Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , ,-87.34%,-208.02%,-209.11%,-39.35%,-57.41%,-43.88%,-7.83%,-13.50%,-36.49%,1.31%,-1.55%, 
MLA,Medical Australia Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , ,"239,594.00","547,817.00","1,364,286.00","4,657,709.00","7,612,308.00","7,298,003.00","8,781,299.00","9,211,228.00","9,152,303.00","11,874,962.00","14,856,014.00", 
MLA,Medical Australia Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , ,"-2,393,196.00","-2,266,839.00","-1,183,669.00","-1,505,746.00","-2,190,381.00","-1,342,889.00","-342,723.00","-668,924.00","-1,316,146.00","73,613.00","-691,525.00", 
MLA,Medical Australia Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , ,"2,740,148.00","1,089,719.00","566,050.00","3,826,507.00","3,815,636.00","3,060,480.00","4,375,005.00","4,956,161.00","3,607,255.00","9,407,598.00","10,348,707.00", 
MLA,Medical Australia Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , ,"3,176,157.00","1,190,026.00","1,028,246.00","7,271,128.00","8,186,104.00","6,582,690.00","7,418,526.00","7,554,248.00","6,505,074.00","12,140,471.00","12,486,008.00", 
MMJ,MMJ Phytotech Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , , , , , ,0.00%,-181.14%, 
MMJ,MMJ Phytotech Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , , , , , ,--,--, 
MMJ,MMJ Phytotech Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , , , , , ,0.00,"-4,882,396.00", 
MMJ,MMJ Phytotech Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , , , , , ,"4,904,186.00","3,593,879.00", 
MMJ,MMJ Phytotech Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , , , , , ,"4,961,432.00","3,814,571.00", 
MSB,Mesoblast Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , ,0.00%,-7.92%,-69.36%,-42.49%,-38.38%,-47.64%,-38.98%,-2.13%,-14.86%,-9.78%,-14.60%,-19.59%, 
MSB,Mesoblast Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , ,--,--,"27,712.00","727,531.00",--,0.00,0.00,"29,483,085.00","27,682,896.00","18,260,000.00","16,410,000.00","20,483,000.00", 
MSB,Mesoblast Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , ,0.00,"-1,517,141.00","-8,298,587.00","-8,728,131.00","-10,062,379.00","-12,285,459.00","-14,780,895.00","90,606,590.00","-71,145,314.00","-61,663,000.00","-80,958,000.00","-119,368,000.00", 
MSB,Mesoblast Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , ,"20,812,400.00","19,150,467.00","11,965,045.00","20,539,339.00","26,216,132.00","25,789,962.00","37,919,260.00","515,844,173.00","478,847,783.00","630,266,000.00","571,718,000.00","609,359,000.00", 
MSB,Mesoblast Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , ,"24,595,191.00","21,353,535.00","16,384,515.00","21,238,238.00","27,788,902.00","26,975,012.00","39,514,770.00","763,250,507.00","720,455,550.00","883,712,000.00","899,314,000.00","1,017,925,000.00", 
MVF,Monash IVF Group Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , , , , , ,3.72%,16.55%, 
MVF,Monash IVF Group Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , , , , , ,"114,012,000.00","121,913,000.00", 
MVF,Monash IVF Group Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , , , , , ,"4,852,000.00","21,373,000.00", 
MVF,Monash IVF Group Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , , , , , ,"124,820,000.00","144,025,000.00", 
MVF,Monash IVF Group Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , , , , , ,"246,358,000.00","283,789,000.00", 
MVP,Medical Developments International Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , ,0.00%,5.74%,2.00%,8.07%,10.95%,7.55%,6.86%,6.91%,12.06%,16.72%,14.67%,5.53%,8.78%, 
MVP,Medical Developments International Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , ,"5,475,000.00","3,048,000.00","5,404,000.00","6,605,000.00","7,460,000.00","9,219,000.00","8,727,000.00","8,296,000.00","10,206,000.00","11,313,000.00","11,733,000.00","9,370,000.00","11,608,000.00", 
MVP,Medical Developments International Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , ,0.00,"481,000.00","168,000.00","797,000.00","1,207,000.00","891,000.00","810,000.00","879,000.00","1,743,000.00","2,704,000.00","2,309,000.00","875,000.00","1,529,000.00", 
MVP,Medical Developments International Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , ,"7,502,000.00","8,374,000.00","8,400,000.00","9,872,000.00","11,021,000.00","11,801,000.00","11,814,000.00","12,712,000.00","14,455,000.00","16,169,000.00","15,744,000.00","15,824,000.00","17,407,000.00", 
MVP,Medical Developments International Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , ,"11,633,000.00","12,472,000.00","11,555,000.00","12,499,000.00","12,115,000.00","13,189,000.00","13,392,000.00","14,215,000.00","16,713,000.00","19,136,000.00","20,259,000.00","22,560,000.00","22,988,000.00", 
MX1,Micro-X Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , , , , , , ,0.00%, 
MX1,Micro-X Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , , , , , , ,--, 
MX1,Micro-X Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , , , , , , ,0.00, 
MX1,Micro-X Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , , , , , , ,"28,425,216.00", 
MX1,Micro-X Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , , , , , , ,"31,125,441.00", 
MXC,MGC Pharmaceuticals Ltd,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , ,0.00%,-7.46%,-97.38%,"22,108.98%",101.61%,-23.52%,-36.94%,-9.65%,-114.68%,-197.10%, 
MXC,MGC Pharmaceuticals Ltd,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , ,--,0.00,0.00,"334,065.00","703,326.00",0.00,0.00,--,0.00,--, 
MXC,MGC Pharmaceuticals Ltd,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , ,0.00,"-284,396.00","-1,886,078.00","-1,945,590.00","-3,180,089.00","1,935,168.00","-290,880.00","-766,897.00","-5,337,815.00","-3,797,791.00", 
MXC,MGC Pharmaceuticals Ltd,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , ,"2,762,327.00","3,814,118.00","1,936,790.00","-8,790.00","-3,138,329.00","828,302.00","787,422.00","7,944,781.00","4,549,136.00","1,926,812.00", 
MXC,MGC Pharmaceuticals Ltd,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , ,"5,370,386.00","4,791,321.00","2,640,695.00","16,419,629.00","14,131,700.00","1,093,823.00","992,363.00","8,703,770.00","4,978,430.00","2,520,603.00", 
MYP,Mayne Pharma Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , ,0.00%,4.75%, , , , , , , , , , 
MYP,Mayne Pharma Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , ,--,"792,009,000.00", , , , , , , , , , 
MYP,Mayne Pharma Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , ,0.00,"-31,335,000.00", , , , , , , , , , 
MYP,Mayne Pharma Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , ,"1,660,588,000.00","1,751,022,000.00", , , , , , , , , , 
MYP,Mayne Pharma Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , ,"1,908,754,000.00","2,008,342,000.00", , , , , , , , , , 
MYX,Mayne Pharma Group Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , ,-12.57%,-30.36%,-48.82%,12.73%,11.10%,13.58%,5.14%,11.63%,4.14%, 
MYX,Mayne Pharma Group Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , ,--,--,0.00,"35,427,602.00","48,504,000.00","50,897,000.00","82,262,000.00","142,181,000.00","140,324,000.00", 
MYX,Mayne Pharma Group Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , ,"-1,823,975.00","-3,472,806.00","-3,761,318.00","3,253,119.00","1,679,000.00","6,153,000.00","-2,843,000.00","21,290,000.00","7,537,000.00", 
MYX,Mayne Pharma Group Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , ,"14,514,302.00","11,438,427.00","7,704,263.00","25,549,756.00","24,174,000.00","30,600,000.00","120,889,000.00","159,274,000.00","322,202,000.00", 
MYX,Mayne Pharma Group Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , ,"15,510,458.00","11,693,279.00","8,035,794.00","71,149,412.00","53,677,000.00","53,933,000.00","233,391,000.00","265,820,000.00","528,946,000.00", 
NAN,Nanosonics Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , ,-18.21%,-29.10%,-53.67%,-34.65%,-78.39%,-17.99%,-26.57%,-12.75%,-12.02%, 
NAN,Nanosonics Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , ,"8,424.00",0.00,"309,000.00","763,000.00","2,247,000.00","12,301,000.00","14,899,000.00","21,492,000.00","22,214,000.00", 
NAN,Nanosonics Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , ,"-5,703,524.00","-7,147,000.00","-8,754,000.00","-8,172,000.00","-11,214,000.00","-4,679,000.00","-5,768,000.00","-2,605,000.00","-5,460,000.00", 
NAN,Nanosonics Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , ,"31,317,211.00","24,559,000.00","16,312,000.00","23,582,000.00","14,306,000.00","26,003,000.00","21,707,000.00","20,435,000.00","44,676,000.00", 
NAN,Nanosonics Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , ,"33,396,993.00","25,632,000.00","17,582,000.00","24,948,000.00","16,848,000.00","36,660,000.00","33,653,000.00","33,544,000.00","60,365,000.00", 
NEU,Neuren Pharmaceuticals Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , ,--,--,-65.18%,-41.78%,-62.65%,-160.95%,-276.70%,1.33%,-136.92%,-48.96%,-78.56%,-46.01%,-42.99%,-93.02%, 
NEU,Neuren Pharmaceuticals Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , ,"2,121,352.00","2,835,768.00","1,516,522.00","429,665.00","172,967.00","944,160.00","2,274,362.00","5,003,237.00","4,648,090.00",0.00,0.00,0.00,0.00,0.00, 
NEU,Neuren Pharmaceuticals Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , ,"-5,458,093.00","-5,647,038.00","-5,694,111.00","-8,308,425.00","-10,115,905.00","-12,152,545.00","-15,419,489.00","-26,711.00","-4,990,509.00","-4,740,966.00","-5,190,355.00","-11,336,519.00","-8,316,000.00","-13,397,000.00", 
NEU,Neuren Pharmaceuticals Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , ,--,--,"8,735,462.00","19,884,177.00","16,146,576.00","7,550,642.00","5,572,563.00","7,348,227.00","3,533,520.00","9,453,023.00","6,340,418.00","24,355,179.00","19,078,000.00","14,402,000.00", 
NEU,Neuren Pharmaceuticals Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , ,--,--,"12,961,971.00","35,204,558.00","19,523,894.00","14,586,048.00","8,544,542.00","10,284,927.00","5,717,105.00","11,136,553.00","8,481,916.00","26,413,273.00","22,106,000.00","16,904,000.00", 
NHL,Nova Health Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , ,0.00%,1.59%,-3.89%,4.23%, , , , , , , , , , , , 
NHL,Nova Health Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , ,"49,200,000.00","14,377,000.00","107,984,000.00","143,778,000.00", , , , , , , , , , , , 
NHL,Nova Health Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , ,0.00,"924,000.00","-65,409,000.00","-7,864,000.00", , , , , , , , , , , , 
NHL,Nova Health Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , ,"59,100,000.00","58,148,000.00","10,522,000.00","20,658,000.00", , , , , , , , , , , , 
NHL,Nova Health Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , ,"87,200,000.00","91,000,000.00","97,705,000.00","90,608,000.00", , , , , , , , , , , , 
NRT,Novogen Limited,Annual Ratio Analysis - ROE, , , , , ,-4.29%,-6.70%,-8.18%,-54.07%,-36.06%,0.00%,-37.87%,-27.50%,-24.99%,-16.86%,-19.61%,-38.22%,-49.25%,-66.03%,-79.94%,-110.33%,-188.34%,-175.05%,-43.42%,-494.27%,-15.98%, 
NRT,Novogen Limited,Annual Profit and Loss - Operating Revenue, , , , , ,"40,000.00","45,000.00","5,000.00","5,084,000.00","19,782,000.00","23,407,000.00","27,260,000.00","19,582,000.00","19,630,000.00","12,720,000.00","13,404,000.00","13,500,000.00","12,515,000.00","9,537,000.00","8,336,000.00","7,985,000.00","1,716,000.00","1,162,000.00","1,067,319.00",0.00,0.00, 
NRT,Novogen Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , ,"-555,000.00","-1,027,000.00","-2,304,000.00","-12,576,000.00","-17,409,000.00","-13,679,000.00","-21,764,000.00","-14,673,000.00","-10,666,000.00","-12,579,000.00","-12,281,000.00","-17,913,000.00","-24,296,000.00","-24,777,000.00","-23,787,000.00","-15,246,000.00","-9,479,000.00","-1,350,000.00","-784,560.00","-7,568,725.00","-7,306,045.00", 
NRT,Novogen Limited,Annual Balance Sheet - Total Equity, , , , , ,"12,945,000.00","15,341,000.00","28,174,000.00","23,004,000.00","48,275,000.00","52,724,000.00","51,906,000.00","54,045,000.00","42,397,000.00","69,211,000.00","60,492,000.00","44,578,000.00","44,626,000.00","35,637,000.00","28,773,000.00","13,176,000.00","4,420,000.00","5,113,000.00","4,040,802.00","1,412,034.00","44,362,053.00", 
NRT,Novogen Limited,Annual Balance Sheet - Total Assets, , , , , ,"13,608,000.00","18,511,000.00","32,348,000.00","28,584,000.00","56,796,000.00","65,018,000.00","61,206,000.00","61,900,000.00","50,812,000.00","77,413,000.00","67,485,000.00","51,098,000.00","51,357,000.00","43,401,000.00","37,842,000.00","19,290,000.00","12,727,000.00","8,985,000.00","5,748,194.00","4,659,097.00","46,139,441.00", 
NVL,National Veterinary Care Ltd,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , , , , , ,0.00%, , 
NVL,National Veterinary Care Ltd,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , , , , , ,--, , 
NVL,National Veterinary Care Ltd,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , , , , , ,0.00, , 
NVL,National Veterinary Care Ltd,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , , , , , ,"45,116,000.00", , 
NVL,National Veterinary Care Ltd,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , , , , , ,"67,610,000.00", , 
OBJ,OBJ Limited,Annual Ratio Analysis - ROE, , , , , , , , , ,0.00%,16.40%,-170.71%,-827.21%,129.89%,-11.04%,-100.45%,-249.36%,-75.22%,-81.76%,-410.33%,-18.93%,-20.02%,-42.75%,-41.35%,-57.59%,-66.08%, 
OBJ,OBJ Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , ,"4,711,000.00","6,594,781.00",0.00,"4,162,950.00","2,011,703.00",0.00,0.00,--,"119,492.00","750,396.00","406,340.00","774,408.00","601,346.00","519,077.00","673,159.00","806,691.00","1,394,623.00", 
OBJ,OBJ Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , ,0.00,"1,473,000.00","-5,664,345.00","-2,960,305.00","-1,555,048.00","721,109.00","-1,234,506.00","-1,433,090.00","-1,396,511.00","-925,519.00","-1,732,579.00","-954,931.00","-897,529.00","-1,411,442.00","-1,331,572.00","-2,205,354.00","-2,353,454.00", 
OBJ,OBJ Limited,Annual Balance Sheet - Total Equity, , , , , , , , , ,"7,368,000.00","8,982,432.00","3,318,172.00","357,867.00","-1,197,181.00","903,539.00","1,229,033.00","574,713.00","1,856,660.00","1,131,991.00","422,242.00","5,044,777.00","4,483,519.00","3,301,347.00","3,220,129.00","3,829,184.00","3,561,633.00", 
OBJ,OBJ Limited,Annual Balance Sheet - Total Assets, , , , , , , , , ,"8,591,000.00","11,347,942.00","5,394,582.00","2,624,975.00","599,632.00","914,983.00","1,364,537.00","645,626.00","2,146,999.00","1,538,609.00","1,547,959.00","5,554,545.00","4,931,468.00","3,724,757.00","3,636,099.00","4,290,300.00","4,126,423.00", 
OCC,Orthocell Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , , , , ,0.00%,"-5,728.42%",-85.38%, 
OCC,Orthocell Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , , , , ,--,"691,405.00","790,430.00", 
OCC,Orthocell Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , , , , ,0.00,"-2,182,185.00","-3,742,715.00", 
OCC,Orthocell Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , , , , ,"7,904,118.00","76,188.00","4,383,790.00", 
OCC,Orthocell Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , , , , ,"9,571,252.00","5,137,881.00","6,536,133.00", 
OHE,Orion Health Group Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , , , , , ,0.00%,-53.92%,-75.89%
OHE,Orion Health Group Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , , , , , ,--,"160,933,791.00","186,427,927.00"
OHE,Orion Health Group Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , , , , , ,0.00,"-59,651,790.00","-49,009,009.00"
OHE,Orion Health Group Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , , , , , ,"27,372,666.00","110,624,816.00","55,727,927.00"
OHE,Orion Health Group Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , , , , , ,"102,447,237.00","197,440,902.00","141,784,684.00"
OIL,Optiscan Imaging Limited,Annual Ratio Analysis - ROE, , , , , , , , ,-11.58%,-19.48%,-15.27%,-35.58%,-12.78%,-16.30%,-25.41%,-40.28%,-38.17%,-21.54%,-64.70%,-187.20%,-126.96%,1.07%,-798.71%,-67.61%,767.73%,796.41%, 
OIL,Optiscan Imaging Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , ,"477,906.00","368,377.00","782,233.00","137,426.00","406,896.00","104,195.00","2,434,700.00","1,102,174.00","3,232,015.00","5,707,536.00","1,840,649.00","2,887,626.00","1,233,748.00","1,776,954.00","381,791.00","1,303,345.00","71,883.00","46,092.00", 
OIL,Optiscan Imaging Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , ,"-1,571,001.00","-1,343,007.00","-2,670,634.00","-4,689,847.00","-2,504,145.00","-3,426,015.00","-3,362,577.00","-5,830,434.00","-3,936,760.00","-2,139,481.00","-4,984,340.00","-6,413,370.00","-1,650,799.00","14,405.00","-2,502,450.00","-643,950.00","-1,417,712.00","-1,395,399.00", 
OIL,Optiscan Imaging Limited,Annual Balance Sheet - Total Equity, , , , , , , , ,"7,737,408.00","6,894,401.00","17,493,537.00","13,181,519.00","19,597,066.00","16,183,369.00","12,899,916.00","13,381,323.00","10,313,494.00","9,933,167.00","7,703,514.00","1,757,167.00","1,300,262.00","1,342,714.00","313,310.00","952,456.00","-184,662.00","-175,211.00", 
OIL,Optiscan Imaging Limited,Annual Balance Sheet - Total Assets, , , , , , , , ,"8,396,766.00","8,036,232.00","18,254,080.00","13,655,178.00","22,043,957.00","19,317,634.00","13,715,461.00","14,419,011.00","11,977,822.00","11,604,304.00","9,230,080.00","2,876,396.00","2,192,401.00","2,199,650.00","1,180,671.00","1,510,433.00","816,352.00","1,018,211.00", 
ONE,Oneview Healthcare Plc,Annual Ratio Analysis - ROE, , , , , , , , ,20.99%,2.30%,-27.27%, , , , , , , , , , , , , , ,0.00%, 
ONE,Oneview Healthcare Plc,Annual Profit and Loss - Operating Revenue, , , , , , , , ,"207,336,000.00","325,984,992.00","653,400,000.00", , , , , , , , , , , , , , ,--, 
ONE,Oneview Healthcare Plc,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , ,"5,910,000.00","6,965,000.00","-291,100,000.00", , , , , , , , , , , , , , ,0.00, 
ONE,Oneview Healthcare Plc,Annual Balance Sheet - Total Equity, , , , , , , , ,"28,161,000.00","363,030,000.00","944,800,000.00", , , , , , , , , , , , , , ,"47,400,000.00", 
ONE,Oneview Healthcare Plc,Annual Balance Sheet - Total Assets, , , , , , , , ,"78,199,000.00","525,966,992.00","1,435,500,000.00", , , , , , , , , , , , , , ,"51,800,000.00", 
ONT,1300 Smiles Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , ,52.83%,33.89%,30.42%,34.62%,41.38%,33.25%,32.79%,23.74%,22.78%,17.07%,20.69%, 
ONT,1300 Smiles Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , ,"5,343,425.00",0.00,"4,334,451.00","15,105,352.00","21,933,000.00","23,138,000.00","27,438,000.00","35,763,000.00","35,605,000.00","31,231,000.00","36,358,000.00", 
ONT,1300 Smiles Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , ,"1,501,920.00","1,857,818.00","1,800,435.00","2,347,961.00","3,810,000.00","4,327,000.00","5,144,000.00","6,175,000.00","6,367,000.00","4,987,000.00","6,580,000.00", 
ONT,1300 Smiles Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , ,"2,842,777.00","5,481,560.00","5,917,967.00","6,781,545.00","9,208,000.00","13,013,000.00","15,690,000.00","26,013,000.00","27,952,000.00","29,219,000.00","31,800,000.00", 
ONT,1300 Smiles Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , ,"3,531,119.00","6,771,188.00","6,782,599.00","15,841,746.00","16,271,000.00","24,891,000.00","27,434,000.00","38,519,000.00","33,846,000.00","38,806,000.00","40,084,000.00", 
OPT,Opthea Limited,Annual Ratio Analysis - ROE,-32.72%,-8.74%,-8.84%,-17.62%,-17.02%,-22.77%,-22.39%,-26.26%,-45.76%,33.12%,-4.98%,-3.34%,-3.99%,-9.64%,13.92%,58.20%,-11.44%,-29.50%,-2.42%,-25.59%,-30.76%,-47.04%,-25.58%,-35.35%,-41.91%,-25.41%, 
OPT,Opthea Limited,Annual Profit and Loss - Operating Revenue,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,"17,500.00","17,500.00",0.00,"22,554.00","15,000.00",0.00,0.00,0.00,0.00,0.00,0.00,0.00, 
OPT,Opthea Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-621,000.00","-181,000.00","-81,000.00","-511,000.00","-62,000.00","-665,000.00","-1,129,000.00","-1,403,969.00","-1,981,036.00","2,370,320.00","1,223,376.00","-1,623,000.00","-5,743,579.00","-3,506,768.00","5,802,611.00","21,764,179.00","-6,515,401.00","6,295,707.00","-2,286,119.00","-9,921,670.00","-6,948,240.00","-10,265,346.00","-4,906,456.00","-5,004,506.00","-3,989,618.00","-5,400,994.00", 
OPT,Opthea Limited,Annual Balance Sheet - Total Equity,"1,898,000.00","1,717,000.00","2,206,000.00","2,435,000.00","2,873,000.00","2,921,000.00","4,869,000.00","5,323,536.00","4,329,192.00","7,155,912.00","25,122,180.00","47,424,163.00","41,348,205.00","36,382,174.00","41,695,543.00","37,545,530.00","56,690,576.00","60,965,707.00","51,407,413.00","38,773,219.00","31,820,094.00","21,824,173.00","20,196,855.00","14,358,946.00","10,479,256.00","21,721,612.00", 
OPT,Opthea Limited,Annual Balance Sheet - Total Assets,"1,930,000.00","1,755,000.00","2,258,000.00","2,467,000.00","2,917,000.00","3,018,000.00","4,990,000.00","5,490,803.00","4,491,130.00","7,298,018.00","25,487,451.00","47,749,254.00","41,719,598.00","36,854,503.00","42,142,283.00","43,170,581.00","59,008,265.00","66,858,680.00","53,852,597.00","41,279,161.00","34,668,418.00","24,502,397.00","22,604,994.00","16,411,959.00","12,461,333.00","24,072,855.00", 
OSL,Oncosil Medical Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , ,-2.94%,-2.35%,-35.77%,-67.71%,-10.28%,-66.42%,-21.91%,-17.36%,-14.53%,-34.68%,-41.36%, 
OSL,Oncosil Medical Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , ,--,"1,511,829.00","1,758,370.00","2,034,055.00","2,302,907.00","2,087,124.00",0.00,0.00,0.00,0.00,0.00, 
OSL,Oncosil Medical Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , ,"-26,420.00","-128,266.00","-1,674,138.00","-2,767,299.00","-440,178.00","-1,712,021.00","-1,458,019.00","-430,970.00","-879,168.00","-4,217,103.00","-2,879,031.00", 
OSL,Oncosil Medical Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , ,"899,564.00","5,457,397.00","4,679,676.00","4,087,090.00","4,282,053.00","2,577,727.00","2,913,145.00","2,482,775.00","6,050,566.00","12,160,130.00","6,961,449.00", 
OSL,Oncosil Medical Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , ,"946,590.00","8,184,518.00","7,001,921.00","6,166,948.00","5,227,984.00","2,958,675.00","3,030,030.00","2,523,562.00","6,243,516.00","12,280,852.00","7,407,148.00", 
OSP,Osprey Medical Inc.,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , , , ,-40.27%,-42.91%,-87.53%,-104.48%, 
OSP,Osprey Medical Inc.,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , , , ,0.00,0.00,"9,412.00","236,914.00", 
OSP,Osprey Medical Inc.,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , , , ,"-5,878,507.00","-9,620,668.00","-11,854,602.00","-16,648,039.00", 
OSP,Osprey Medical Inc.,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , , , ,"14,597,019.00","22,421,438.00","13,543,126.00","15,934,712.00", 
OSP,Osprey Medical Inc.,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , , , ,"15,194,456.00","23,820,525.00","15,038,931.00","17,252,485.00", 
OVN,Oventus Medical Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , , , , , , ,0.00%, 
OVN,Oventus Medical Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , , , , , , ,--, 
OVN,Oventus Medical Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , , , , , , ,0.00, 
OVN,Oventus Medical Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , , , , , , ,"14,686,027.00", 
OVN,Oventus Medical Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , , , , , , ,"15,675,778.00", 
PAA,PharmAust Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , ,-52.23%,-106.80%,-114.29%,-386.70%,-53.95%,-41.66%,-46.02%,-68.78%,-31.95%,-7.55%,-505.10%,-351.30%,-205.60%,-16.97%,-21.78%, 
PAA,PharmAust Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , ,--,"678,804.00","311,147.00","350,132.00","3,233,308.00","6,105,754.00","4,585,314.00","2,794,581.00","1,755,622.00","1,640,838.00","1,552,477.00","1,617,814.00","1,710,255.00","1,880,793.00","1,869,204.00", 
PAA,PharmAust Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , ,"-2,094,482.00","-3,705,897.00","-2,073,134.00","-2,584,719.00","-3,363,712.00","-2,752,284.00","-3,606,048.00","-5,767,973.00","-179,596.00","-438,600.00","-5,797,886.00","-4,260,420.00","-514,883.00","-1,317,853.00","-1,925,091.00", 
PAA,PharmAust Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , ,"4,010,108.00","3,469,794.00","1,814,000.00","741,022.00","3,868,393.00","7,686,448.00","7,835,162.00","5,914,246.00","5,856,611.00","5,807,239.00","1,147,860.00","1,212,760.00","310,877.00","7,764,157.00","8,839,066.00", 
PAA,PharmAust Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , ,"4,989,908.00","4,925,787.00","2,512,494.00","904,885.00","5,274,665.00","9,169,658.00","10,168,022.00","7,992,603.00","7,570,230.00","6,827,622.00","1,450,806.00","2,408,664.00","905,421.00","8,209,633.00","9,522,285.00", 
PAB,Patrys Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , ,0.00%,-31.88%,-48.89%,-49.47%,-55.12%,-41.05%,-32.76%,-58.62%,-78.38%, 
PAB,Patrys Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , ,--,--,"3,735.00","4,654.00","7,599.00","4,851.00","2,643.00",0.00,0.00, 
PAB,Patrys Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , ,0.00,"-7,323,602.00","-8,662,339.00","-7,535,123.00","-7,421,670.00","-5,108,891.00","-3,529,095.00","-7,289,090.00","-8,470,382.00", 
PAB,Patrys Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , ,"818,810.00","22,975,675.00","17,717,576.00","15,232,766.00","13,465,487.00","12,445,818.00","10,772,602.00","12,434,269.00","3,970,340.00", 
PAB,Patrys Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , ,"818,810.00","23,857,975.00","19,177,243.00","16,306,876.00","14,846,227.00","13,362,175.00","11,853,845.00","14,813,698.00","4,772,623.00", 
PAR,Paradigm Biopharmaceuticals Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , , , , , , ,0.00%, 
PAR,Paradigm Biopharmaceuticals Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , , , , , , ,--, 
PAR,Paradigm Biopharmaceuticals Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , , , , , , ,0.00, 
PAR,Paradigm Biopharmaceuticals Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , , , , , , ,"14,464,259.00", 
PAR,Paradigm Biopharmaceuticals Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , , , , , , ,"15,041,584.00", 
PBO,PanBio Limited,Annual Ratio Analysis - ROE, , , , , , , , ,7.80%,7.60%,0.02%,-0.53%,-8.19%,-28.10%,-25.62%,-15.34%,2.81%,4.29%, , , , , , , , , 
PBO,PanBio Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , ,"5,216,197.00","6,235,089.00","7,573,892.00","11,413,311.00","17,604,391.00","15,088,333.00","14,616,317.00","15,397,749.00","18,229,000.00","18,828,000.00", , , , , , , , , 
PBO,PanBio Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , ,"171,855.00","187,729.00","3,548.00","-96,254.00","-1,360,258.00","-4,319,815.00","-3,119,135.00","-1,696,634.00","351,000.00","554,000.00", , , , , , , , , 
PBO,PanBio Limited,Annual Balance Sheet - Total Equity, , , , , , , , ,"2,203,241.00","2,470,734.00","18,180,762.00","18,225,998.00","16,616,989.00","12,189,859.00","12,174,815.00","11,059,353.00","12,494,000.00","12,921,000.00", , , , , , , , , 
PBO,PanBio Limited,Annual Balance Sheet - Total Assets, , , , , , , , ,"3,960,756.00","4,134,996.00","23,421,576.00","25,537,329.00","24,464,625.00","18,722,785.00","15,554,118.00","14,261,512.00","16,644,000.00","16,904,000.00", , , , , , , , , 
PBP,Probiotec Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , ,0.00%,13.09%,14.31%,17.02%,12.91%,10.47%,3.57%,2.32%,1.47%,-6.79%, 
PBP,Probiotec Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , ,--,"53,991,931.00","66,138,816.00","87,146,623.00","75,040,646.00","71,770,144.00","66,046,188.00","67,342,884.00","68,214,622.00","65,679,685.00", 
PBP,Probiotec Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , ,0.00,"4,977,524.00","6,309,098.00","8,900,922.00","9,480,874.00","-10,337,787.00","1,249,380.00","596,869.00","903,668.00","-24,742,302.00", 
PBP,Probiotec Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , ,"30,535,000.00","38,022,400.00","44,079,844.00","52,284,179.00","73,453,476.00","61,315,353.00","62,474,150.00","63,519,089.00","64,320,407.00","39,631,155.00", 
PBP,Probiotec Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , ,"63,911,000.00","77,914,121.00","85,905,143.00","102,258,413.00","126,247,372.00","106,561,756.00","101,165,392.00","109,862,566.00","104,490,677.00","73,007,404.00", 
PBT,Prana Biotechnology Limited,Annual Ratio Analysis - ROE, , , , , , , , , ,-0.36%,-6.40%,-19.35%,-32.69%,-28.97%,-25.54%,-127.63%,-134.25%,-198.54%,-137.44%,-200.62%,-93.83%,-92.79%,-93.17%,-55.72%,-35.37%,-15.05%, 
PBT,Prana Biotechnology Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , ,--,--,"226,000.00","567,250.00",238.00,0.00,"6,286.00","1,050,286.00",0.00,170.00,--,--,0.00,0.00,0.00,0.00,0.00, 
PBT,Prana Biotechnology Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , ,"-80,000.00","-1,326,000.00","-4,138,979.00","-5,448,467.00","-4,584,838.00","-9,885,614.00","-25,008,597.00","-11,719,309.00","-11,142,320.00","-13,560,678.00","-7,522,789.00","-4,906,922.00","-6,431,185.00","-5,239,469.00","-7,787,242.00","-13,329,239.00","-5,885,069.00", 
PBT,Prana Biotechnology Limited,Annual Balance Sheet - Total Equity, , , , , , , , , ,"21,961,232.00","20,729,307.00","21,392,877.00","16,668,986.00","15,823,703.00","38,702,559.00","19,594,176.00","8,729,350.00","5,612,195.00","9,866,327.00","3,749,816.00","5,229,316.00","6,931,202.00","5,623,447.00","13,974,713.00","37,686,287.00","39,113,264.00", 
PBT,Prana Biotechnology Limited,Annual Balance Sheet - Total Assets, , , , , , , , , ,"21,961,232.00","20,876,444.00","22,314,743.00","17,581,319.00","16,389,926.00","41,415,398.00","22,289,159.00","10,421,146.00","7,722,185.00","11,698,313.00","4,597,250.00","6,801,417.00","9,010,952.00","7,341,868.00","17,073,821.00","41,640,855.00","41,834,382.00", 
PGC,Paragon Care Limited,Annual Ratio Analysis - ROE, , , , , , , , , ,-8.28%,-92.50%,429.62%,185.39%,"-2,602.26%",-91.31%,-84.65%,-67.39%,-145.11%,-323.61%,-11.47%,4.41%,16.84%,-5.04%,7.13%,8.16%,10.22%, 
PGC,Paragon Care Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , ,"10,856,000.00","2,563,947.00","34,092,229.00","29,317,775.00",0.00,0.00,"249,584.00","699,128.00","290,815.00",0.00,"1,100,374.00","8,284,917.00","14,661,391.00","15,718,566.00","17,065,462.00","19,355,131.00","32,192,460.00", 
PGC,Paragon Care Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , ,"-528,000.00","-3,943,682.00","-8,209,438.00","-5,224,782.00","-1,789,384.00","-529,525.00","-1,645,578.00","-1,401,723.00","-1,716,555.00","-1,811,737.00","-355,832.00","147,782.00","851,183.00","-77,484.00","739,603.00","1,084,891.00","2,103,156.00", 
PGC,Paragon Care Limited,Annual Balance Sheet - Total Equity, , , , , , , , , ,"6,375,513.00","4,263,223.00","6,336,447.00","2,166,776.00","126,763.00","579,944.00","1,943,895.00","2,080,039.00","1,182,894.00","559,847.00","3,103,302.00","3,348,625.00","5,054,878.00","6,446,067.00","10,369,476.00","18,208,265.00","20,583,582.00", 
PGC,Paragon Care Limited,Annual Balance Sheet - Total Assets, , , , , , , , , ,"6,691,122.00","6,262,337.00","10,594,477.00","9,460,439.00","368,333.00","733,197.00","2,404,140.00","2,690,373.00","1,460,294.00","1,343,781.00","3,958,591.00","11,797,810.00","18,054,873.00","16,511,765.00","18,389,289.00","26,950,713.00","40,585,967.00", 
PHG,Pulse Health Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , ,-4.37%,-43.32%,-271.73%,-285.19%,-111.52%,-9.92%,-61.44%,-8.81%,6.92%,3.74%,18.67%,4.43%,7.32%, 
PHG,Pulse Health Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , ,441.00,"16,583.00","98,108.00",--,--,"23,956,212.00","31,114,383.00","34,520,000.00",0.00,"39,363,000.00",0.00,"52,255,000.00","56,138,000.00", 
PHG,Pulse Health Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , ,"-121,600.00","-1,281,323.00","-2,140,033.00","-631,886.00","-1,295,743.00","-1,121,808.00","-6,160,482.00","-1,311,000.00","385,000.00","697,000.00","2,734,000.00","875,000.00","2,547,000.00", 
PHG,Pulse Health Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , ,"2,780,951.00","2,627,589.00","787,556.00","221,570.00","1,161,933.00","11,305,959.00","4,787,403.00","10,571,000.00","11,005,000.00","19,610,000.00","22,285,000.00","52,074,000.00","53,448,000.00", 
PHG,Pulse Health Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , ,"2,780,951.00","2,691,324.00","960,212.00","309,759.00","3,335,439.00","35,677,434.00","44,832,577.00","44,848,000.00","44,561,000.00","53,328,000.00","51,995,000.00","62,757,000.00","96,099,000.00", 
PHL,Pearl Healthcare Limited,Annual Ratio Analysis - ROE, , , , ,-10.48%,-12.19%,13.73%,-36.93%,-202.24%,475.14%,-33.63%,-735.43%,"1,878.29%",1.80%,-3.88%,-17.44%,-224.31%,-588.53%,206.34%,-245.58%,35.60%,323.70%, , , , , 
PHL,Pearl Healthcare Limited,Annual Profit and Loss - Operating Revenue, , , , ,0.00,0.00,0.00,0.00,0.00,"33,222.00","605,806.00","617,572.00","156,598.00","11,831,964.00","19,318,282.00","16,677,903.00","15,589,528.00","14,328,373.00","13,822,626.00","13,959,495.00","13,966,705.00","13,057,707.00", , , , , 
PHL,Pearl Healthcare Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , ,"-83,000.00","-318,000.00","681,504.00","-2,444,818.00","-5,271,474.00","3,115,904.00","-2,468,410.00","-8,116,229.00","-1,953,067.00","386,124.00","-6,038,611.00","-2,520,524.00","-16,752,541.00","-1,410,122.00","-1,133,888.00","-509,463.00","124,625.00","-506,569.00", , , , , 
PHL,Pearl Healthcare Limited,Annual Balance Sheet - Total Equity, , , , ,"3,516,000.00","5,121,000.00","7,189,615.00","6,961,322.00","2,767,229.00","655,788.00","7,339,513.00","1,103,599.00","-98,564.00","21,494,233.00","16,354,193.00","14,448,701.00","1,374,739.00","239,602.00","-549,526.00","207,449.00","350,074.00","-156,495.00", , , , , 
PHL,Pearl Healthcare Limited,Annual Balance Sheet - Total Assets, , , , ,"3,776,000.00","5,393,000.00","7,406,025.00","7,338,590.00","2,969,730.00","909,980.00","7,917,995.00","1,744,682.00","649,833.00","29,512,635.00","21,706,839.00","19,671,490.00","6,734,397.00","5,672,138.00","4,744,211.00","4,417,874.00","4,280,098.00","3,977,966.00", , , , , 
PIQ,Proteomics International Laboratories Ltd,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , , , , , ,0.00%,-63.66%, 
PIQ,Proteomics International Laboratories Ltd,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , , , , , ,--,"608,394.00", 
PIQ,Proteomics International Laboratories Ltd,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , , , , , ,0.00,"-1,149,202.00", 
PIQ,Proteomics International Laboratories Ltd,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , , , , , ,"4,940,699.00","1,805,285.00", 
PIQ,Proteomics International Laboratories Ltd,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , , , , , ,"5,234,394.00","2,532,298.00", 
PLI,Peplin Inc.,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , ,0.00%,-160.08%,"-2,361.23%", , , , , , , 
PLI,Peplin Inc.,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , ,--,"43,044.00","19,462.00", , , , , , , 
PLI,Peplin Inc.,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , ,0.00,"-26,964,728.00","-54,064,158.00", , , , , , , 
PLI,Peplin Inc.,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , ,"23,255,719.00","16,844,724.00","2,289,663.00", , , , , , , 
PLI,Peplin Inc.,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , ,"28,382,809.00","37,366,607.00","28,794,068.00", , , , , , , 
PLT,Polartechnics Limited,Annual Ratio Analysis - ROE,-64.56%,-55.16%,-29.50%,-69.08%,-70.51%,-77.00%,-55.13%,-80.68%,-314.29%,-164.92%,-68.89%,-174.00%,-101.09%,-147.62%,-63.11%,-199.24%,"-1,623.08%",-433.23%,-163.49%, , , , , , , , 
PLT,Polartechnics Limited,Annual Profit and Loss - Operating Revenue,"10,000.00",0.00,0.00,0.00,0.00,0.00,0.00,0.00,"70,740.00",0.00,0.00,"932,731.00","127,380.00","517,797.00","3,502,946.00","5,996,038.00","6,522,661.00","3,630,060.00","1,605,570.00", , , , , , , , 
PLT,Polartechnics Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-337,000.00","-246,000.00","-290,000.00","-1,499,000.00","-336,000.00","-1,940,000.00","-1,305,291.00","-443,914.00","-4,523,018.00","-4,908,820.00","-6,368,000.00","-7,606,404.00","-8,895,923.00","-7,577,141.00","-6,059,337.00","-8,367,938.00","-6,572,335.00","-7,788,105.00","-8,987,787.00", , , , , , , , 
PLT,Polartechnics Limited,Annual Balance Sheet - Total Equity,"522,000.00","446,000.00","983,000.00","2,170,000.00","2,262,000.00","2,657,000.00","5,240,312.00","5,980,858.00","1,699,674.00","4,611,274.00","11,884,869.00","4,371,472.00","8,800,146.00","5,132,960.00","9,601,631.00","4,199,879.00","404,931.00","1,797,681.00","5,497,508.00", , , , , , , , 
PLT,Polartechnics Limited,Annual Balance Sheet - Total Assets,"548,000.00","465,000.00","1,032,000.00","2,548,000.00","6,791,000.00","2,908,000.00","11,502,976.00","12,163,004.00","8,940,494.00","26,791,686.00","28,657,790.00","20,483,027.00","25,190,013.00","21,192,277.00","10,816,733.00","5,471,585.00","2,430,197.00","4,039,598.00","6,593,421.00", , , , , , , , 
PME,Pro Medicus Limited,Annual Ratio Analysis - ROE, , , , , , , , , ,40.65%,99.61%,79.49%,64.57%,42.30%,32.30%,42.85%,46.30%,49.46%,50.39%,35.20%,23.30%,3.31%,4.72%,-16.59%,7.29%,14.66%, 
PME,Pro Medicus Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , ,"5,087,000.00","8,905,000.00","9,987,000.00","7,258,000.00","9,100,000.00","7,900,000.00","10,276,000.00","11,298,000.00","12,539,000.00","9,157,000.00","9,940,000.00","19,197,000.00","13,969,000.00","11,249,000.00","11,154,000.00","14,250,000.00","17,468,000.00", 
PME,Pro Medicus Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , ,"1,242,000.00","3,291,000.00","4,086,000.00","4,812,000.00","4,546,000.00","3,577,000.00","5,493,000.00","6,115,000.00","7,052,000.00","7,933,000.00","5,683,000.00","3,920,000.00","503,000.00","1,791,000.00","5,131,000.00","1,509,000.00","3,217,000.00", 
PME,Pro Medicus Limited,Annual Balance Sheet - Total Equity, , , , , , , , , ,"3,410,000.00","3,304,000.00","5,140,000.00","7,452,000.00","10,748,000.00","11,075,000.00","12,818,000.00","13,206,000.00","14,257,000.00","15,744,000.00","16,143,000.00","16,825,000.00","15,198,000.00","16,002,000.00","20,959,000.00","20,707,000.00","21,938,000.00", 
PME,Pro Medicus Limited,Annual Balance Sheet - Total Assets, , , , , , , , , ,"5,175,000.00","6,948,000.00","9,375,000.00","11,384,000.00","12,543,000.00","13,058,000.00","15,418,000.00","15,512,000.00","17,554,000.00","19,543,000.00","21,978,000.00","24,136,000.00","23,108,000.00","23,144,000.00","29,418,000.00","29,223,000.00","29,749,000.00", 
PNM,Pallane Medical Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , ,0.00%,-19.55%,-101.66%,-167.19%,249.25%,79.89%, , , , , , , 
PNM,Pallane Medical Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , ,--,"533,686.00",--,--,--,400.00, , , , , , , 
PNM,Pallane Medical Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , ,0.00,"-997,786.00","-2,299,330.00","-2,846,609.00","-3,100,496.00","-3,432,208.00", , , , , , , 
PNM,Pallane Medical Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , ,"5,312,282.00","5,104,147.00","2,261,715.00","1,702,603.00","-1,243,953.00","-4,296,393.00", , , , , , , 
PNM,Pallane Medical Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , ,"5,341,161.00","5,193,006.00","2,894,620.00","1,884,715.00","973,389.00","1,289,291.00", , , , , , , 
PNO,PharmaNet Group Limited,Annual Ratio Analysis - ROE,-17.06%,-95.97%,14.56%,10.02%,350.00%,-61.23%,"-68,938.28%",100.38%,142.68%,-18.65%,-28.14%,-60.82%,-53.22%,-78.85%,"-1,709.54%",35.22%,229.23%,203.28%,215.25%,90.93%,-236.30%,-629.93%,-209.76%,-21.18%,65.49%, , 
PNO,PharmaNet Group Limited,Annual Profit and Loss - Operating Revenue,"74,000.00","48,000.00","43,000.00","54,000.00","36,000.00","52,000.00","31,404.00","32,444.00","23,373.00","13,793.00","14,819.00","18,330.00","8,633.00","12,361.00","3,816,037.00","5,484,374.00","2,497.00","89,032.00",0.00,0.00,0.00,"140,402.00","201,024.00","813,049.00","204,603.00", , 
PNO,PharmaNet Group Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-496,000.00","-2,485,000.00","-1,040,000.00","-41,000.00","-126,000.00","-169,000.00","-275,621.00","-75,635.00","-238,120.00","-1,608,802.00","-2,791,416.00","-3,907,548.00","-2,033,631.00","-698,584.00","-2,092,887.00","-833,690.00","-3,546,889.00","-1,157,963.00","-937,706.00","-948,860.00","-1,075,790.00","-1,507,621.00","-2,146,826.00","-2,245,884.00","-2,158,897.00", , 
PNO,PharmaNet Group Limited,Annual Balance Sheet - Total Equity,"2,907,000.00","422,000.00","-618,000.00","-659,000.00","-36,000.00","276,000.00",290.00,"-75,345.00","-144,965.00","3,234,316.00","7,182,949.00","3,455,400.00","1,749,951.00","1,071,367.00","122,424.00","1,824,533.00","-730,796.00","-569,643.00","-429,823.00","-1,072,093.00","417,891.00","211,448.00","99,475.00","-1,236,359.00","-3,410,278.00", , 
PNO,PharmaNet Group Limited,Annual Balance Sheet - Total Assets,"3,712,000.00","1,206,000.00","162,000.00","139,000.00","778,000.00","391,000.00","98,208.00","75,411.00","32,175.00","3,796,749.00","7,559,508.00","4,045,633.00","1,977,715.00","1,250,564.00","2,335,448.00","2,727,131.00","972,283.00","566,107.00","705,842.00","561,869.00","2,175,552.00","2,383,392.00","2,096,343.00","856,339.00","236,573.00", , 
PNV,Polynovo Limited,Annual Ratio Analysis - ROE, , , , , , , , , ,-24.58%,-31.10%,-79.13%,-34.83%,-136.88%,-57.20%,-62.29%,-49.61%,-64.49%,-26.98%,-12.55%,-13.54%,-27.32%,-33.62%,-18.98%,-33.68%,-36.79%, 
PNV,Polynovo Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , ,"222,572.00",0.00,0.00,--,0.00,836.00,0.00,178.00,"4,366.00",0.00,0.00,"121,910.00","388,201.00",0.00,0.00,"55,375.00","3,000.00", 
PNV,Polynovo Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , ,"-1,635,642.00","-3,563,405.00","-5,071,000.00","-5,731,276.00","-8,570,079.00","-9,543,526.00","-10,764,589.00","-11,293,869.00","-13,406,939.00","-4,441,167.00","-1,830,175.00","-2,305,353.00","-2,944,402.00","-2,702,726.00","-1,497,555.00","-2,941,975.00","-1,414,321.00", 
PNV,Polynovo Limited,Annual Balance Sheet - Total Equity, , , , , , , , , ,"6,655,299.00","11,458,422.00","6,408,197.00","12,148,571.00","6,261,207.00","16,684,516.00","17,281,740.00","22,764,614.00","20,788,032.00","16,461,066.00","15,822,858.00","13,741,844.00","10,640,479.00","7,988,617.00","7,817,880.00","8,668,011.00","7,393,306.00", 
PNV,Polynovo Limited,Annual Balance Sheet - Total Assets, , , , , , , , , ,"7,077,935.00","11,962,309.00","7,222,797.00","12,614,331.00","7,474,346.00","18,651,033.00","18,686,235.00","24,948,501.00","22,017,251.00","17,162,756.00","17,287,778.00","15,021,442.00","11,771,471.00","8,909,102.00","8,618,688.00","9,413,718.00","8,125,790.00", 
POH,Phosphagenics Limited,Annual Ratio Analysis - ROE, , , ,-8.70%,9.76%,-21.97%,-11.39%,-398.12%,-243.28%,10.02%,-5.68%,-14.09%,-29.37%,-9.06%,-2.78%,-5.54%,-4.52%,-6.61%,23.97%,-17.01%,-28.91%,1.52%,-17.66%,-33.39%,-19.16%,-38.15%, 
POH,Phosphagenics Limited,Annual Profit and Loss - Operating Revenue, , , ,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,"139,014.00",0.00,0.00,"184,000.00","1,379,000.00","1,586,000.00","2,508,000.00","670,000.00","4,660,000.00","2,516,000.00","1,284,000.00","1,376,000.00","2,053,000.00","1,880,000.00", 
POH,Phosphagenics Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , ,"816,000.00","-341,000.00","17,622,000.00","-3,096,184.00","-21,692,944.00","-3,861,570.00","503,571.00","-1,174,000.00","-5,365,120.00","-4,348,764.00","-2,661,601.00","-3,148,261.00","-7,323,000.00","-6,125,000.00","-8,844,000.00","-91,206,000.00","-8,501,000.00","-11,275,000.00","1,106,000.00","-11,055,000.00","-12,673,000.00","-8,935,000.00","-20,120,000.00", 
POH,Phosphagenics Limited,Annual Balance Sheet - Total Equity, , , ,"10,416,000.00","10,813,000.00","28,903,000.00","27,175,053.00","5,448,883.00","1,587,313.00","5,024,114.00","20,674,736.00","18,340,983.00","14,808,464.00","29,383,188.00","113,222,855.00","132,184,000.00","135,474,000.00","133,762,000.00","51,553,000.00","49,989,000.00","39,007,000.00","72,946,000.00","62,612,000.00","40,771,000.00","49,028,000.00","28,928,000.00", 
POH,Phosphagenics Limited,Annual Balance Sheet - Total Assets, , , ,"11,875,000.00","11,193,000.00","34,482,000.00","33,010,823.00","5,522,365.00","1,620,477.00","5,096,276.00","20,859,986.00","18,397,402.00","14,838,814.00","29,408,306.00","114,033,586.00","171,072,000.00","173,494,000.00","171,521,000.00","69,189,000.00","67,364,000.00","53,768,000.00","76,577,000.00","64,121,000.00","42,958,000.00","50,901,000.00","30,744,000.00", 
PPH,Pan Pharmaceuticals Limited,Annual Ratio Analysis - ROE, , , , , , , ,--,--,2.24%,8.59%,9.65%,9.75%, , , , , , , , , , , , , , 
PPH,Pan Pharmaceuticals Limited,Annual Profit and Loss - Operating Revenue, , , , , , , ,"59,169,554.00","65,385,673.00","70,728,458.00","45,352,000.00","86,824,000.00","101,556,000.00", , , , , , , , , , , , , , 
PPH,Pan Pharmaceuticals Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , ,"5,654,904.00","7,522,908.00","10,623,778.00","6,791,000.00","13,582,000.00","14,540,000.00", , , , , , , , , , , , , , 
PPH,Pan Pharmaceuticals Limited,Annual Balance Sheet - Total Equity, , , , , , , ,--,--,"131,450,437.00","79,069,000.00","140,712,000.00","149,088,000.00", , , , , , , , , , , , , , 
PPH,Pan Pharmaceuticals Limited,Annual Balance Sheet - Total Assets, , , , , , , ,--,--,"149,663,653.00","139,374,000.00","166,213,000.00","171,729,000.00", , , , , , , , , , , , , , 
PRR,Prima BioMed Limited,Annual Ratio Analysis - ROE,-3.32%,-6.67%,-51.87%,10.34%,-0.83%,-2.39%,-61.89%,-242.63%,-32.84%,-18.73%,-37.51%,-25.22%,-69.15%,-140.14%,-98.07%,-74.60%,-67.34%,-76.94%,-71.67%,-162.53%,-60.90%,-38.26%,-53.67%,-52.06%,-59.06%,-130.22%, 
PRR,Prima BioMed Limited,Annual Profit and Loss - Operating Revenue,"34,000.00","7,000.00","103,000.00","832,000.00","1,514,000.00","1,663,000.00","2,679,250.00","658,707.00","47,841.00",0.00,--,--,0.00,"2,501.00","211,003.00","403,095.00","86,738.00","130,345.00",--,--,0.00,"1,066,196.00","25,766.00",0.00,"15,929.00","168,322.00", 
PRR,Prima BioMed Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-43,000.00","-322,000.00","-333,000.00","74,000.00","-92,000.00","-278,000.00","-953,494.00","-1,551,964.00","286,359.00","-1,902,514.00","-703,845.00","-2,064,636.00","-3,965,058.00","-5,781,644.00","-5,664,015.00","-7,076,303.00","-4,357,874.00","-3,139,034.00","-1,887,378.00","-2,946,442.00","-12,159,115.00","-21,081,167.00","-19,940,960.00","-15,225,671.00","-13,343,381.00","-32,151,696.00", 
PRR,Prima BioMed Limited,Annual Balance Sheet - Total Equity,"1,297,000.00","975,000.00","642,000.00","716,000.00","2,424,000.00","2,470,000.00","1,355,184.00","399,480.00","677,541.00","2,199,245.00","1,876,400.00","4,142,832.00","5,460,409.00","3,093,448.00","5,126,211.00","8,343,101.00","6,316,598.00","4,080,070.00","2,633,433.00","1,812,522.00","16,787,514.00","55,099,130.00","37,157,871.00","29,248,418.00","22,592,320.00","24,689,743.00", 
PRR,Prima BioMed Limited,Annual Balance Sheet - Total Assets,"1,351,000.00","1,016,000.00","703,000.00","1,205,000.00","2,642,000.00","4,717,000.00","5,095,947.00","4,257,924.00","1,708,087.00","2,354,211.00","2,094,961.00","4,244,271.00","5,926,161.00","3,968,331.00","5,767,688.00","9,131,212.00","7,359,924.00","4,358,277.00","2,821,250.00","2,489,620.00","19,011,184.00","57,640,661.00","41,612,671.00","32,814,298.00","25,377,955.00","30,983,445.00", 
PRY,Primary Health Care Limited,Annual Ratio Analysis - ROE, , , , , , , , ,8.94%,8.78%,4.93%,5.68%,3.86%,6.76%,7.78%,8.73%,11.97%,13.91%,3.22%,5.42%,5.35%,4.15%,4.54%,5.61%,5.92%,10.96%, 
PRY,Primary Health Care Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , ,"12,277,672.00","36,919,000.00","62,931,000.00","89,763,000.00","102,931,000.00","126,817,000.00","150,424,000.00","197,999,000.00","240,716,000.00","271,189,000.00","649,332,000.00","1,327,989,000.00","1,286,822,000.00","1,308,980,000.00","1,390,880,000.00","1,455,772,000.00","1,520,378,000.00","1,614,002,000.00", 
PRY,Primary Health Care Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , ,"2,281,529.00","4,128,000.00","5,438,000.00","6,325,000.00","6,329,000.00","12,590,000.00","18,041,000.00","27,936,000.00","47,480,000.00","56,762,000.00","7,589,000.00","110,705,000.00","134,153,000.00","79,763,000.00","118,942,000.00","152,008,000.00","162,554,000.00","136,495,000.00", 
PRY,Primary Health Care Limited,Annual Balance Sheet - Total Equity, , , , , , , , ,"25,508,323.00","47,009,000.00","110,253,000.00","111,333,000.00","172,539,000.00","186,287,000.00","198,554,000.00","320,013,000.00","392,415,000.00","409,406,000.00","1,761,145,000.00","2,116,704,000.00","2,470,237,000.00","2,504,389,000.00","2,573,113,000.00","2,682,097,000.00","2,747,557,000.00","2,447,384,000.00", 
PRY,Primary Health Care Limited,Annual Balance Sheet - Total Assets, , , , , , , , ,"40,266,321.00","85,908,000.00","162,246,000.00","220,775,000.00","283,354,000.00","292,331,000.00","302,387,000.00","447,901,000.00","544,424,000.00","606,502,000.00","4,798,310,000.00","3,778,527,000.00","3,696,253,000.00","3,825,654,000.00","3,861,947,000.00","3,993,638,000.00","4,118,723,000.00","3,945,491,000.00", 
PSD,pSivida Limited,Annual Ratio Analysis - ROE,0.70%,3.14%,2.80%,11.50%,16.40%,4.81%,-14.55%,-35.11%, , ,0.00%,-19.47%,-27.59%,-45.37%,-10.00%,-18.41%,-16.09%,-42.02%, , , , , , , , , 
PSD,pSivida Limited,Annual Profit and Loss - Operating Revenue,"83,200,000.00","82,200,000.00","97,504,000.00","107,330,000.00","111,377,000.00","102,462,000.00","96,911,360.00","79,813,672.00", , ,--,--,0.00,--,0.00,0.00,"932,074.00","944,000.00", , , , , , , , , 
PSD,pSivida Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"136,000.00","-3,084,000.00","495,000.00","1,782,000.00","1,975,000.00","1,384,000.00","-6,727,154.00","-4,963,305.00", , ,0.00,"-851,730.00","-3,997,024.00","-5,356,328.00","-7,518,976.00","-15,125,719.00","-28,166,129.00","-122,258,000.00", , , , , , , , , 
PSD,pSivida Limited,Annual Balance Sheet - Total Equity,"15,695,000.00","12,419,000.00","13,374,000.00","14,452,000.00","15,174,000.00","26,288,000.00","19,561,264.00","14,597,959.00", , ,"9,743,000.00","8,962,130.00","10,712,821.00","6,299,519.00","38,428,943.00","79,987,614.00","175,032,585.00","77,720,000.00", , , , , , , , , 
PSD,pSivida Limited,Annual Balance Sheet - Total Assets,"43,910,000.00","40,223,000.00","38,123,000.00","40,266,000.00","42,124,000.00","48,923,000.00","45,167,926.00","38,231,073.00", , ,"10,069,000.00","9,247,729.00","11,273,860.00","7,175,342.00","40,367,058.00","82,035,313.00","235,486,077.00","101,554,000.00", , , , , , , , , 
PSQ,Pacific Smiles Group Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , , , , , ,0.00%,20.39%, 
PSQ,Pacific Smiles Group Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , , , , , ,--,"74,898,000.00", 
PSQ,Pacific Smiles Group Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , , , , , ,0.00,"8,360,000.00", 
PSQ,Pacific Smiles Group Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , , , , , ,"36,800,000.00","41,009,000.00", 
PSQ,Pacific Smiles Group Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , , , , , ,"55,200,000.00","59,199,000.00", 
PTX,Prescient Therapeutics Limited,Annual Ratio Analysis - ROE,27.78%,7.20%,-21.09%,105.86%,-392.56%,855.22%,"1,682.45%","-3,965.77%",-87.92%,-53.21%,-178.79%,-63.45%,-181.83%,-328.78%,-108.97%,-141.30%,-228.17%,-150.88%,"-2,427.65%",222.66%,-668.60%,163.65%,105.90%,--,-25.80%,-47.94%, 
PTX,Prescient Therapeutics Limited,Annual Profit and Loss - Operating Revenue,"18,619,000.00","20,736,000.00","23,150,000.00","24,379,000.00","24,162,000.00","20,122,000.00","1,517,369.00",0.00,0.00,0.00,--,0.00,0.00,"154,046.00",0.00,0.00,"208,693.00","1,543,406.00","364,877.00",0.00,0.00,0.00,0.00,0.00,--,0.00, 
PTX,Prescient Therapeutics Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"411,000.00","2,000.00","-203,000.00","-302,000.00","-1,437,000.00","-216,000.00","98,082.00","-1,307,255.00","-1,031,409.00","-1,424,998.00","-2,282,318.00","-2,293,200.00","-2,647,494.00","-3,135,288.00","-3,963,451.00","-3,998,826.00","-4,625,343.00","-2,667,326.00","-1,773,449.00","-1,345,933.00","-1,864,246.00","-1,361,594.00","-1,892,370.00","1,787,000.00","-1,296,896.00","-2,133,375.00", 
PTX,Prescient Therapeutics Limited,Annual Balance Sheet - Total Equity,"1,792,000.00","1,659,000.00","1,171,000.00","546,000.00","336,000.00","-134,000.00","-41,547.00","24,336.00","1,173,068.00","2,678,039.00","1,276,550.00","3,614,450.00","1,456,015.00","953,603.00","3,637,243.00","2,830,018.00","2,027,114.00","1,767,898.00","73,052.00","-604,478.00","278,829.00","-832,034.00","-1,787,000.00",0.00,"5,026,822.00","4,450,486.00", 
PTX,Prescient Therapeutics Limited,Annual Balance Sheet - Total Assets,"7,181,000.00","7,084,000.00","6,846,000.00","5,549,000.00","5,901,000.00","2,249,000.00","24,156.00","161,764.00","1,235,046.00","2,797,739.00","1,384,163.00","4,282,180.00","1,904,438.00","1,633,603.00","4,148,056.00","4,182,793.00","3,707,626.00","3,244,294.00","1,750,467.00","1,181,674.00","1,567,567.00","701,856.00","61,824.00",--,"5,279,715.00","4,891,614.00", 
PVA,pSivida Corp,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , ,0.00%,-251.58%,-10.67%,26.49%,-23.05%,-182.13%,-154.55%,-89.49%,27.16%, 
PVA,pSivida Corp,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , ,--,"3,457,303.00","14,857,037.00","26,481,285.00","3,363,441.00",0.00,0.00,"3,686,836.00","34,589,843.00", 
PVA,pSivida Corp,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , ,0.00,"-78,610,014.00","-3,094,651.00","10,269,858.00","-8,034,267.00","-24,369,541.00","-12,830,188.00","-14,177,282.00","8,264,322.00", 
PVA,pSivida Corp,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , ,"88,265,000.00","31,246,623.00","29,012,817.00","38,766,866.00","34,857,063.00","13,380,433.00","8,301,886.00","15,842,887.00","30,427,083.00", 
PVA,pSivida Corp,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , ,"107,220,000.00","57,951,381.00","45,728,370.00","50,468,145.00","43,870,937.00","20,210,970.00","17,519,137.00","24,066,878.00","42,144,531.00", 
PVL,Provalis Plc,Annual Ratio Analysis - ROE,-4.81%,-16.15%,-14.28%,-16.90%,-12.43%,-9.64%,-4.37%,-13.89%,-70.59%,-234.33%,-426.39%,-49.06%, , , , , , , , , , , , , , , 
PVL,Provalis Plc,Annual Profit and Loss - Operating Revenue,"7,700,000.00","5,317,000.00","8,139,000.00","10,513,000.00","9,755,000.00","13,491,000.00","17,483,000.00","13,734,000.00","19,729,730.00","22,721,660.00","16,236,867.00","21,648,626.00", , , , , , , , , , , , , , , 
PVL,Provalis Plc,Annual Profit and Loss - Reported NPAT After Abnorma,"-4,716,000.00","-27,374,000.00","-18,567,000.00","-10,642,000.00","-10,537,000.00","-8,979,000.00","-7,932,000.00","-24,657,000.00","-48,648,649.00","-39,268,955.00","-42,761,006.00","-12,212,045.00", , , , , , , , , , , , , , , 
PVL,Provalis Plc,Annual Balance Sheet - Total Equity,"115,371,000.00","64,474,000.00","83,090,000.00","66,851,000.00","84,284,000.00","82,578,000.00","180,559,000.00","177,736,000.00","81,351,351.00","16,547,296.00","10,028,653.00","29,419,927.00", , , , , , , , , , , , , , , 
PVL,Provalis Plc,Annual Balance Sheet - Total Assets,"134,219,000.00","81,276,000.00","90,044,000.00","73,817,000.00","92,189,000.00","106,370,000.00","208,746,000.00","212,457,000.00","124,654,055.00","57,251,123.00","44,412,607.00","49,403,275.00", , , , , , , , , , , , , , , 
PVT,Provet Holdings Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , ,0.00%,11.14%, , , , , , 
PVT,Provet Holdings Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , ,--,"282,206,000.00", , , , , , 
PVT,Provet Holdings Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , ,0.00,"6,741,000.00", , , , , , 
PVT,Provet Holdings Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , ,"54,638,859.00","60,487,000.00", , , , , , 
PVT,Provet Holdings Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , ,"107,973,323.00","112,444,000.00", , , , , , 
PXS,Pharmaxis Ltd,Annual Ratio Analysis - ROE, , , , , , , , , , , , , ,-5.03%,-22.41%,-28.77%,-17.93%,-31.58%,-17.16%,-25.54%,-40.29%,-64.60%,-35.19%,-64.12%,-286.81%,51.60%, 
PXS,Pharmaxis Ltd,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , ,"41,441.00",0.00,500.00,"8,000.00","205,000.00","527,000.00","595,000.00","1,170,000.00","1,202,000.00","1,466,000.00","3,237,000.00","5,036,000.00","57,741,000.00", 
PXS,Pharmaxis Ltd,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , ,"-1,467,789.00","-6,000,669.00","-10,232,357.00","-17,733,000.00","-24,179,000.00","-20,440,000.00","-35,171,000.00","-46,345,000.00","-45,758,000.00","-38,644,000.00","-43,537,000.00","-51,818,000.00","18,466,000.00", 
PXS,Pharmaxis Ltd,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , ,"29,190,061.00","26,780,231.00","35,568,726.00","98,888,000.00","76,559,000.00","119,121,000.00","137,691,000.00","115,016,000.00","70,830,000.00","109,803,000.00","67,895,000.00","18,067,000.00","36,321,000.00", 
PXS,Pharmaxis Ltd,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , ,"29,794,556.00","28,261,020.00","37,937,437.00","104,267,000.00","82,648,000.00","125,049,000.00","163,997,000.00","140,767,000.00","94,572,000.00","131,700,000.00","112,280,000.00","66,747,000.00","82,558,000.00", 
PYC,Phylogica Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , ,-27.46%,-188.78%,-177.03%,-166.40%,-234.97%,"1,046.22%",-82.83%,-144.94%,-287.87%,-87.60%,-310.95%, 
PYC,Phylogica Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , ,"52,556.00",0.00,"275,385.00","90,752.00","1,274,942.00","596,256.00","2,358,532.00","1,918,368.00",0.00,"692,150.00","763,393.00", 
PYC,Phylogica Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , ,"-1,587,323.00","-3,991,475.00","-3,888,673.00","-4,483,938.00","-4,490,920.00","-4,572,825.00","-3,605,169.00","-3,904,524.00","-3,439,624.00","-3,257,695.00","-2,991,479.00", 
PYC,Phylogica Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , ,"5,780,882.00","2,114,304.00","2,196,662.00","2,694,638.00","1,911,244.00","-437,080.00","4,352,723.00","2,693,858.00","1,194,873.00","3,718,659.00","962,034.00", 
PYC,Phylogica Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , ,"6,084,495.00","2,832,213.00","3,533,984.00","3,519,002.00","3,487,221.00","1,570,040.00","5,661,077.00","3,495,024.00","2,262,461.00","4,524,135.00","1,785,839.00", 
QRX,QRxPharma Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , ,-0.65%,-129.17%,-79.41%,-237.73%,-394.83%,-87.42%,-101.79%,-146.10%,-171.50%, 
QRX,QRxPharma Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , ,0.00,--,0.00,0.00,0.00,0.00,"4,156,000.00","592,000.00",0.00, 
QRX,QRxPharma Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , ,"-405,300.00","-36,602,000.00","-13,495,000.00","-27,474,000.00","-25,635,000.00","-16,045,000.00","-10,080,000.00","-13,341,000.00","-5,392,000.00", 
QRX,QRxPharma Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , ,"61,980,473.00","28,337,000.00","16,995,000.00","11,779,000.00","6,527,000.00","18,198,000.00","9,847,000.00","9,070,000.00","2,812,000.00", 
QRX,QRxPharma Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , ,"62,812,346.00","30,361,000.00","18,679,000.00","13,873,000.00","8,249,000.00","24,811,000.00","12,623,000.00","10,910,000.00","3,556,000.00", 
RAC,Race Oncology Ltd,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , , , , , , ,0.00%, 
RAC,Race Oncology Ltd,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , , , , , , ,--, 
RAC,Race Oncology Ltd,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , , , , , , ,0.00, 
RAC,Race Oncology Ltd,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , , , , , , ,"7,053,071.00", 
RAC,Race Oncology Ltd,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , , , , , , ,"7,112,543.00", 
RAP,ResApp Health Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , ,--,-13.48%,-8.84%,-29.40%,-89.48%,-253.10%,181.28%,-49.54%,-30.40%,-76.55%,-539.09%,-386.92%,-130.24%, 
RAP,ResApp Health Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , ,456.00,--,--,"142,080.00","1,405,352.00",--,502.00,0.00,0.00,"2,108.00",50.00,--,0.00, 
RAP,ResApp Health Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , ,"-822,794.00","-1,180,530.00","-706,467.00","-1,815,829.00","-3,682,615.00","-3,658,685.00","-1,331,985.00","224,122.00","-527,165.00","-832,000.00","-922,808.00","-578,388.00","-489,321.00", 
RAP,ResApp Health Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , ,--,"8,759,317.00","7,991,990.00","6,177,319.00","4,327,256.00","651,898.00","-599,018.00","-379,876.00","1,734,161.00","1,086,921.00","171,180.00","121,412.00","484,941.00", 
RAP,ResApp Health Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , ,--,"8,759,317.00","8,167,751.00","6,751,673.00","5,125,321.00","1,160,045.00","896,629.00","134,993.00","1,750,374.00","1,173,833.00","245,263.00","338,426.00","4,780,589.00", 
RBC,Rubicon Limited,Annual Ratio Analysis - ROE, , , , , , , , , , ,0.00%, , , , , , , , , , , , , , , , 
RBC,Rubicon Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , ,--, , , , , , , , , , , , , , , , 
RBC,Rubicon Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , ,0.00, , , , , , , , , , , , , , , , 
RBC,Rubicon Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , ,"250,280,763.00", , , , , , , , , , , , , , , , 
RBC,Rubicon Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , ,"268,730,948.00", , , , , , , , , , , , , , , , 
RBY,Rockeby Biomed Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , ,-30.32%,-30.07%,-105.99%,-53.36%,-84.29%,-89.40%, , , , , , , 
RBY,Rockeby Biomed Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , ,"30,736.00","140,143.00","290,139.00","1,127,472.00","397,112.00","936,100.00", , , , , , , 
RBY,Rockeby Biomed Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , ,"-5,324,068.00","-4,703,955.00","-7,399,069.00","-4,031,542.00","-4,391,822.00","-2,955,688.00", , , , , , , 
RBY,Rockeby Biomed Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , ,"17,557,420.00","15,644,624.00","6,980,973.00","7,554,947.00","5,210,165.00","3,306,110.00", , , , , , , 
RBY,Rockeby Biomed Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , ,"18,683,523.00","16,412,582.00","11,294,223.00","12,177,446.00","9,669,323.00","8,468,135.00", , , , , , , 
RCE,Recce Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , , , , , , ,0.00%, 
RCE,Recce Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , , , , , , ,--, 
RCE,Recce Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , , , , , , ,0.00, 
RCE,Recce Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , , , , , , ,"4,714,110.00", 
RCE,Recce Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , , , , , , ,"4,986,581.00", 
REG,Regis Healthcare Limited,Annual Ratio Analysis - ROE, , , , , , , , ,--,--,6.69%,7.15%,7.95%,8.81%,9.64%, , , , , , , , , ,0.00%,36.79%, 
REG,Regis Healthcare Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , ,"29,961,656.00","36,600,002.00","46,358,701.00","56,073,657.00","57,129,309.00","59,515,268.00","64,751,779.00", , , , , , , , , ,--,"123,899,000.00", 
REG,Regis Healthcare Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , ,"6,361,637.00","5,437,105.00","6,554,114.00","7,217,328.00","8,199,039.00","9,628,523.00","10,468,988.00", , , , , , , , , ,0.00,"57,514,000.00", 
REG,Regis Healthcare Limited,Annual Balance Sheet - Total Equity, , , , , , , , ,--,--,"97,923,481.00","100,952,479.00","103,137,485.00","109,329,418.00","112,299,229.00", , , , , , , , , ,"167,600,000.00","209,221,000.00", 
REG,Regis Healthcare Limited,Annual Balance Sheet - Total Assets, , , , , , , , ,--,--,"166,762,327.00","165,017,884.00","179,649,007.00","183,741,520.00","184,110,176.00", , , , , , , , , ,"885,400,000.00","992,782,000.00", 
RGS,Regeneus Ltd,Annual Ratio Analysis - ROE, , ,-6.48%,4.00%,0.64%,0.11%,-0.70%,-0.22%,11.67%,25.69%,19.34%,11.85%,-1.36%, , , , , , , , , ,0.00%, ,-60.37%,-79.86%, 
RGS,Regeneus Ltd,Annual Profit and Loss - Operating Revenue, , ,"3,484,000.00","4,782,000.00",0.00,0.00,0.00,0.00,"74,169,000.00","154,415,008.00","185,303,000.00","195,020,000.00","86,046,000.00", , , , , , , , , ,--, ,"998,036.00","1,820,353.00", 
RGS,Regeneus Ltd,Annual Profit and Loss - Reported NPAT After Abnorma, , ,"-669,000.00","1,082,000.00","18,211,000.00","-460,000.00","6,441,000.00","-168,000.00","23,448,000.00","16,117,000.00","30,057,000.00","21,652,000.00","-87,165,000.00", , , , , , , , , ,0.00, ,"-7,523,218.00","-6,606,521.00", 
RGS,Regeneus Ltd,Annual Balance Sheet - Total Equity, , ,"8,509,000.00","10,027,000.00","46,848,000.00","49,654,000.00","67,231,000.00","101,202,000.00","126,350,000.00","130,559,000.00","161,094,000.00","196,209,000.00","40,538,000.00", , , , , , , , , ,"15,704,000.00", ,"8,308,028.00","8,272,134.00", 
RGS,Regeneus Ltd,Annual Balance Sheet - Total Assets, , ,"14,319,000.00","13,249,000.00","55,535,000.00","52,022,000.00","77,777,000.00","171,144,000.00","290,516,000.00","281,417,000.00","289,365,000.00","325,409,000.00","50,204,000.00", , , , , , , , , ,"16,733,000.00", ,"10,259,054.00","9,579,261.00", 
RHC,Ramsay Health Care Limited,Annual Ratio Analysis - ROE, , , , , , , ,7.12%,6.79%,6.37%,5.22%,8.30%,13.74%,14.64%,15.54%,5.15%,9.21%,10.76%,11.53%,14.22%,13.89%,16.11%,16.62%,17.84%,19.51%,19.99%, 
RHC,Ramsay Health Care Limited,Annual Profit and Loss - Operating Revenue, , , , , , , ,"194,261,000.00","203,620,000.00","249,676,000.00","318,163,000.00","377,012,000.00","538,876,000.00","655,500,000.00","760,842,000.00","1,431,812,000.00","1,973,994,000.00","2,115,945,000.00","2,691,876,000.00","3,272,619,000.00","3,403,419,000.00","3,748,821,000.00","3,966,839,000.00","4,134,064,000.00","4,909,314,000.00","7,319,517,000.00", 
RHC,Ramsay Health Care Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , ,"-2,083,000.00","13,961,000.00","5,964,000.00","6,616,000.00","16,004,000.00","31,071,000.00","37,055,000.00","38,353,000.00","30,398,000.00","87,636,000.00","107,105,000.00","92,236,000.00","106,505,000.00","148,846,000.00","200,366,000.00","245,858,000.00","268,375,000.00","310,064,000.00","419,086,000.00", 
RHC,Ramsay Health Care Limited,Annual Balance Sheet - Total Equity, , , , , , , ,"125,475,000.00","205,563,000.00","203,477,000.00","161,315,000.00","201,206,000.00","223,076,000.00","253,129,000.00","270,589,000.00","800,117,000.00","838,574,000.00","883,637,000.00","914,164,000.00","909,162,000.00","1,223,943,000.00","1,303,863,000.00","1,406,201,000.00","1,541,815,000.00","1,743,644,000.00","1,833,087,000.00", 
RHC,Ramsay Health Care Limited,Annual Balance Sheet - Total Assets, , , , , , , ,"355,539,000.00","458,202,000.00","521,431,984.00","467,440,000.00","510,660,000.00","545,206,000.00","654,052,000.00","690,169,000.00","2,830,048,000.00","2,191,055,000.00","2,187,831,000.00","3,091,198,000.00","3,187,128,000.00","3,576,379,000.00","3,551,463,000.00","3,585,949,000.00","4,062,391,000.00","4,550,799,000.00","7,616,978,000.00", 
RHS,Reproductive Health Science Limited,Annual Ratio Analysis - ROE,-0.35%,-11.25%,-4.58%,-3.70%,-1.90%,-1.51%,-7.30%,-10.65%,-14.30%,-11.44%,-36.45%,-17.39%,-30.49%,-51.44%,300.08%,151.81%,-257.72%,-7.89%,-17.43%,-9.36%,-287.25%,-26.05%,-391.42%,-322.75%,-342.98%,-121.09%, 
RHS,Reproductive Health Science Limited,Annual Profit and Loss - Operating Revenue,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,"1,382,813.00","6,215,000.00","8,672,000.00","858,091.00",--,"12,000.00",--,--,--,0.00,--,0.00,0.00,"73,363.00", 
RHS,Reproductive Health Science Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-18,000.00","-514,000.00","-200,000.00","-160,000.00","-227,000.00","-111,000.00","-3,128,497.00","-1,573,694.00","-508,988.00","-453,617.00","-1,467,360.00","-724,177.00","-2,004,696.00","-4,260,000.00","-16,806,000.00","-49,074.00","-1,697,323.00","-331,961.00","-781,645.00","-880,921.00","-6,972,361.00","-585,134.00","-3,291,616.00","-1,474,578.00","-6,091,210.00","-1,635,179.00", 
RHS,Reproductive Health Science Limited,Annual Balance Sheet - Total Equity,"5,081,000.00","4,567,000.00","4,367,000.00","4,085,000.00","5,482,000.00","6,216,000.00","3,228,512.00","2,601,998.00","3,558,570.00","3,964,729.00","4,025,969.00","4,163,427.00","6,764,501.00","8,282,000.00","-1,305,000.00","-1,368,407.00","1,317,177.00","4,209,742.00","4,484,269.00","9,412,174.00","2,427,295.00","2,192,944.00","504,865.00","456,874.00","1,735,310.00","1,350,384.00", 
RHS,Reproductive Health Science Limited,Annual Balance Sheet - Total Assets,"5,164,000.00","4,634,000.00","4,539,000.00","4,576,000.00","5,608,000.00","6,363,000.00","3,308,223.00","2,846,956.00","3,739,083.00","4,093,534.00","5,093,385.00","10,257,940.00","14,950,384.00","16,843,000.00","3,580,000.00","2,088,145.00","1,949,309.00","4,501,033.00","10,010,740.00","9,812,957.00","3,004,774.00","2,323,427.00","939,191.00","695,000.00","2,135,567.00","1,947,182.00", 
RHT,Resonance Health Limited,Annual Ratio Analysis - ROE,-3.87%,-4.77%,-3.17%,-4.81%,-7.82%,-2.87%,-7.00%,-18.23%,-21.08%,-79.41%,-92.75%, ,17.23%,-55.68%,-41.16%,-13.51%,-641.50%,-26.65%,-1.55%,18.69%,-3.19%,-10.94%,-10.47%,-9.12%,1.41%,10.52%, 
RHT,Resonance Health Limited,Annual Profit and Loss - Operating Revenue,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,"576,812.00","7,121,933.00","7,595,272.00", ,0.00,--,"3,300.00","121,568.00","316,070.00","1,868,790.00","3,444,170.00","2,259,191.00","1,837,795.00","1,745,864.00","1,562,242.00","1,527,188.00","2,284,565.00","2,443,476.00", 
RHT,Resonance Health Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-221,000.00","-260,000.00","-186,000.00","-258,000.00","-405,000.00","-144,000.00","-830,392.00","-2,538,187.00","-3,956,317.00","-18,663,076.00","-7,675,000.00", ,"-2,461,126.00","6,102,558.00","-2,020,277.00","-3,015,925.00","-16,060,845.00","-725,319.00","-41,392.00","617,051.00","-102,335.00","-316,829.00","-268,601.00","-204,481.00","-72,415.00","463,234.00", 
RHT,Resonance Health Limited,Annual Balance Sheet - Total Equity,"5,707,000.00","5,448,000.00","5,262,000.00","5,097,000.00","5,177,000.00","5,025,000.00","11,860,605.00","13,923,342.00","20,577,095.00","7,379,885.00","9,609,214.00", ,"-7,140,283.00","690,968.00","2,869,125.00","14,106,799.00","510,356.00","2,721,143.00","2,675,129.00","3,302,259.00","3,208,505.00","2,895,562.00","2,566,016.00","2,240,961.00","3,338,595.00","4,405,288.00", 
RHT,Resonance Health Limited,Annual Balance Sheet - Total Assets,"5,728,000.00","5,462,000.00","5,284,000.00","5,175,000.00","5,348,000.00","7,363,000.00","25,418,771.00","28,635,230.00","36,897,845.00","8,970,847.00","23,014,785.00", ,"1,069,482.00","720,314.00","3,131,993.00","14,512,553.00","938,503.00","3,154,555.00","2,928,446.00","3,688,952.00","3,728,999.00","3,475,143.00","3,354,069.00","3,074,707.00","4,276,443.00","5,192,448.00", 
RMD,ResMed Inc.,Annual Ratio Analysis - ROE, , , , , , , , ,20.90%,22.47%,23.65%,29.75%,20.14%,15.96%,15.85%,14.39%,12.05%,11.46%,10.55%,13.13%,14.76%,13.11%,15.97%,19.10%,20.00%,22.23%, 
RMD,ResMed Inc.,Annual Profit and Loss - Operating Revenue, , , , , , , , ,"108,425,427.00","134,364,766.00","175,280,473.00","305,726,108.00","373,351,628.00","409,904,105.00","492,579,474.00","557,162,498.00","815,171,532.00","844,187,581.00","868,316,019.00","1,133,261,030.00","1,281,364,543.00","1,157,601,266.00","1,342,866,254.00","1,632,837,735.00","1,650,714,437.00","2,186,083,333.00", 
RMD,ResMed Inc.,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , ,"17,295,843.00","24,411,764.00","33,696,179.00","22,916,256.00","66,405,807.00","68,518,130.00","83,152,852.00","84,830,430.00","118,674,828.00","78,121,833.00","114,588,614.00","180,488,045.00","223,025,929.00","211,366,048.00","250,073,594.00","331,140,700.00","366,531,847.00","459,486,979.00", 
RMD,ResMed Inc.,Annual Balance Sheet - Total Equity, , , , , , , , ,"82,759,576.00","108,621,892.00","142,468,162.00","197,765,517.00","341,589,943.00","429,177,404.00","524,748,149.00","620,747,675.00","993,068,747.00","1,097,233,415.00","1,123,805,318.00","1,374,404,732.00","1,510,660,565.00","1,611,637,023.00","1,577,496,810.00","1,736,405,390.00","1,866,505,307.00","2,066,805,989.00", 
RMD,ResMed Inc.,Annual Balance Sheet - Total Assets, , , , , , , , ,"105,326,813.00","136,278,047.00","175,248,635.00","567,665,024.00","666,060,552.00","688,635,001.00","789,895,485.00","1,013,678,145.00","1,355,066,594.00","1,475,246,848.00","1,460,627,467.00","1,858,476,706.00","1,908,244,749.00","1,926,549,958.00","2,097,801,000.00","2,383,526,684.00","2,506,329,087.00","2,844,088,541.00", 
RNO,Rhinomed Limited ,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , ,-72.42%,-92.44%,-193.16%,-7.92%,-3.70%,-71.53%,-53.87%,-88.58%, 
RNO,Rhinomed Limited ,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , ,"3,030.00",--,--,"33,720.00",0.00,0.00,"210,854.00","432,460.00", 
RNO,Rhinomed Limited ,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , ,"-1,317,984.00","-881,025.00","-858,411.00","-1,128,712.00","-1,308,494.00","-19,559,713.00","-3,534,577.00","-5,316,992.00", 
RNO,Rhinomed Limited ,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , ,"1,819,953.00","953,041.00","444,395.00","15,245,076.00","20,401,549.00","5,675,695.00","6,561,625.00","5,967,479.00", 
RNO,Rhinomed Limited ,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , ,"1,985,456.00","1,051,813.00","493,825.00","15,718,809.00","25,872,261.00","6,437,566.00","7,066,130.00","6,816,606.00", 
RSH,Respiri Limited,Annual Ratio Analysis - ROE, , , , , , , ,--,--,-5.72%,-80.23%,-65.47%,-767.68%,451.94%,-19.74%,-47.92%,-306.75%,-213.00%,-240.65%,-170.54%,-207.20%,-316.49%,-249.68%,-334.55%,-113.59%,-140.10%, 
RSH,Respiri Limited,Annual Profit and Loss - Operating Revenue, , , , , , , ,"1,741,899.00","734,534.00","875,560.00","404,828.00","321,745.00","50,748.00","2,900.00",0.00,--,--,"149,158.00","100,191.00","225,432.00","348,493.00","332,087.00","12,968.00","10,859.00","18,975.00",500.00, 
RSH,Respiri Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , ,"256,083.00","-311,032.00","-912,093.00","-6,094,780.00","-8,695,000.00","-11,862,496.00","-4,293,066.00","-225,446.00","-724,190.00","-1,191,338.00","-5,124,413.00","-11,678,053.00","-6,701,092.00","-5,939,761.00","-6,677,311.00","-5,585,172.00","-5,580,768.00","-10,309,957.00","-5,464,443.00", 
RSH,Respiri Limited,Annual Balance Sheet - Total Equity, , , , , , , ,--,--,"15,940,983.00","7,596,502.00","13,280,760.00","1,379,789.00","-949,924.00","1,142,262.00","1,511,162.00","388,369.00","2,405,630.00","4,852,716.00","3,929,387.00","2,866,724.00","2,109,796.00","2,114,439.00","1,622,417.00","9,076,405.00","3,900,397.00", 
RSH,Respiri Limited,Annual Balance Sheet - Total Assets, , , , , , , ,--,--,"17,062,028.00","10,311,186.00","14,879,479.00","2,538,202.00","559,536.00","1,304,953.00","1,592,147.00","422,385.00","3,052,385.00","5,767,632.00","5,101,456.00","4,595,092.00","3,353,518.00","3,112,830.00","2,837,756.00","10,604,209.00","5,184,960.00", 
RVA,Reva Medical Inc,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , ,-149.89%,-32.37%,-53.28%,-134.08%,192.96%,102.52%, 
RVA,Reva Medical Inc,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , ,0.00,--,--,--,"89,002.00","80,755.00", 
RVA,Reva Medical Inc,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , ,"-23,129,981.00","-20,586,845.00","-22,896,764.00","-31,204,738.00","-62,225,067.00","-113,049,548.00", 
RVA,Reva Medical Inc,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , ,"80,632,687.00","63,590,980.00","42,975,731.00","23,273,357.00","-32,247,012.00","-110,271,010.00", 
RVA,Reva Medical Inc,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , ,"82,136,180.00","66,285,939.00","45,644,260.00","27,698,927.00","36,814,191.00","27,471,940.00", 
SCU,Stemcell United Limited,Annual Ratio Analysis - ROE, , , , , , , , , ,-0.07%,-5.65%,-0.86%,2.22%,-6.15%,12.98%,1.70%,-54.51%,-11.28%, , , , , , ,0.00%,-754.94%, 
SCU,Stemcell United Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , ,--,"819,020.00","12,718,000.00","9,619,298.00","127,186,640.00","312,823,364.00","477,769,000.00","769,138,000.00","1,013,432,000.00", , , , , , ,--,0.00, 
SCU,Stemcell United Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , ,"-4,092.00","-293,306.00","-97,000.00","256,077.00","1,083,427.00","2,329,531.00","2,649,000.00","-9,967,000.00","402,000.00", , , , , , ,0.00,"75,041,240.00", 
SCU,Stemcell United Limited,Annual Balance Sheet - Total Equity, , , , , , , , , ,"5,626,879.00","5,191,691.00","11,290,000.00","11,552,633.00","12,636,060.00","17,947,961.00","61,151,000.00","67,481,000.00","67,970,000.00", , , , , , ,"-76,251,378.00","149,845.00", 
SCU,Stemcell United Limited,Annual Balance Sheet - Total Assets, , , , , , , , , ,"12,040,314.00","13,106,887.00","17,661,000.00","17,638,946.00","37,812,089.00","80,483,026.00","138,008,000.00","205,926,000.00","280,755,000.00", , , , , , ,"21,105.00","3,580,672.00", 
SDI,SDI Limited,Annual Ratio Analysis - ROE,-8.50%,3.30%,2.95%,5.79%,3.27%,-11.75%,17.15%,12.60%,13.98%,10.64%,15.13%,18.15%,22.69%,24.74%,28.55%,7.53%,16.84%,11.91%,3.24%,8.15%,8.53%,3.02%,4.64%,9.90%,12.42%,10.67%, 
SDI,SDI Limited,Annual Profit and Loss - Operating Revenue,"7,674,000.00","8,549,000.00","9,423,000.00","11,628,000.00","12,311,000.00","11,920,000.00","14,144,000.00","16,605,000.00","17,938,000.00","19,417,000.00","21,979,000.00","27,226,000.00","34,792,000.00","36,699,000.00","43,348,000.00","45,981,000.00","45,465,000.00","48,727,000.00","49,084,000.00","56,495,000.00","53,093,000.00","54,864,000.00","56,402,000.00","56,629,000.00","65,330,000.00","68,655,000.00", 
SDI,SDI Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-1,115,000.00","219,000.00","335,000.00","645,000.00","359,000.00","-2,334,000.00","1,726,000.00","1,306,000.00","1,082,000.00","1,089,000.00","1,943,000.00","2,697,000.00","4,008,000.00","5,451,000.00","8,028,000.00","2,148,000.00","5,119,000.00","4,060,000.00","1,129,000.00","3,120,000.00","3,473,000.00","1,206,000.00","1,967,000.00","4,690,000.00","6,467,000.00","6,200,000.00", 
SDI,SDI Limited,Annual Balance Sheet - Total Equity,"10,413,000.00","11,234,000.00","11,354,000.00","11,148,000.00","10,979,000.00","8,496,000.00","9,771,000.00","10,367,000.00","11,025,000.00","11,621,000.00","12,844,000.00","14,861,000.00","17,665,000.00","22,030,000.00","28,119,000.00","28,522,000.00","30,397,000.00","34,103,000.00","34,832,000.00","38,300,000.00","40,696,000.00","39,941,000.00","42,407,000.00","47,356,000.00","52,075,000.00","58,091,000.00", 
SDI,SDI Limited,Annual Balance Sheet - Total Assets,"14,423,000.00","14,122,000.00","14,625,000.00","14,624,000.00","14,835,000.00","13,123,000.00","14,399,000.00","16,436,000.00","19,335,000.00","19,887,000.00","21,083,000.00","25,420,000.00","28,429,000.00","33,369,000.00","45,672,000.00","50,246,000.00","52,051,000.00","54,429,000.00","59,071,000.00","59,561,000.00","59,690,000.00","62,988,000.00","64,612,000.00","70,826,000.00","74,092,000.00","79,165,000.00", 
SHC,"Sunshine Heart, Inc",Annual Ratio Analysis - ROE, , , , , , , , , , , , , ,--,-9.74%,-52.26%,-119.09%,-142.05%,-98.02%,-398.21%,-138.20%,-704.79%,-108.62%, , , , 
SHC,"Sunshine Heart, Inc",Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , ,--,"33,515.00","373,028.00",0.00,0.00,--,"134,195.00","298,799.00",--,--, , , , 
SHC,"Sunshine Heart, Inc",Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , ,"-3,026,495.00","-1,449,422.00","-5,005,573.00","-7,035,448.00","-11,539,413.00","-9,738,183.00","-8,079,055.00","-6,532,720.00","-15,947,223.00","-13,544,876.00", , , , 
SHC,"Sunshine Heart, Inc",Annual Balance Sheet - Total Equity, , , , , , , , , , , , , ,--,"14,885,029.00","9,578,046.00","5,907,736.00","8,123,748.00","9,934,902.00","2,028,850.00","4,727,143.00","4,525,403.00","12,470,146.00", , , , 
SHC,"Sunshine Heart, Inc",Annual Balance Sheet - Total Assets, , , , , , , , , , , , , ,--,"15,024,661.00","10,020,517.00","6,401,692.00","8,381,507.00","10,178,454.00","2,457,020.00","5,265,496.00","7,316,857.00","14,479,969.00", , , , 
SHL,Sonic Healthcare Limited,Annual Ratio Analysis - ROE,-8.78%,6.42%,5.82%,14.47%,20.25%,21.89%,14.24%,14.16%,20.74%,31.11%,6.96%,4.36%,4.06%,4.92%,6.70%,8.76%,13.39%,13.95%,12.57%,12.46%,11.47%,11.71%,12.20%,11.57%,12.49%,10.70%, 
SHL,Sonic Healthcare Limited,Annual Profit and Loss - Operating Revenue,"26,200,000.00","30,775,000.00","33,121,000.00","32,409,000.00","33,329,000.00","56,941,000.00","88,082,000.00","132,860,000.00","145,667,008.00","171,380,992.00","384,663,000.00","621,531,000.00","849,262,000.00","964,598,000.00","1,025,895,000.00","1,359,902,000.00","1,632,188,000.00","1,862,514,000.00","2,342,621,000.00","2,968,992,000.00","2,945,072,000.00","3,063,636,000.00","3,306,732,000.00","3,439,174,000.00","3,854,989,000.00","4,141,094,000.00", 
SHL,Sonic Healthcare Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-1,363,000.00","-8,566,000.00","41,000.00","1,208,000.00","3,734,000.00","4,305,000.00","6,808,000.00","7,951,000.00","11,477,000.00","17,451,000.00","21,910,000.00","26,127,000.00","32,207,000.00","39,945,000.00","57,883,000.00","89,408,000.00","185,815,000.00","210,054,000.00","250,406,000.00","172,555,000.00","293,784,000.00","294,489,000.00","317,685,000.00","339,668,000.00","388,860,000.00","354,037,000.00", 
SHL,Sonic Healthcare Limited,Annual Balance Sheet - Total Equity,"13,512,000.00","5,046,000.00","5,413,000.00","7,798,000.00","16,221,000.00","19,668,000.00","36,828,000.00","53,671,000.00","55,350,000.00","56,098,000.00","268,735,000.00","608,420,000.00","837,465,000.00","831,292,000.00","847,787,000.00","882,633,000.00","1,302,345,000.00","1,438,445,000.00","1,962,079,000.00","2,532,083,000.00","2,558,741,000.00","2,516,435,000.00","2,610,199,000.00","2,918,101,000.00","3,108,994,000.00","3,325,998,000.00", 
SHL,Sonic Healthcare Limited,Annual Balance Sheet - Total Assets,"23,960,000.00","17,964,000.00","16,790,000.00","17,177,000.00","34,220,000.00","43,007,000.00","106,461,000.00","114,887,000.00","121,026,000.00","155,999,000.00","725,640,000.00","1,271,793,000.00","1,598,709,000.00","1,543,389,000.00","1,694,133,000.00","1,737,066,000.00","2,345,220,000.00","2,900,462,000.00","3,629,001,000.00","4,761,246,000.00","4,863,725,000.00","4,712,897,000.00","4,928,805,000.00","5,518,226,000.00","5,797,606,000.00","6,348,705,000.00", 
SIE,SciGen Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , ,0.00%,-13.52%,-13.57%,-5.43%,3.12%,-22.69%,-125.05%,129.18%,22.83%,9.20%,-0.19%,-0.68%,-4.38%,-2.21%, 
SIE,SciGen Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , ,--,"2,269,787.00","5,215,921.00","5,288,125.00","3,900,107.00","9,438,520.00","20,005,773.00","12,544,319.00","12,170,618.00","15,520,874.00","17,478,813.00","23,234,242.00","28,779,565.00","32,202,299.00", 
SIE,SciGen Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , ,0.00,"-4,154,042.00","-3,643,201.00","-4,325,375.00","217,588.00","-4,608,666.00","-12,245,958.00","-45,001,672.00","-10,034,438.00","-17,454,706.00","3,989,791.00","-790,120.00","-2,075,103.00","1,735,559.00", 
SIE,SciGen Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , ,"41,465,906.00","30,714,893.00","26,856,249.00","79,604,945.00","27,311,464.00","23,341,651.00","17,735,277.00","-28,641,989.00","-38,180,655.00","-55,869,436.00","-51,196,070.00","-61,936,745.00","-71,420,385.00","-78,547,768.00", 
SIE,SciGen Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , ,"47,292,504.00","35,926,808.00","29,464,210.00","62,040,594.00","62,798,977.00","85,021,551.00","138,109,122.00","79,410,190.00","64,507,527.00","57,227,254.00","50,630,778.00","52,206,079.00","39,207,510.00","43,547,768.00", 
SIG,Sigma Company Limited,Annual Ratio Analysis - ROE, , , , , , , , ,6.44%,7.67%,4.36%,6.70%,8.37%,11.12%,13.61%,16.01%, , , , , , , , , , , 
SIG,Sigma Company Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , ,"1,184,956,000.00","1,314,700,000.00","1,558,943,000.00","1,783,535,000.00","1,663,970,000.00","1,744,660,000.00","1,916,737,000.00","2,106,031,000.00", , , , , , , , , , , 
SIG,Sigma Company Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , ,"8,812,000.00","8,911,000.00","10,437,000.00","8,943,000.00","21,935,000.00","30,963,000.00","44,195,000.00","59,576,000.00", , , , , , , , , , , 
SIG,Sigma Company Limited,Annual Balance Sheet - Total Equity, , , , , , , , ,"133,392,000.00","161,317,000.00","254,509,000.00","250,644,000.00","261,281,000.00","276,163,000.00","324,598,000.00","357,614,000.00", , , , , , , , , , , 
SIG,Sigma Company Limited,Annual Balance Sheet - Total Assets, , , , , , , , ,"383,716,000.00","452,748,000.00","545,802,000.00","609,041,000.00","515,357,000.00","631,009,000.00","782,005,000.00","865,237,000.00", , , , , , , , , , , 
SIP,Sigma Pharmaceuticals Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , ,48.91%,61.36%,45.98%,56.57%, ,5.56%,8.30%,7.84%,6.69%,8.21%,-2.07%,7.13%,11.13%,8.82%,9.26%,10.56%
SIP,Sigma Pharmaceuticals Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , ,"137,740,012.00","247,830,000.00","263,215,000.00","336,296,000.00", ,"2,194,552,000.00","2,734,722,000.00","2,966,502,000.00","3,081,287,000.00","3,220,430,000.00","2,914,271,000.00","2,878,233,000.00","2,956,838,000.00","3,001,195,000.00","3,142,126,000.00","3,514,562,000.00"
SIP,Sigma Pharmaceuticals Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , ,"5,301,985.00","9,037,000.00","12,537,000.00","19,294,000.00", ,"104,848,000.00","101,788,000.00","77,154,000.00","80,124,000.00","-389,042,000.00","-235,382,000.00","49,172,000.00","18,686,000.00","53,536,000.00","52,772,000.00","50,415,000.00"
SIP,Sigma Pharmaceuticals Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , ,"10,816,866.00","14,727,000.00","27,265,000.00","34,108,000.00", ,"1,269,167,000.00","1,344,456,000.00","1,200,653,000.00","1,197,932,000.00","1,066,954,000.00","832,919,000.00","682,527,000.00","610,806,000.00","578,829,000.00","573,001,000.00","553,654,000.00"
SIP,Sigma Pharmaceuticals Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , ,"56,455,346.00","64,190,000.00","81,090,000.00","98,952,000.00", ,"1,960,846,000.00","2,068,608,000.00","2,066,902,000.00","2,201,464,000.00","1,926,046,000.00","1,552,998,000.00","1,081,403,000.00","1,056,171,000.00","945,169,000.00","1,055,663,000.00","1,108,651,000.00"
SLA,Solagran Limited,Annual Ratio Analysis - ROE,-103.15%,-257.14%,-850.00%,-15.77%,-143.08%,-190.14%,-60.75%,-602.10%,162.17%,-492.47%,-35.48%,-229.27%,895.91%,-7.38%,-14.24%,-21.34%,-21.12%,-33.38%,-17.08%,-57.45%,-20.44%,-47.42%,"2,616.46%",118.85%,44.86%,38.47%, 
SLA,Solagran Limited,Annual Profit and Loss - Operating Revenue,0.00,0.00,"14,000.00",0.00,0.00,0.00,0.00,0.00,0.00,--,"978,841.00",0.00,0.00,0.00,0.00,"64,977.00",0.00,"124,541.00","335,187.00","575,678.00","1,221,103.00","1,019,383.00","1,813,155.00","1,610,255.00","2,085,725.00","2,533,081.00", 
SLA,Solagran Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-1,729,000.00","-113,000.00","-102,000.00","-347,000.00","-3,318,000.00","-1,430,000.00","-1,817,643.00","-627,786.00","-570,452.00","-246,672.00","-3,957,353.00","-11,424,961.00","-2,101,911.00","-165,265.00","-1,312,316.00","-2,115,204.00","-2,113,001.00","-3,649,964.00","-3,762,040.00","-10,375,504.00","-4,548,007.00","-9,103,863.00","-18,439,749.00","-4,892,800.00","-3,930,046.00","-6,441,971.00", 
SLA,Solagran Limited,Annual Balance Sheet - Total Equity,"127,000.00","14,000.00","12,000.00","1,268,000.00","130,000.00","142,000.00","465,873.00","38,087.00","-351,765.00","102,504.00","10,026,254.00","1,979,286.00","-122,625.00","9,119,628.00","9,217,482.00","9,914,135.00","10,006,214.00","10,936,052.00","21,732,362.00","17,578,474.00","20,861,065.00","18,546,028.00","-366,892.00","-4,116,942.00","-8,760,106.00","-16,746,833.00", 
SLA,Solagran Limited,Annual Balance Sheet - Total Assets,"267,000.00","101,000.00","146,000.00","1,456,000.00","495,000.00","550,000.00","796,134.00","414,217.00","412,108.00","413,841.00","12,023,437.00","3,220,395.00","422,663.00","9,818,619.00","9,378,323.00","10,068,728.00","10,326,260.00","12,688,773.00","26,898,513.00","19,411,255.00","23,337,652.00","28,046,335.00","13,973,114.00","14,475,379.00","13,577,623.00","6,833,004.00", 
SNZ,Summerset Group Holdings Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , , , , ,7.86%,7.35%,9.22%, 
SNZ,Summerset Group Holdings Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , , , , ,--,--,--, 
SNZ,Summerset Group Holdings Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , , , , ,"31,457,854.00","51,780,730.00","78,977,219.00", 
SNZ,Summerset Group Holdings Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , , , , ,"259,134,111.00","317,597,017.00","384,162,369.00", 
SNZ,Summerset Group Holdings Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , , , , ,"776,663,296.00","997,121,965.00","1,278,277,866.00", 
SOM,SomnoMed Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , ,"1,391.82%",-45.36%,-129.49%,-83.68%,-45.45%,-41.97%,13.91%,11.90%,6.01%,5.37%,3.29%,0.01%, 
SOM,SomnoMed Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , ,"28,147.00","377,123.00","1,785,921.00","2,273,468.00","3,658,173.00","7,995,474.00","10,902,611.00","12,512,827.00","15,328,827.00","18,488,871.00","25,894,846.00","34,437,903.00", 
SOM,SomnoMed Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , ,"-556,997.00","-3,266,637.00","-4,188,304.00","-3,274,364.00","-2,731,119.00","-1,818,673.00","786,143.00","739,537.00","699,745.00","704,675.00","214,956.00","533,761.00", 
SOM,SomnoMed Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , ,"-160,077.00","7,201,392.00","3,234,356.00","3,913,116.00","6,008,676.00","4,333,246.00","5,650,638.00","6,217,082.00","8,919,747.00","11,572,722.00","12,569,702.00","21,507,982.00", 
SOM,SomnoMed Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , ,"624,706.00","7,917,692.00","4,069,074.00","4,698,616.00","7,004,405.00","6,038,004.00","7,833,812.00","8,731,880.00","12,311,511.00","16,110,988.00","19,142,630.00","27,750,617.00", 
SPL,Starpharma Holdings Limited,Annual Ratio Analysis - ROE, , , , , , , , ,--,--,-6.14%,-15.68%,-46.48%,-83.52%,-31.25%,-76.12%,-35.29%,-28.16%,-36.75%,-16.18%,-18.30%,-32.25%,-28.07%,-11.38%,-44.41%,-50.46%, 
SPL,Starpharma Holdings Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , ,0.00,0.00,0.00,0.00,"384,703.00","911,335.00","15,730.00","13,922.00",500.00,"863,854.00","1,412,000.00","2,019,000.00","1,404,000.00","1,144,000.00","44,000.00","20,000.00","273,000.00","804,000.00", 
SPL,Starpharma Holdings Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , ,"-1,270,797.00","-1,169,167.00","-1,772,014.00","-3,906,427.00","-7,959,289.00","-7,544,721.00","-5,497,850.00","-7,585,992.00","-7,522,789.00","-7,244,996.00","-7,491,000.00","-4,127,000.00","-6,378,000.00","-8,930,000.00","-13,658,000.00","-5,229,000.00","-14,635,000.00","-18,950,000.00", 
SPL,Starpharma Holdings Limited,Annual Balance Sheet - Total Equity, , , , , , , , ,--,--,"28,853,274.00","24,915,653.00","17,266,327.00","9,243,130.00","17,592,496.00","9,965,965.00","21,315,986.00","25,724,030.00","20,383,000.00","25,499,000.00","34,844,000.00","27,693,000.00","48,651,000.00","45,968,000.00","32,951,000.00","37,558,000.00", 
SPL,Starpharma Holdings Limited,Annual Balance Sheet - Total Assets, , , , , , , , ,--,--,"29,052,555.00","26,025,455.00","18,859,433.00","10,715,440.00","18,490,942.00","12,499,740.00","25,013,065.00","30,423,479.00","24,653,000.00","28,847,000.00","37,567,000.00","29,807,000.00","54,268,000.00","48,550,000.00","36,862,000.00","44,383,000.00", 
SRX,Sirtex Medical Limited,Annual Ratio Analysis - ROE, , , , , , , ,--,--,-7.25%,-33.49%,-12.21%,-26.73%,19.33%,3.84%,-8.59%,9.47%,7.20%,5.20%,36.97%,31.20%,19.09%,23.25%,20.73%,22.19%,27.89%, 
SRX,Sirtex Medical Limited,Annual Profit and Loss - Operating Revenue, , , , , , , ,"19,206.00","529,384.00","400,129.00","250,775.00","378,000.00","783,000.00","10,216,000.00","9,517,000.00","11,830,000.00","22,963,000.00","33,636,000.00","38,186,000.00","65,820,000.00","64,333,000.00","70,330,000.00","82,627,000.00","96,774,000.00","129,363,000.00","176,088,000.00", 
SRX,Sirtex Medical Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , ,"-201,506.00","-533,754.00","-1,355,047.00","-1,133,000.00","-1,978,000.00","-3,416,000.00","3,150,000.00","697,000.00","-1,442,000.00","1,807,000.00","1,566,000.00","1,210,000.00","18,229,000.00","16,080,000.00","11,479,000.00","17,103,000.00","18,270,000.00","23,868,000.00","40,345,000.00", 
SRX,Sirtex Medical Limited,Annual Balance Sheet - Total Equity, , , , , , , ,--,--,"18,680,348.00","3,383,554.00","16,194,000.00","12,778,000.00","16,293,000.00","18,170,000.00","16,781,000.00","19,077,000.00","21,764,000.00","23,287,000.00","39,179,000.00","51,543,000.00","60,142,000.00","73,548,000.00","88,138,000.00","107,583,000.00","144,636,000.00", 
SRX,Sirtex Medical Limited,Annual Balance Sheet - Total Assets, , , , , , , ,--,--,"18,838,455.00","4,759,682.00","16,691,000.00","13,341,000.00","18,104,000.00","20,791,000.00","20,012,000.00","25,040,000.00","28,714,000.00","28,372,000.00","49,923,000.00","66,660,000.00","76,641,000.00","96,656,000.00","117,767,000.00","148,710,000.00","201,476,000.00", 
STC,Asset Realisation Company Plc,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , ,0.00%,-88.01%, , , , , , , , , 
STC,Asset Realisation Company Plc,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , ,--,"1,344,061.00", , , , , , , , , 
STC,Asset Realisation Company Plc,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , ,0.00,"-7,948,776.00", , , , , , , , , 
STC,Asset Realisation Company Plc,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , ,"15,392,059.00","9,032,184.00", , , , , , , , , 
STC,Asset Realisation Company Plc,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , ,"18,501,240.00","11,058,476.00", , , , , , , , , 
STI,Stirling Products Limited,Annual Ratio Analysis - ROE, , , , , , , ,-1.88%,-52.83%,-22.83%,-12.24%,-14.16%,-37.95%,-416.09%,-21.21%,-35.64%,-57.34%,-97.61%,-80.40%,-334.16%,"-1,329.65%",160.73%,--,--,--,--, 
STI,Stirling Products Limited,Annual Profit and Loss - Operating Revenue, , , , , , , ,--,--,--,0.00,--,0.00,0.00,0.00,0.00,0.00,"1,840.00","398,952.00","157,988.00","84,434.00","961,133.00",--,--,--,--, 
STI,Stirling Products Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , ,"-399,026.00","-1,489,325.00","-1,427,114.00","-636,330.00","-1,158,682.00","-7,804,902.00","-4,305,787.00","-3,134,026.00","-4,889,008.00","-5,807,400.00","-5,587,249.00","-3,810,132.00","-5,084,168.00","-7,868,484.00","-13,650,123.00","7,607,624.00",0.00,0.00,0.00, 
STI,Stirling Products Limited,Annual Balance Sheet - Total Equity, , , , , , , ,"3,292,994.00","2,818,891.00","3,888,426.00","5,199,319.00","8,182,391.00","3,869,335.00","1,034,810.00","14,774,062.00","14,895,145.00","10,108,442.00","5,723,906.00","4,739,173.00","1,521,494.00","591,772.00","-7,607,624.00",0.00,0.00,0.00,0.00, 
STI,Stirling Products Limited,Annual Balance Sheet - Total Assets, , , , , , , ,"3,633,152.00","3,504,807.00","4,026,542.00","5,847,078.00","8,709,953.00","4,021,768.00","1,123,301.00","15,342,863.00","15,164,404.00","10,320,933.00","6,164,317.00","6,644,099.00","4,237,983.00","7,314,295.00","6,814,648.00",--,--,--,--, 
SUD,Suda Ltd,Annual Ratio Analysis - ROE, , , , , , , , , , , ,-1.30%,-25.06%,-28.27%,-7.29%,-16.45%,0.20%,-14.01%,-93.57%,-32.91%,-44.25%,-26.39%,-23.67%,-24.93%,-14.71%,-19.50%, 
SUD,Suda Ltd,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , ,0.00,--,"140,768.00","4,745,548.00","8,172,827.00","8,614,000.00","9,508,161.00","11,856,260.00","19,353.00","14,215.00","3,003,798.00","3,908,869.00","4,045,060.00","8,648,187.00","5,624,815.00", 
SUD,Suda Ltd,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , ,"-79,187.00","-751,340.00","-1,064,905.00","-967,848.00","-1,928,929.00","26,079.00","-2,007,363.00","-9,647,554.00","-3,168,182.00","-4,856,312.00","-4,423,195.00","-4,437,023.00","-1,667,519.00","-2,060,850.00","-3,378,331.00", 
SUD,Suda Ltd,Annual Balance Sheet - Total Equity, , , , , , , , , , , ,"6,113,488.00","2,997,918.00","3,767,226.00","13,274,895.00","11,724,581.00","13,351,404.00","14,327,171.00","10,509,687.00","8,842,200.00","8,345,615.00","11,032,235.00","7,012,033.00","6,690,080.00","15,991,556.00","19,300,587.00", 
SUD,Suda Ltd,Annual Balance Sheet - Total Assets, , , , , , , , , , , ,"6,117,077.00","3,144,163.00","4,652,561.00","16,095,569.00","14,951,358.00","16,629,261.00","20,998,253.00","16,063,952.00","16,610,963.00","11,902,445.00","13,525,959.00","9,754,576.00","10,728,946.00","20,347,024.00","22,820,743.00", 
SVA,Simavita Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , , , , ,0.00%,-112.58%,-92.86%, 
SVA,Simavita Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , , , , ,--,"349,895.00","778,574.00", 
SVA,Simavita Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , , , , ,0.00,"-10,491,790.00","-9,463,209.00", 
SVA,Simavita Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , , , , ,"14,284,217.00","7,530,763.00","10,190,987.00", 
SVA,Simavita Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , , , , ,"15,355,542.00","8,789,924.00","11,416,809.00", 
SYB,Symbion Health Limited,Annual Ratio Analysis - ROE,15.35%,12.98%,8.93%,8.80%,10.15%,10.66%,7.68%,10.33%,10.36%,10.05%,8.61%,7.64%,4.16%,1.90%,4.05%,3.32%,11.05%,11.79%, , , , , , , , , 
SYB,Symbion Health Limited,Annual Profit and Loss - Operating Revenue,"2,053,700,000.00","2,300,355,000.00","2,504,393,000.00","2,765,032,000.00","2,837,406,000.00","3,000,732,000.00","2,917,346,000.00","2,835,374,080.00","2,634,934,016.00","2,797,694,976.00","3,100,402,000.00","3,158,663,000.00","4,991,957,000.00","5,194,510,000.00","4,089,669,000.00","3,840,903,000.00","3,441,112,000.00","3,826,369,000.00", , , , , , , , , 
SYB,Symbion Health Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"114,057,000.00","106,918,000.00","177,334,000.00","57,414,000.00","69,491,000.00","79,230,000.00","11,752,000.00","100,498,000.00","44,223,000.00","483,107,000.00","-170,186,000.00","165,450,000.00","177,215,000.00","-452,589,000.00","97,965,000.00","84,360,000.00","-4,112,000.00","94,226,000.00", , , , , , , , , 
SYB,Symbion Health Limited,Annual Balance Sheet - Total Equity,"720,829,000.00","757,686,000.00","1,224,359,000.00","1,204,226,000.00","1,217,392,000.00","1,189,259,000.00","1,110,143,000.00","1,121,109,976.00","1,273,259,992.00","1,137,423,008.00","892,820,000.00","1,409,675,000.00","3,617,824,000.00","2,987,792,000.00","2,520,672,000.00","2,516,204,000.00","819,557,000.00","875,681,000.00", , , , , , , , , 
SYB,Symbion Health Limited,Annual Balance Sheet - Total Assets,"1,508,413,000.00","1,663,018,000.00","2,183,624,000.00","2,415,233,000.00","2,331,177,000.00","2,700,384,000.00","2,810,250,000.00","3,006,057,000.00","3,093,212,040.00","2,412,128,016.00","2,378,171,000.00","3,213,795,000.00","5,391,235,000.00","4,658,555,000.00","4,122,386,000.00","4,090,728,000.00","2,164,481,000.00","2,225,908,000.00", , , , , , , , , 
TDL,TBG Diagnostics Limited,Annual Ratio Analysis - ROE, , , , , , ,-44.16%,-72.80%,-196.56%,-58.79%,-40.25%,-4.56%,-33.27%,-51.79%,-32.55%,-23.29%,-42.46%,-22.92%,-34.74%,-17.76%,-105.47%,-67.82%,-60.65%,-21.52%,-22.55%,-135.31%, 
TDL,TBG Diagnostics Limited,Annual Profit and Loss - Operating Revenue, , , , , , ,"994,341.00","1,382,377.00","1,486,025.00","1,420,784.00","2,441,219.00","2,434,000.00","3,850,000.00","5,544,000.00","3,490,000.00","2,286,000.00","905,000.00","920,000.00","1,086,000.00","1,724,000.00","1,973,000.00","2,585,000.00","2,008,145.00","2,816,281.00","5,410,951.00","3,341,107.00", 
TDL,TBG Diagnostics Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , ,"-2,912,474.00","-3,363,733.00","-5,387,233.00","-7,372,331.00","-7,322,244.00","-1,147,000.00","-6,156,000.00","-7,578,000.00","-4,781,000.00","-5,937,000.00","-7,609,000.00","-22,454,000.00","-26,148,000.00","-5,467,000.00","-15,839,000.00","-6,098,000.00","-3,440,398.00","-2,092,134.00","-1,806,945.00","-4,684,104.00", 
TDL,TBG Diagnostics Limited,Annual Balance Sheet - Total Equity, , , , , , ,"6,595,661.00","4,620,435.00","2,740,747.00","12,539,352.00","15,857,107.00","25,160,000.00","18,501,000.00","14,631,000.00","16,780,000.00","25,491,000.00","17,920,000.00","97,977,000.00","75,259,000.00","30,790,000.00","15,017,000.00","8,991,000.00","5,673,002.00","9,722,511.00","8,013,922.00","3,461,752.00", 
TDL,TBG Diagnostics Limited,Annual Balance Sheet - Total Assets, , , , , , ,"7,098,909.00","5,420,333.00","4,179,626.00","13,831,292.00","17,485,906.00","26,758,000.00","20,882,000.00","17,218,000.00","18,625,000.00","27,018,000.00","19,793,000.00","100,640,000.00","82,591,000.00","32,662,000.00","17,184,000.00","12,180,000.00","7,375,972.00","10,554,638.00","9,668,220.00","5,056,665.00", 
TDX,Tyrian Diagnostics Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , ,--,--,--, ,-151.49%,-140.95%,-263.24%,-115.52%,-218.67%,-123.81%,-158.04%,-203.48%,-16.87%,9.22%,-54.73%, 
TDX,Tyrian Diagnostics Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , ,"3,969,000.00","5,391,000.00",--, ,"3,584,619.00","4,558,056.00","3,353,010.00","1,551,474.00","790,573.00","1,516,776.00","467,606.00","101,752.00",0.00,"460,961.00","22,383.00", 
TDX,Tyrian Diagnostics Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , ,"-7,473,000.00","-16,248,000.00","-16,397,000.00", ,"-19,766,147.00","-10,214,981.00","-8,772,571.00","-8,726,511.00","-6,995,002.00","-4,155,911.00","-4,383,868.00","-1,865,210.00","-132,360.00","79,709.00","-305,624.00", 
TDX,Tyrian Diagnostics Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , ,--,--,--, ,"6,407,276.00","7,247,443.00","3,332,532.00","7,553,986.00","2,934,323.00","3,336,273.00","2,762,219.00","916,734.00","784,374.00","864,083.00","558,459.00", 
TDX,Tyrian Diagnostics Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , ,--,--,--, ,"11,097,637.00","10,092,655.00","5,275,196.00","9,767,037.00","4,583,307.00","4,489,765.00","4,102,765.00","1,267,722.00","976,871.00","898,205.00","596,089.00", 
TEO,Telesso Technologies Limited,Annual Ratio Analysis - ROE, , , , , , , ,-14.56%,0.21%,"12,348.00%",-147.64%,-174.22%,-104.73%,-68.43%,-187.09%,-172.92%,-64.65%,-18.98%,-20.98%,-49.48%,-43.62%,-30.74%,-30.71%,-407.82%, , , 
TEO,Telesso Technologies Limited,Annual Profit and Loss - Operating Revenue, , , , , , , ,"6,150,000.00","20,064,000.00","17,417,000.00","13,017,000.00","9,187,746.00","144,845.00","36,134.00","34,621.00","383,159.00","773,629.00","320,399.00","423,484.00","441,376.00",--,--,0.00,0.00, , , 
TEO,Telesso Technologies Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , ,"-1,091,000.00","-5,000.00","-5,812,000.00","-1,235,000.00","-3,661,343.00","-2,472,312.00","-4,877,935.00","-3,836,893.00","-3,518,847.00","-783,391.00","-1,214,156.00","-1,124,703.00","-1,777,323.00","-1,082,212.00","-583,349.00","-445,935.00","-1,191,974.00", , , 
TEO,Telesso Technologies Limited,Annual Balance Sheet - Total Equity, , , , , , , ,"5,354,000.00","5,824,000.00","-25,000.00","2,206,000.00","1,349,647.00","991,110.00","5,575,156.00","2,057,900.00","1,679,095.00","1,211,683.00","6,397,551.00","5,361,721.00","3,591,920.00","2,481,149.00","1,897,800.00","1,451,865.00","292,280.00", , , 
TEO,Telesso Technologies Limited,Annual Balance Sheet - Total Assets, , , , , , , ,"13,060,000.00","15,510,000.00","10,702,000.00","13,599,000.00","5,219,334.00","4,544,006.00","7,219,546.00","3,028,047.00","2,132,191.00","1,516,260.00","7,607,146.00","5,587,820.00","3,935,604.00","2,582,512.00","2,069,811.00","1,551,094.00","596,991.00", , , 
TLZ,Telezon Limited,Annual Ratio Analysis - ROE,-19.79%,-27.54%,-12.28%,-5.86%,-23.48%,-120.26%,-28.63%,-62.16%,-39.58%,-46.52%,-24.85%,"-3,357.93%",303.28%,"12,610.12%",--,100.00%,-5.63%,-5.60%,-8.85%,-13.81%,-15.80%,-11.13%, , , , , 
TLZ,Telezon Limited,Annual Profit and Loss - Operating Revenue,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,0.00,--,"101,342.00","4,279,885.00","112,599.00","92,537.00",--,"2,000.00",--,--,--,0.00,0.00,0.00, , , , , 
TLZ,Telezon Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-364,000.00","-442,000.00","-135,000.00","-37,000.00","-120,000.00","-279,000.00","-311,099.00","-346,056.00","262,439.00","-977,227.00","-2,602,000.00","-13,567,557.00","-183,632.00","61,033.00",-484.00,"-86,959.00","-170,549.00","-178,353.00","-268,963.00","-371,143.00","-389,131.00","-300,273.00", , , , , 
TLZ,Telezon Limited,Annual Balance Sheet - Total Equity,"566,000.00","276,000.00","391,000.00","631,000.00","511,000.00","232,000.00","644,652.00","556,691.00","1,737,130.00","1,629,422.00","10,324,845.00","123,083.00","-60,549.00",484.00,0.00,"-86,959.00","3,030,353.00","3,186,915.00","3,037,952.00","2,687,283.00","2,462,721.00","2,698,172.00", , , , , 
TLZ,Telezon Limited,Annual Balance Sheet - Total Assets,"589,000.00","287,000.00","403,000.00","648,000.00","568,000.00","266,000.00","700,484.00","591,297.00","2,013,957.00","1,950,123.00","11,645,064.00","284,715.00","31,988.00",484.00,--,"120,985.00","3,074,229.00","3,227,241.00","3,049,542.00","2,702,216.00","2,611,630.00","2,828,870.00", , , , , 
TPE,TPI Enterprises Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , , , , , , ,0.00%, 
TPE,TPI Enterprises Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , , , , , , ,"2,064,578.00", 
TPE,TPI Enterprises Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , , , , , , ,"-25,899,838.00", 
TPE,TPI Enterprises Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , , , , , , ,"38,800,000.00", 
TPE,TPI Enterprises Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , , , , , , ,"50,900,000.00", 
TTC,Traditional Therapies Clinics Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , , , , , ,0.00%,36.27%, 
TTC,Traditional Therapies Clinics Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , , , , , ,--,"44,799,000.00", 
TTC,Traditional Therapies Clinics Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , , , , , ,0.00,"17,127,000.00", 
TTC,Traditional Therapies Clinics Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , , , , , ,"31,963,000.00","46,528,000.00", 
TTC,Traditional Therapies Clinics Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , , , , , ,"61,542,000.00","78,117,000.00", 
UBI,"Universal Biosensors, Inc.",Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , ,-7.95%,-14.00%,-24.63%,2.79%,-14.00%,-41.95%,-23.19%,-39.19%,-47.19%,-49.61%, 
UBI,"Universal Biosensors, Inc.",Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , ,"2,527,486.00","999,981.00","4,557,254.00","22,042,570.00","18,180,036.00","14,696,452.00","29,646,443.00","15,089,672.00","9,529,684.00","16,774,978.00", 
UBI,"Universal Biosensors, Inc.",Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , ,"-2,804,295.00","-7,372,049.00","-11,995,886.00","1,430,463.00","-6,610,525.00","-14,692,117.00","-9,131,222.00","-11,633,807.00","-9,316,127.00","-6,576,416.00", 
UBI,"Universal Biosensors, Inc.",Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , ,"35,277,044.00","52,675,265.00","48,703,230.00","51,314,002.00","47,219,079.00","35,022,606.00","39,372,139.00","29,683,940.00","19,740,945.00","13,255,705.00", 
UBI,"Universal Biosensors, Inc.",Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , ,"37,976,867.00","55,992,321.00","52,505,321.00","56,083,468.00","53,837,949.00","45,216,467.00","49,066,850.00","54,619,699.00","47,532,638.00","44,951,745.00", 
UCM,USCOM Ltd,Annual Ratio Analysis - ROE, , , , , , , , , , , , , ,0.00%,-8.76%,-21.67%,-39.65%,-58.16%,-63.85%,-35.99%,-71.74%,-85.66%,-124.11%,-58.25%,-40.44%,-50.50%, 
UCM,USCOM Ltd,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , ,--,"384,390.00","480,107.00","1,119,622.00","871,263.00","1,051,713.00","1,630,371.00","836,913.00","837,995.00","794,135.00","578,753.00","1,056,502.00","1,515,381.00", 
UCM,USCOM Ltd,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , ,0.00,"-1,251,684.00","-2,545,918.00","-3,374,210.00","-3,196,824.00","-2,174,484.00","-1,099,889.00","-1,757,677.00","-2,685,913.00","-1,824,547.00","-1,371,683.00","-1,520,500.00","-1,215,654.00", 
UCM,USCOM Ltd,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , ,"15,442,741.00","14,292,725.00","11,746,807.00","8,509,267.00","5,496,266.00","3,405,526.00","3,056,217.00","2,450,035.00","3,135,605.00","1,470,066.00","2,354,667.00","3,319,393.00","2,288,661.00", 
UCM,USCOM Ltd,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , ,"15,517,797.00","14,604,417.00","12,119,267.00","9,150,572.00","5,934,647.00","3,759,837.00","3,525,524.00","2,831,418.00","3,524,290.00","1,828,358.00","2,815,188.00","3,769,209.00","2,936,355.00", 
UNS,Unilife Corporation,Annual Ratio Analysis - ROE,-31.04%,-72.89%,3.15%,-196.30%,-101.59%, , ,--,100.00%,49.43%, , ,-141.53%,-13.91%,-28.32%,-33.53%,-48.48%,-54.06%,-48.20%,35.30%,-67.05%,-75.94%,-119.56%,-177.53%,-944.36%,507.14%, 
UNS,Unilife Corporation,Annual Profit and Loss - Operating Revenue,"5,395,000.00","5,359,000.00","6,908,000.00","6,009,000.00","3,719,000.00", , ,--,--,--, , ,"394,913.00",0.00,0.00,0.00,0.00,"2,150,661.00","3,482,139.00","4,154,474.00","13,401,384.00","3,129,714.00","59,856.00","129,380.00","15,593,418.00","17,132,812.00", 
UNS,Unilife Corporation,Annual Profit and Loss - Reported NPAT After Abnorma,"-6,581,000.00","-1,117,000.00","74,000.00","-1,934,000.00","-1,245,000.00", , ,"-92,119.00","-88,259.00","-86,281.00", , ,"182,368.00","-1,442,965.00","-5,770,982.00","-7,399,919.00","-9,208,122.00","-10,906,076.00","-8,617,238.00","12,806,494.00","-34,903,203.00","-37,882,484.00","-51,321,754.00","-68,138,005.00","-61,463,906.00","-118,292,968.00", 
UNS,Unilife Corporation,Annual Balance Sheet - Total Equity,"2,606,000.00","1,490,000.00","2,414,000.00","649,000.00","941,000.00", , ,0.00,"-88,260.00","-174,541.00", , ,"-42,951.00","10,375,632.00","20,374,483.00","22,071,918.00","18,992,626.00","20,173,367.00","17,877,101.00","36,277,965.00","52,059,134.00","49,885,464.00","42,925,130.00","38,380,592.00","6,508,492.00","-23,325,520.00", 
UNS,Unilife Corporation,Annual Balance Sheet - Total Assets,"5,492,000.00","4,619,000.00","5,260,000.00","4,505,000.00","4,392,000.00", , ,--,"414,421.00","632,748.00", , ,"108,912.00","14,295,307.00","21,905,792.00","23,470,982.00","20,515,556.00","27,306,292.00","27,286,120.00","49,413,334.00","76,049,513.00","83,320,607.00","80,765,381.00","73,747,708.00","86,802,547.00","122,563,802.00", 
VBS,Vectus Biosystems Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , , , , , , ,0.00%, 
VBS,Vectus Biosystems Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , , , , , , ,--, 
VBS,Vectus Biosystems Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , , , , , , ,0.00, 
VBS,Vectus Biosystems Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , , , , , , ,"11,218,005.00", 
VBS,Vectus Biosystems Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , , , , , , ,"11,728,577.00", 
VCR,Ventracor Limited,Annual Ratio Analysis - ROE, , ,-23.80%,-17.60%,-13.27%,-79.38%,8.46%,-432.28%,-219.58%,-116.03%,-57.08%,-64.07%,-41.29%,-91.09%,-25.04%,-69.55%,-51.35%,-69.13%,-87.14%, , , , , , , , 
VCR,Ventracor Limited,Annual Profit and Loss - Operating Revenue, , ,"457,000.00","608,000.00","1,745,000.00","3,105,000.00","5,403,529.00","3,439,301.00","2,330,456.00","2,185,532.00","2,273,372.00","4,362,228.00","2,099,846.00","1,741,000.00",0.00,0.00,"1,096,000.00","4,913,000.00","17,340,000.00", , , , , , , , 
VCR,Ventracor Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , ,"-690,000.00","-462,000.00","-869,000.00","-4,862,000.00","155,952.00","-2,540,086.00","-4,329,046.00","-3,295,746.00","-3,059,045.00","-3,216,573.00","-8,500,404.00","-9,370,000.00","-15,899,000.00","-26,637,000.00","-30,073,000.00","-36,471,000.00","-24,948,000.00", , , , , , , , 
VCR,Ventracor Limited,Annual Balance Sheet - Total Equity, , ,"2,899,000.00","2,437,000.00","6,550,000.00","1,688,000.00","1,843,944.00","489,858.00","1,733,312.00","2,674,138.00","4,902,768.00","5,020,104.00","20,589,355.00","13,077,000.00","63,494,000.00","38,301,000.00","58,564,000.00","52,758,000.00","28,629,000.00", , , , , , , , 
VCR,Ventracor Limited,Annual Balance Sheet - Total Assets, , ,"4,092,000.00","4,587,000.00","7,197,000.00","8,002,000.00","8,811,452.00","7,262,255.00","8,585,185.00","9,039,894.00","5,889,751.00","6,653,903.00","22,577,758.00","14,657,000.00","65,610,000.00","41,123,000.00","62,064,000.00","59,533,000.00","37,099,000.00", , , , , , , , 
VEI,Vision Eye Institute Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , ,30.69%,10.31%,12.31%,13.29%,14.33%,12.30%,10.95%,7.93%,15.84%,14.26%,16.58%,14.60%, 
VEI,Vision Eye Institute Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , ,--,0.00,"75,801,000.00","98,722,000.00","110,273,000.00","113,502,000.00","107,739,000.00","106,960,000.00","111,220,000.00","107,128,000.00","110,587,000.00","112,860,000.00", 
VEI,Vision Eye Institute Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , ,"14,703,000.00","6,685,000.00","11,954,000.00","14,203,000.00","16,915,000.00","12,587,000.00","-58,397,000.00","-23,962,000.00","8,943,000.00","-16,860,000.00","13,211,000.00","12,031,000.00", 
VEI,Vision Eye Institute Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , ,"47,902,000.00","64,856,000.00","97,088,000.00","106,879,000.00","118,060,000.00","128,276,000.00","69,537,000.00","46,886,000.00","56,449,000.00","66,176,000.00","79,659,000.00","99,515,000.00", 
VEI,Vision Eye Institute Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , ,"105,294,000.00","159,910,000.00","219,454,000.00","232,844,000.00","247,944,000.00","258,522,000.00","192,483,000.00","162,610,000.00","156,964,000.00","130,632,000.00","137,429,000.00","151,828,000.00", 
VHT,Volpara Health Technologies Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , , , , , , ,0.00%, 
VHT,Volpara Health Technologies Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , , , , , , ,--, 
VHT,Volpara Health Technologies Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , , , , , , ,0.00, 
VHT,Volpara Health Technologies Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , , , , , , ,"11,170,000.00", 
VHT,Volpara Health Technologies Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , , , , , , ,"11,846,000.00", 
VLA,Viralytics Limited,Annual Ratio Analysis - ROE,-17.28%,-131.91%,-566.43%,101.39%,36.96%,139.86%,44.40%,-33.20%,-133.92%,-180.90%,-415.02%,-563.09%,-178.29%,-64.78%,1.71%,-67.76%,-97.26%,-35.87%,-42.34%,-93.73%,-55.77%,-29.82%,-49.99%,-46.00%,-19.15%,-17.11%, 
VLA,Viralytics Limited,Annual Profit and Loss - Operating Revenue,"200,000.00","181,000.00","213,000.00","509,000.00","631,000.00","623,000.00","823,190.00","892,077.00","1,012,169.00","911,758.00","1,073,447.00","1,069,122.00","1,003,911.00","1,047,792.00","953,258.00","419,233.00","7,533.00","359,473.00",0.00,--,0.00,"1,405,503.00","871,603.00",0.00,0.00,0.00, 
VLA,Viralytics Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-491,000.00","-1,050,000.00","-653,000.00","-7,355,000.00","7,258,000.00","106,000.00","214,226.00","-434,025.00","-762,862.00","-1,251,679.00","-887,629.00","-3,455,250.00","-1,425,760.00","-2,436,978.00","-3,129,315.00","-6,940,616.00","-9,272,383.00","-4,195,590.00","-3,681,125.00","-4,585,443.00","-4,804,370.00","-2,701,287.00","-4,778,819.00","-4,129,729.00","-5,528,629.00","-4,254,777.00", 
VLA,Viralytics Limited,Annual Balance Sheet - Total Equity,"1,835,000.00","796,000.00","143,000.00","-7,212,000.00","46,000.00","429,000.00","1,161,912.00","1,303,087.00","550,225.00","601,506.00","213,877.00","613,627.00","1,782,938.00","3,046,131.00","8,159,907.00","8,703,198.00","9,533,294.00","11,695,864.00","8,694,450.00","4,892,184.00","8,614,325.00","9,058,460.00","9,559,874.00","8,977,885.00","28,876,542.00","24,872,281.00", 
VLA,Viralytics Limited,Annual Balance Sheet - Total Assets,"3,616,000.00","2,461,000.00","403,000.00","282,000.00","261,000.00","5,218,000.00","5,546,263.00","7,115,395.00","6,499,956.00","6,304,207.00","3,460,452.00","3,486,214.00","35,454,713.00","3,743,182.00","8,965,918.00","9,136,356.00","12,382,731.00","12,251,852.00","9,176,045.00","6,540,160.00","9,539,534.00","10,039,649.00","10,305,957.00","10,212,771.00","29,643,327.00","26,557,545.00", 
VLS,Vita Life Sciences Limited,Annual Ratio Analysis - ROE,19.32%,-7.32%,-54.88%,-11.06%,9.24%,14.00%,12.25%,7.06%,22.02%,23.98%,12.87%,0.42%,-13.31%, , , , , , , , , , , , , , 
VLS,Vita Life Sciences Limited,Annual Profit and Loss - Operating Revenue,"9,709,000.00","2,329,000.00","3,765,000.00",0.00,"935,000.00",0.00,0.00,0.00,0.00,"21,095,506.00","36,000,889.00","39,243,027.00","32,764,356.00", , , , , , , , , , , , , , 
VLS,Vita Life Sciences Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-1,121,000.00","-576,000.00","-2,850,000.00","-1,721,000.00","427,000.00","280,000.00","279,285.00","903,549.00","784,827.00","2,109,161.00","5,245,738.00","167,313.00","-29,959,412.00", , , , , , , , , , , , , , 
VLS,Vita Life Sciences Limited,Annual Balance Sheet - Total Equity,"3,690,000.00","5,864,000.00","3,014,000.00","1,293,000.00","1,720,000.00","2,000,000.00","2,279,278.00","3,182,827.00","3,967,654.00","26,358,452.00","28,944,316.00","40,182,219.00","9,116,507.00", , , , , , , , , , , , , , 
VLS,Vita Life Sciences Limited,Annual Balance Sheet - Total Assets,"7,150,000.00","6,108,000.00","3,129,000.00","1,947,000.00","1,725,000.00","2,139,000.00","2,291,723.00","3,213,327.00","3,987,654.00","38,731,724.00","48,948,384.00","66,051,864.00","28,886,927.00", , , , , , , , , , , , , , 
VRT,Virtus Health Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , , , , , , ,0.00%,9.42%,13.50%,14.05%, 
VRT,Virtus Health Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , , , , , , ,--,"185,304,000.00","200,019,000.00","232,417,000.00", 
VRT,Virtus Health Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , , , , , , ,0.00,"10,104,000.00","30,957,000.00","30,441,000.00", 
VRT,Virtus Health Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , , , , , , ,"205,700,000.00","214,589,000.00","239,626,000.00","246,321,000.00", 
VRT,Virtus Health Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , , , , , , ,"372,400,000.00","385,464,000.00","429,781,000.00","465,246,000.00", 
VSC,Vita Life Sciences Limited,Annual Ratio Analysis - ROE, , , , , , , , , , , , , , , , , ,-50.64%,-21.36%,-9.62%,58.28%,14.28%,21.03%,29.35%,33.91%,19.24%, 
VSC,Vita Life Sciences Limited,Annual Profit and Loss - Operating Revenue, , , , , , , , , , , , , , , , , ,"11,869,884.00","14,356,081.00","17,015,128.00","20,190,561.00","24,266,646.00","30,191,000.00","35,411,000.00","36,580,000.00","38,584,000.00", 
VSC,Vita Life Sciences Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , , , , , , , , , , , ,"-204,265.00","353,477.00","-328,193.00","4,459,519.00","1,212,521.00","2,316,000.00","4,746,000.00","7,284,000.00","4,351,000.00", 
VSC,Vita Life Sciences Limited,Annual Balance Sheet - Total Equity, , , , , , , , , , , , , , , , , ,"2,879,728.00","3,845,624.00","3,900,881.00","8,129,883.00","8,956,045.00","11,342,000.00","16,269,000.00","21,565,000.00","22,876,000.00", 
VSC,Vita Life Sciences Limited,Annual Balance Sheet - Total Assets, , , , , , , , , , , , , , , , , ,"6,729,107.00","8,640,588.00","8,810,066.00","14,512,224.00","13,349,160.00","16,813,000.00","22,009,000.00","30,271,000.00","32,388,000.00", 
VSG,Visiomed Group Limited,Annual Ratio Analysis - ROE,-1.23%,-20.34%,-28.34%,-33.63%,-32.59%,-36.79%,-6.88%,-4.23%,7.47%,-68.08%,-18.16%,-18.27%,-60.23%,-114.46%,-685.83%,-584.14%,-153.18%,-24.16%, , , , , , , , , 
VSG,Visiomed Group Limited,Annual Profit and Loss - Operating Revenue,0.00,0.00,"359,000.00","1,778,000.00","420,000.00","26,000.00",0.00,0.00,0.00,0.00,0.00,0.00,"53,543.00","214,718.00","753,997.00","644,934.00","234,077.00","1,456,033.00", , , , , , , , , 
VSG,Visiomed Group Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"-197,000.00","-4,433,000.00","-666,000.00","-858,000.00","-1,237,000.00","-1,501,000.00","-852,718.00","-565,727.00","-1,241,854.00","-2,524,945.00","-1,227,082.00","-1,890,033.00","-5,123,627.00","-2,370,089.00","-4,361,936.00","-1,198,771.00","-1,281,902.00","-1,075,355.00", , , , , , , , , 
VSG,Visiomed Group Limited,Annual Balance Sheet - Total Equity,"5,775,000.00","1,342,000.00","1,736,000.00","2,828,000.00","3,566,000.00","4,080,000.00","4,303,152.00","6,320,925.00","6,088,086.00","3,708,702.00","6,758,419.00","5,318,386.00","2,674,638.00","2,070,616.00","361,448.00","205,219.00","1,049,000.00","4,450,549.00", , , , , , , , , 
VSG,Visiomed Group Limited,Annual Balance Sheet - Total Assets,"5,784,000.00","1,398,000.00","3,479,000.00","3,598,000.00","4,045,000.00","4,387,000.00","4,382,084.00","6,426,804.00","6,187,691.00","4,541,570.00","6,876,464.00","5,377,706.00","3,071,996.00","3,959,229.00","2,273,982.00","1,093,061.00","1,613,000.00","6,891,428.00", , , , , , , , , 
VSL,Vision Systems Limited,Annual Ratio Analysis - ROE,2.89%,17.29%,42.02%,21.93%,24.13%,15.31%,15.29%,6.99%,9.77%,9.23%,4.61%,8.89%,6.10%,5.40%,4.85%,3.81%,-50.66%, , , , , , , , , , 
VSL,Vision Systems Limited,Annual Profit and Loss - Operating Revenue,"9,497,000.00","8,408,000.00","9,528,000.00","10,230,000.00","34,900,000.00","57,017,000.00","84,775,000.00","79,659,000.00","105,881,000.00","125,795,000.00","144,089,000.00","144,731,000.00","111,305,000.00","130,592,000.00","134,451,000.00","167,919,000.00","110,518,000.00", , , , , , , , , , 
VSL,Vision Systems Limited,Annual Profit and Loss - Reported NPAT After Abnorma,"381,000.00","912,000.00","2,853,000.00","2,037,000.00","6,615,000.00","9,139,000.00","10,641,000.00","7,130,000.00","10,645,000.00","9,609,000.00","12,117,000.00","98,849,000.00","-14,947,000.00","12,848,000.00","11,288,000.00","6,290,000.00","170,678,000.00", , , , , , , , , , 
VSL,Vision Systems Limited,Annual Balance Sheet - Total Equity,"4,364,000.00","5,275,000.00","7,644,000.00","9,289,000.00","38,009,000.00","59,693,000.00","69,585,000.00","102,047,000.00","108,902,000.00","104,073,000.00","123,627,000.00","217,505,000.00","199,170,000.00","217,922,000.00","232,660,000.00","229,122,000.00","366,044,000.00", , , , , , , , , , 
VSL,Vision Systems Limited,Annual Balance Sheet - Total Assets,"10,312,000.00","11,242,000.00","13,650,000.00","14,917,000.00","80,025,000.00","238,152,000.00","239,144,000.00","282,357,000.00","214,973,000.00","225,653,000.00","174,698,000.00","276,543,000.00","259,837,000.00","269,594,000.00","301,700,000.00","310,020,000.00","508,349,000.00", , , , , , , , , , 
ZTL,Zenyth Therapeutics Limited,Annual Ratio Analysis - ROE, , , , , , , ,-3.99%,-12.97%,-15.15%,-25.47%,-21.18%,-23.23%,1.70%,-2.69%,2.09%,-8.97%, , , , , , , , , , 
ZTL,Zenyth Therapeutics Limited,Annual Profit and Loss - Operating Revenue, , , , , , , ,"112,181,000.00","124,363,000.00","117,675,000.00","109,238,000.00","43,606,000.00","3,166,000.00","1,015,000.00","598,000.00","764,000.00","431,000.00", , , , , , , , , , 
ZTL,Zenyth Therapeutics Limited,Annual Profit and Loss - Reported NPAT After Abnorma, , , , , , , ,"-2,498,000.00","-6,454,000.00","-10,767,000.00","-20,223,000.00","-4,337,000.00","-14,402,000.00","7,388,000.00","-3,523,000.00","-1,622,000.00","-4,429,000.00", , , , , , , , , , 
ZTL,Zenyth Therapeutics Limited,Annual Balance Sheet - Total Equity, , , , , , , ,"110,243,000.00","108,261,000.00","94,747,000.00","71,445,000.00","61,354,000.00","61,988,000.00","69,376,000.00","64,167,000.00","53,653,000.00","49,369,000.00", , , , , , , , , , 
ZTL,Zenyth Therapeutics Limited,Annual Balance Sheet - Total Assets, , , , , , , ,"135,067,000.00","162,905,000.00","153,542,000.00","117,282,000.00","88,890,000.00","86,048,000.00","78,575,000.00","67,362,000.00","56,636,000.00","52,648,000.00", , , , , , , , , , 
